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1. Introduction
Streptococcus suis is one of the principal etiologic agents of contagious bacterial disease in pigs.
The pathogen can cause a variety of clinical syndromes including meningitis, arthritis, pericarditis,
polyserositis, septicaemia, pneumonia and sudden death (de Moor, 1963; Elliott, 1966; Windsor,
1977; Clifton Hadley, 1983; Vecht et al., 1985; Erickson, 1987; Cook et al., 1988; Higgins et al.,
1990; Hariharan et al., 1992; Chanter et al., 1993; Reams et al., 1994; Tarradas et al., 1994).
S. suis is a gram-positive facultatively anaerobic coccus, originally defined as Lancefield groups
R, S, R/S or T (de Moor, 1963). In the United Kingdom, Windsor and Elliott designed a new typing
system based on the type-specific capsular polysaccharide antigens located in the cell wall (Elliott,
1966; Windsor and Elliott, 1975). They proposed the name S. suis serotype 2 for de Moor’s group
R, S. suis serotype 1 for de Moor’s group S, and S. suis serotype 1/2 for de Moor’s group R/S
(Elliott, 1966; Windsor and Elliott, 1975). The original group T reference strain was later designated
as S. suis serotype 15 (Gottschalk et al., 1989). In 1983, Perch et al. presented six new serotypes of
S. suis (serotypes 3-8). Strains belonging to these new serotypes were isolated from various lesions
in pigs (Perch et al., 1983). All these strains were morphologically and biochemically very similar.
In the following two decades, 26 additional serotypes have been described extending the number
of known serotypes to 35 (Gottschalk et al., 1989; 1991; Higgins et al., 1995).
Initially, when Windsor and Elliott renamed de Moor’s R and S streptococci into S. suis serotype
1 and 2 (Elliott, 1966; Windsor and Elliott, 1975), S. suis was classified largely on the basis of
serological evidence as a subgroup of Lancefield’s serological group D (Elliott et al., 1977). Later
on, in 1987, when S. suis was officially proposed as a new species, genetic characterization of the
serotypes 1 to 8 (including 1/2) showed that S. suis formed a well defined group, distinct from group
D as well as from other streptococci (Kilpper Balz and Schleifer, 1987). Comparison of the 16S
rRNA gene sequences of the 35 S. suis reference strains revealed that, despite the existence of
groupable sequence variations, all reference strains were clearly distinct from the other streptococci
indicating that all analyzed serotypes belonged to S. suis (Chatellier et al., 1998; Rasmussen and
Andresen, 1998).
Since the first description of de Moor, S. suis has been isolated from pigs in all countries where
the swine industry is important. In a survey in 1983, more than 50 per cent of the streptococcal
infections in pigs in the Netherlands was caused by S. suis (Vecht et al., 1985). A few years later,
the number of affected farms had further increased (Van Leengoed et al., 1987). At present, S. suis
is one of the major pathogens in pigs causing economical damage to the swine industry of more than
300 million dollar in the United States only (Staats et al., 1997). This includes costs due to mortality
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and medical treatment, labour costs associated with the nursing of sick pigs, and costs of preventive
measures and reduced product yields due to impaired growth rate of the pigs (Clifton Hadley et al.,
1986a; Chengappa et al., 1990; Staats et al., 1997).
Control of S. suis infections in pig herds is hampered by the lack of effective vaccines and of
diagnostic tests with high specificity and sensitivity. The limited availability of these tools is likely
caused by the large number of existing serotypes, the variation in virulence among strains and the
scarce knowledge of the factors that contribute to virulence and protection (Stockhofe-Zurwieden
et al. 1996; Vecht et al., 1996; Staats et al., 1997). Therefore, research focused on the identification
of virulence-associated markers that discriminate between virulent and less virulent or avirulent
isolates, has gained considerable interest in recent years. Use of these markers in diagnostic assays
and/or in vaccines may provide new opportunities to control S. suis infections.
2. Epidemiology
2.1 Prevalence of serotypes
Disease caused by S. suis has been diagnosed across Europe (Hommez et al., 1984; Vecht et al.,
1985; Clifton Hadley et al., 1986a; Salasia and Lammler, 1995; Aarestrup et al., 1998; Luque et al.,
1998; Awad-Masalmeh et al., 1999), in Japan (Kataoka et al., 1993), in Australia and New Zealand
(Robertson and Blackmore, 1989; Gogolewski et al., 1990), in Canada (Touil et al., 1988; Higgins
and Gottschalk, 2000), and in the United States (Galina et al., 1992; Reams et al., 1993).
Worldwide, S. suis serotype 2 is the most frequently isolated serotype from diseased pigs (Staats
et al., 1997). However, the distribution of serotypes can vary between regions and can change over
time. For example, S. suis serotype 9 prevailed in Australia, while in the same period serotype 7 was
the most prevalent serotype in Finland (Sihvonen et al., 1988; Gogolewski et al., 1990). In the
Netherlands, the most frequently isolated serotype from diseased pigs changed from serotype 2 in
1985 into serotype 9 in 1995 (Vecht et al., 1985; Jacobs et al., 1995). In Denmark, the predominant
serotype changed from serotype 7 in 1983 (Perch et al., 1983) into serotype 2 in 1998 (Aarestrup
et al., 1998). Recently, in Scotland and the UK, serotype 14 was most frequently isolated from
diseased pigs (Heath et al., 1996; MacLennan et al., 1996; Heath and Hunt, 2001), replacing
serotype 2 as the predominant serotype (Clifton Hadley et al., 1986a). In addition to the frequently
isolated serotypes, other serotypes have been associated with disease, including serotypes 3, 4 and
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7 in the UK (Heath et al., 1995; 2001) and in the United States (Galina et al., 1992), and serotypes
3, 1/2, 8 and 5 in Canada (Higgins and Gottschalk, 2000).
2.2 Epidemiology of S. suis infection
Both adult and young pigs can carry S. suis in the nose, tonsils, and nasopharynx without
showing symptoms (Williams et al., 1973; Clifton Hadley and Alexander, 1980; Arends et al., 1984;
Mogollon et al., 1991; Prieto et al., 1994). S. suis may also colonize in the genital and alimentary
tract of pigs (Clifton Hadley et al., 1986a; Devriese et al., 1991; Robertson et al., 1991). Outbreaks
of disease have frequently been attributed to the introduction of a carrier into the herd (Clifton
Hadley and Alexander, 1980; Van Leengoed et al., 1987). These carriers were considered the most
important source from which the bacteria were transmitted to sensitive young pigs (Clifton Hadley
et al., 1984a; Robertson and Blackmore, 1989; Mogollon et al., 1990; Amass et al., 1997). Sows
presumable infected their own litters orally or nasally (Clifton Hadley et al., 1986a; Amass et al.,
1997), but transmission during birth or suckling has also been reported (Robertson and Blackmore,
1989; 1991; Dee et al., 1993; Amass et al., 1995).
Within herds carrier rates of S. suis serotype 2 may vary between 0 tot 100% (Arends et al., 1984;
Van Leengoed et al., 1987; Mwaniki et al., 1994) but this number does not correlate with the
incidence of disease (Arends et al., 1984; Clifton Hadley et al., 1984b; Van Leengoed et al., 1987).
Even when carrier rates approached 100%, the incidence of disease may not exceed 5% (Clifton
Hadley et al., 1986a). This may indicate differences in susceptibility between hosts and/or
differences in virulence among strains. It is known that environmental factors such as stress due to
moving, mixing, weighting, vaccination, castration, overcrowding and poor ventilation increases
the risk of an infection particularly in weaning pigs (Clifton Hadley et al., 1986a; Dee et al., 1993).
The carrier pigs are probably not the sole source of infection. S. suis serotype 2 has been detected
in SPF herds and in completely closed, hysterectomy-derived herds (Lamont et al., 1980; Robertson
and Blackmore, 1989), suggesting the existence of other reservoirs.
2.3 Age
Disease caused by S. suis is usually observed in pigs younger than 16 weeks with a peak between
3 and 12 weeks and less cases following weaning (Lamont et al., 1980; Clifton Hadley, 1984;
Chengappa et al., 1986; Van Leengoed et al., 1987). S. suis serotype 1 appears to affect younger
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piglets between 2 to 6 weeks (Elliott, 1966; Reams et al., 1993), but this serotype can also cause
disease in older pigs (Akkermans and Vecht, 1994).
2.4 Zoonosis
S. suis can cause meningitis and/or septicaemia in humans (Arends and Zanen, 1988; Higgins
and Gottschalk, 1990; Trottier et al., 1991). These infections are usually caused by serotype 2, but
serotypes 4 and 14 have also been isolated (Higgins and Gottschalk, 1990; Trottier et al., 1991). The
organisms probably gained entry via small wounds or through inhalation (Arends and Zanen, 1988).
Individuals who are frequently exposed to pigs or pork appear to particularly be at risk for acquiring
the disease (Arends and Zanen, 1988; Amass, 1998; Halaby et al., 2000).
3. Virulence
3.1 Pathogenesis
The pathogenesis of S. suis infections is not well understood. Most studies are limited to serotype
2 and cases of meningitis. It has been suggested that the microorganisms use the palatine tonsils as
the port of entry (Williams et al., 1973), then enter the mononuclear leucocytes and travel to the
cerebrospinal fluid (CSF) via the choroid plexus. Stimulation of cytokine production by infected
macrophages is supposed to cause an inflammatory infiltrate from the blood to the CSF (Williams,
1990; Chanter et al., 1993). The increase in cells in the CSF blocks sites of fluid efflux, increases
intracranial pressure and possibly, damages neurons, leading to clinical signs of neurological disease
(Williams and Blakemore, 1990).
3.2 Animal models
To study the virulence of S. suis serotype 2 isolates in pigs several infection models have been
developed. The bacteria were inoculated intravenously (Clifton Hadley, 1984; Holt et al., 1988;
Robertson and Blackmore, 1990; Kataoka et al., 1991; Staats et al., 1998), intranasally (Vecht et al.,
1989; Iglesias et al., 1992; Vecht et al., 1992; Galina et al., 1994) or subcutaneously (Pedersen et
al., 1981; Andresen and Tegtmeier, 2001). In the field, the nasopharynx and the tonsils are
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presumable portals of entry for S. suis infections in pigs. It has, however, been difficult to study the
clinical disease caused by S. suis infection because the disease is difficult to reproduce by using
natural routes of exposure when challenging with S. suis alone (Clifton Hadley and Alexander,
1981; Vecht et al., 1989; Iglesias et al., 1992; Galina et al., 1994). The intravenous inoculation of
S. suis serotype 2 has been shown to result in a higher incidence of disease in pigs when compared
to that from the intranasal route of inoculation (Clifton Hadley and Alexander, 1981). Preinoculating
of pigs with Bordetella bronchiseptica, followed by intranasal inoculation with S. suis serotype 2,
significantly enhanced the virulence of the S. suis (Vecht et al., 1989). Reproducible results have
been obtained using this model of infection (Vecht et al., 1989; 1992; 1997a; 1997b).
Mice have been used as a model for S. suis disease in pigs (Williams et al., 1988; Kebede et al.,
1990; Kataoka et al., 1991; Beaudoin et al., 1992; Quessy et al., 1995; Charland et al., 1997).
However, several studies indicate that the pathogenicity of S. suis may be species dependent (Vecht
et al., 1997a; 1997b; Staats et al., 1998). S. suis serotype 2 isolates, which proved virulent for young
pigs after intranasal or intravenous inoculation, appeared less virulent in mice (Vecht et al., 1997a;
1997b). Conversely, it was found that isolates which were weakly-virulent or non-virulent for pigs
were highly virulent in mice. In contrast to the pathology of S. suis infection in pigs which is
characterized by specific lesions, mice often showed histologically non-specific lesions such as
necrotizing encephalitis and focal or diffuse hepatitis sometimes with abscesses (Vecht et al., 1997a;
1997b). These observations led to the conclusion that the murine models used for S. suis infection
do not mimic the events in the pig. This important notion implies that experimental infections in the
natural host are required to evaluate the virulence of S. suis isolates and the efficacy of newly
developed vaccines and drugs.
3.3 Virulence factors
A number of factors, putatively involved in virulence of S. suis serotype 2 have been described.
These include extracellular and membrane-associated proteins, capsular polysaccharides (CPS),
adhesins, and proteins identified by the selection of genes specifically in vivo expressed.
3.3.1 CPS
The capsular polysaccharide (CPS) has been recognized as an important virulence factor in many
gram- positive and negative bacteria (Moxon and Kroll, 1990). Several studies showed that CPS
also plays an essential role in the pathogenesis of S. suis serotype 2 infections (Charland et al., 1998;
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Smith et al., 1999a). Recently, a non-encapsulated isogenic mutant of a virulent S. suis serotype 2
strain was obtained by insertional mutagenesis (Smith et al., 1999a). This mutant was rapidly
ingested and killed once taken up by porcine lung macrophages and appeared avirulent in young
germfree pigs. Similar results were obtained with S. suis serotype 2 transposon mutants that were
impaired in capsule production (Charland et al., 1998). Absence of CPS correlated with increased
hydrophobicity and phagocytosis by murine and porcine phagocytes. The transposon mutants also
showed reduced virulence in pigs and mice.
CPS of S. suis is mainly composed of carbohydrates. Previous work has shown that the CPS of
S. suis serotype 2 has a molecular mass of at least 100 kDa and is composed of rhamnose, galactose,
glucose, N-acetylglucosamine and sialic acid (Soprey and Slade, 1972; Elliott and Tai, 1978).
Serotype 1 CPS has a similar composition except that N-acetylgalactosamine is substituted for
rhamnose (Elliott and Tai, 1978). So far, the chemical composition and structure of the CPS of the
other S. suis serotypes has not been elucidated.
Sialic acid has been shown to be an important virulence factor in other bacteria that are able to
cause meningitis (Wessels et al., 1989). The precise role of sialic acid in virulence of S. suis strains
is unclear. Sialidase-treated S. suis serotype 2 strains were as virulent for mice as untreated strains
and the same low concentrations of sialic acid were found in the capsule of virulent and avirulent
strains (Charland et al., 1996). Based on these data, the authors suggested that sialic acid is not a key
virulence factor for S. suis serotype 2. However, these results were obtained in a murine model
which was previously demonstrated to be unsuitable for studying S. suis infections (Vecht et al.,
1997a; 1997b). Experimental infections in pigs will be necessary to examine the virulence of the
sialidase deficient S. suis serotype 2 strains. Recently, genes involved in the synthesis of sialic acid
in S. suis serotype 2 have been cloned (Smith et al., 2000). This provides the opportunity to
construct isogenic mutants and to establish the role of sialic acid in virulence.
3.3.2 MRP and EF
The finding that different fully encapsulated serotype 2 strains can differ in virulence (Vecht et
al., 1992) indicates that additional virulence factors exist in S. suis. Two proteins, a 136-kDa
muramidase-released-protein (MRP) and a 110-kDa extracellular factor (EF) have been reported
to be associated with virulence in serotype 1 and 2 strains (Vecht et al., 1989; 1991; 1992;
Stockhofe-Zurwieden et al., 1996 ). Serotype 2 strains with the phenotype MRP+EF+ induced severe
specific clinical signs of disease such as nervous disorders and lameness after experimental infection
in pigs, while serotype 2 strains with the phenotype MRP–EF– did not (Vecht et al., 1989; 1992). S.
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suis serotype 2 strains with the phenotype MRP+EF*, which produce an enlarged variant of the 110-
kDa EF protein (Smith et al., 1993), were isolated from human patients and induced only aspecific
clinical signs of disease such as recumbency, lack of appetite, and fever after experimental infection
in pigs (Vecht et al., 1992). Strains of S. suis type 1 exhibit either the MRPsEF+ or the MRP–EF–
phenotype. The MRPsEF+ strains, which produce an MRP protein of reduced size (molecular mass
of about 120-kDa) and the 110-kDa EF protein, were highly virulent for young pigs. Strains with
the phenotype MRP–EF– were less virulent than the MRPsEF+ strains but were still able to induce
disease (Stockhofe-Zurwieden et al., 1996; Vecht et al., 1996).
Biochemical studies have demonstrated that MRP is predominantly present in protoplast
supernatants and therefore may be associated with peptidoglycan (Vecht et al., 1991). The amino
acid sequence of MRP has features common to cell surface proteins of gram-positive bacteria, such
as a signal peptide at the N-terminus and a domain at the C-terminus that is probably responsible
for the anchoring of the protein to the cell envelope (Smith et al., 1992). A particular region within
the amino acid sequence of MRP showed similarities to the fibronectin-binding protein of
Staphyloccus aureus (Smith et al., 1992). Binding of MRP to human fibronectin, however, could
not be demonstrated.
Because EF appeared only in culture supernatant, it is considered to be a protein that is secreted.
Sequence analysis of the genes encoding the EF and EF* proteins revealed that the N-termini of EF
and EF* were nearly identical (Smith et al., 1993). However, at their C-terminus EF* proteins
contained several repeated amino acid units which were absent in the smaller EF protein (Smith et
al., 1993). With respect to the possible functions of these proteins, no information could be provided
from the amino acid sequences of the deduced EF proteins (Smith et al., 1997b).
Although there is a strong positive correlation between expression of MRP and EF and virulence,
these proteins are dispensable for causing disease. Isogenic mutant strains of S. suis serotypes 1 and
2 lacking MRP and/or EF were as virulent for pigs as the parent strains (Smith et al., 1996; 1997b).
Moreover, most strains isolated from diseased pigs in Canada did not express MRP and EF
(Gottschalk et al., 1998). Nevertheless, most of the S. suis serotype 2 strains isolated from diseased
pigs in America, Austria, Germany and Spain showed the MRP+EF+ phenotype (Salasia and
Lammler, 1995; Galina et al., 1996; Awad-Masalmeh et al., 1999; Luque et al., 1999; Allgaier et
al., 2001) suggesting that in these strains MRP and EF were associated with virulence. Interestingly,
comparison of genotypic features by using different molecular typing methods such as ribotyping
or pulsed-field gel electrophoresis suggested a clonal relationship of S. suis serotype 2 strains with
the phenotype MRP+EF+ (Mogollon et al., 1991; Smith et al., 1997a; Staats et al., 1998; Chatellier
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et al., 1999; Allgaier et al., 2001).
So far, an association between virulence and the production of MRP and EF was only studied
for serotype 1 and 2 strains. Whether these proteins could be used as indicators of the virulence of
other S. suis serotypes remains to be established.
3.3.3 Suilysin
Jacobs et al. (1994) identified suilysin as a 54 kDa-protein which belongs to the family of thiol-
activated membrane damaging toxins. This family of toxins is known to act as virulence factors in
several gram-positive species. The gene encoding for S. suis suilysin has been cloned and
sequenced, and shows a high similarity with a gene encoding pneumolysin, a toxin produced by
Streptococcus pneumoniae (Segers et al., 1998). A role of suilysin in the disease process has been
suggested on the basis of its toxicity for HEp-2 larynx epithelial cells (Norton et al., 1999). This idea
was strengthened by the observation that an isogenic S. suis serotype 2 mutant, defective in
production of this toxin was avirulent in mice and seemed slightly attenuated in pigs (Allen et al.,
2001). The importance of suilysin in virulence however is still controversial, mainly because most
European clinical S. suis serotype 2 isolates are suilysin-positive, while in Canada production of this
protein appears to vary between such strains (Gottschalk et al., 1998; Segers et al., 1998).
Furthermore, the hemolysin does not seem to be produced by all virulent serotypes (Feder et al.,
1994; Jacobs et al., 1995; Segers et al., 1998; Allgaier et al., 2001). These results suggest the
existence of additional virulence factors.
3.3.4 Adhesins
Attachment of virulent bacteria to host cells is required to colonize host tissues. S. suis proteins
that act as adhesins have been described (Haataja et al., 1993; 1994). Hemagglutination inhibition
experiments with mono- and oligosaccharides and glycoproteins indicated that galactose-binding
strains of S. suis serotype 2 recognised the Galα1–4Gal sequence present on P1 and Pk blood group
erythrocytes (Haataja et al., 1993). Binding to frozen sections of pig pharyngeal tissue was inhibited
by free trihexosylceramide (GbO3), a glycolipid, which belongs to the P blood group antigen system
and represents the Pk antigen (Haataja et al., 1994). These data suggest that GbO3, which is
expressed in many pig and human tissues, serves as a binding site for galactose-binding strains of
S. suis serotype 2 (Haataja et al., 1993). The Galα1–4Gal binding adhesin has been purified from
S. suis (Tikkanen et al., 1995; Haataja et al., 1996). This adhesin was classified into two subtypes,
Pn and Po, based on differences in their binding capacity. The 18 kDa adhesin was detected by
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immunoblot analysis in all 23 S. suis strains examined, was highly immunogenic and showed
opsonizing activity (Tikkanen et al., 1995; 1996; Haataja et al., 1996). Purified adhesin retained its
hemagglutination activity and specificity for Galα1–4Gal (Tikkanen et al., 1995).
Ultrastructural study of the surface components of S. suis serotypes 1 to 8 and 1/2 revealed that
they possessed petrichious, thin, flexible fimbriae that varied in density and length from cell to cell
(Jacques et al., 1990). Agglutination of human erythrocytes was reported for some isolates of the
S. suis serotypes 1 to 8 and 1/2 (Kurl et al., 1989; Gottschalk et al., 1990). However,
morphologically similar fimbriae were observed on hemagglutinating as well as on
nonhemagglutinating strains of S. suis (Gottschalk et al., 1990). Therefore, the possible role of
fimbriae in hemagglutination remains unclear to be defined.
3.3.5 In vivo expression
All of the putative virulence factors of S. suis, described so far, have been identified after growth
in standard nutrient-rich media under laboratory conditions. However, it is known that bacteria
respond to the in vivo environment by altering their gene expression. Therefore, virulence factors,
specifically required for the infection process, are exclusively induced in vivo (Mahan et al., 1995).
Recently, the identification of environmentally regulated genes of S. suis by the use of iron-restricted
conditions in vitro and by experimental infection of piglets was described (Smith et al., 2001a).
Using an in vivo expression technology (IVET), a number of genes was identified that showed
homology with genes involved in virulence in other bacteria. One of the identified genes showed
similarity to the agrA gene of Staphylococcus aureus, a key locus involved in the regulation of
numerous virulence proteins. Another selected gene had homology to the gene encoding the
fibronectin binding protein of Streptococcus gordonii. However, their precise role in virulence needs
to be determined.
3.3.6 Other virulence factors
Binding activity of S. suis serotype 2 to albumin was observed for virulent as well as for avirulent
strains (Quessy et al., 1997). Western blot analysis revealed that a 39-kDa protein was responsible
for this activity. Furthermore, the addition of albumin to the culture broth resulted in an increase in
the virulence of S. suis strains in mice (Quessy et al., 1997).
A 60 kDa IgG binding protein (IBP) was observed in all serotypes of S. suis and all serotype 2
isolates originating from diseased or clinically healthy pigs (Serhir et al., 1993b; Benkirane et al.,
1998). This IBP showed some similarities with IBPs expressed by group A streptococci (Serhir et
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al., 1995). Little is known about the role of these proteins in group A streptococci, but it is
commonly believed that they act as virulence factors and contribute to the ability of group A
streptococci to establish infections (Lindahl and Stenberg, 1990; Stenberg et al., 1992). Further
analysis of the IBP, expressed by S. suis, suggested that this IBP was induced under conditions of
heat shock (Benkirane et al., 1998).
Recently, a gene encoding a 45-kDa glutamate dehydrogenase (GDH) from a virulent strain of
S. suis serotype 2 was cloned and characterized (Okwumabua et al., 2001). GDH has been shown
previously to be an important antigen for the diagnosis of infections caused by Clostridium difficile
(Lyerly et al., 1991). It has also been associated with the virulence of Clostridium botulinum
(Hammer and Johnson, 1988). It was found that the gene was conserved among the S. suis serotype
2 strains tested and that it belongs to the NAD(P)H-dependent GDH enzyme family, involved in
intermediary metabolism. The 45-kDa recombinant protein was antigenic and reacted with serum
of pigs experimentally infected with a virulent S. suis serotype 2 strain (Okwumabua et al., 2001).
Recently, an important virulence factor seemed to be identified by using a complementation
strategy (Smith et al., 2001b). From a virulent S. suis serotype 2 strain with the phenotype MRP+EF+
a DNA fragment was identified which, after introduction into a weakly-virulent strain (MRP+EF*),
increased the virulence of these strains considerably. The selected fragments encoded two putative
proteins, of which both could be responsible for the observed effect on virulence. Further research
is required to determine the role of these proteins in virulence.
4. Diagnosis and typing
4.1 Clinical cases
The diagnosis of S. suis in herds with cases of clinical disease is usually confirmed by the
isolation of the infectious agent in pure culture and its specific identification by serological tests.
S. suis could be isolated from cerebrospinal and synovial fluid, from brain, heart, and lung tissues,
and from abdominal and thoracic cavities (Staats et al., 1997). S. suis grows on blood agar plates,
that are incubated aerobically overnight at 37°C. Typical mucoid grey/white colonies are surrounded
by zones of partial hemolysis on calf or sheep blood agar and complete, or almost complete,
hemolysis on horse blood agar. Growth and hemolysis are enhanced when organisms were cultured
anaerobically. Commercially available galleries of biochemical tests identified most (90%) but not
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all of the S. suis strains (Hommez et al., 1986). As proposed by Devriese et al. (1991) streptococcal
strains could be identified biochemically as S. suis on the basis of their ability to produce amylase
but not acetoin.
Serological typing of the isolated S. suis strains requires the demonstration of the type-specific
polysaccharide capsular antigens by using a panel of specific hyperimmune sera (Vecht et al., 1985).
For serotyping a slide agglutination test appears to be a reliable method (Vecht et al., 1985).
4.2 Subclinical cases
S. suis strains may be endemic in some herds without causing any clinical signs (Clifton Hadley
et al., 1984a). This non-symptomatic carriership can be identified by detecting the agent in tonsillar
specimens via classical microbiological techniques. However, tonsils may also be colonized by
avirulent S. suis strains and other streptococcal species, which are difficult to distinguish on the
basis of colony morphology only. This makes such a method laborious and time-consuming.
To address this problem, various methods have been developed to selectively isolate or detect
serotype 2 strains from carrier animals (Arends et al., 1984; Clifton Hadley et al., 1984a; Van
Leengoed et al., 1987; Robertson and Blackmore, 1989; Davies and Ossowicz, 1991; Monter Flores
et al., 1993). These methods include isolation using a selective medium containing antibodies
against S. suis serotype 2. On these media, colonies of S. suis serotype 2 showed distinct haloes of
immunoprecipitation. However, high amounts of antibodies were needed and cross-reactions with
other serotypes complicated the diagnosis (Clifton Hadley et al., 1986b; Moreau et al., 1989; Davies
and Ossowicz, 1991).
Another method for the serotype-specific isolation from clinical specimens is an immunocapture
procedure (Gottschalk et al., 1999). In this assay, immunomagnetic beads are coated with a
monoclonal antibody (MAb) directed against a capsular sialic acid-containing epitope. This method
was successfully applied to selectively isolate S. suis serotype 2 and 1/2 strains.
An indirect fluorescence test on smears of tonsillar tissues has also been used for the detection
of S. suis serotype 2 (Hunt and Edwards, 1982; Arends et al., 1984; Davies and Ossowicz, 1991;
Paterson et al., 1993). However, due to cross reactivity with other organisms, the specificity of this
test was low (Clifton Hadley et al., 1986b; 1988; Davies and Ossowicz, 1991).
In addition, Serhir et al (1993a), developed an ELISA for detecting S. suis serotypes directly in
tissue samples. However, this ELISA showed a low sensitivity and results did not concur with
culture results. Although detection and identification of S. suis serotype 1, 2, 1/2, 3 and 22 from pure
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cultures was achieved, differentiation between serotypes 2 and 1/2 was not possible with this
ELISA.
To overcome these limitations, further research needs to be done to develop sensitive and reliable
tests for direct detection not only of virulent serotype 2 strains but also of virulent S. suis strains
belonging to other serotypes. One possible method to achieve this goal is PCR detection of serotype-
specific DNA. To date no PCR is used routinely to detect S. suis strains in tonsillar specimens. A
rapid method has been described for isolating bacterial DNA suitable for use in PCR (Reek et al.,
1995). This method was based on the guanidine thiocyanate (GuSCN)-lysis method of Boom et al
(1990) and was carried out in a 96-well microplate format allowing large scale application.
Recently, serotype-specific PCR assays for the detection of S. suis serotypes 1 (and 14), 2 (and 1/2),
7 and 9 in tonsillar specimens of pigs were developed (Smith et al., 1999b; 1999c). However, before
these PCR assays can be applicated in the field, these tests need to be optimized for sensitivity and
evaluated for specificity. Moreover, for a more convenient application in routine diagnostics, a
multiplex PCR-based approach is preferable. To detect also virulent S. suis serotype 2 strains and
highly virulent serotype 1 strains, a PCR, based on the sequence encoding the epf gene, could be
developed and subsequently included in the multiplex PCR.
4.3 Serology
So far, results obtained with tests based on the detection of antibodies have been disappointing.
Screening of sera from pigs of infected and non-infected herds by ELISAs gave low titers and
animals from infected and non-infected herds could not be distinguished by this assay (Clifton
Hadley et al., 1984b; Del Campo Sepulveda et al., 1996). Similar disappointing results were
obtained when CPS was used as antigen instead of whole cells of S. suis serotype 2 (Clifton Hadley
et al., 1984b; Blouin et al., 1994; Del Campo Sepulveda et al., 1996; Kataoka et al., 1996). The
results cast doubt on the specificity of serological tests and their possible value for determining the
S. suis serotype 2 infection status in a herd.
5. Immunization
5.1 Whole cell vaccines
At present, no effective vaccine is available that protects against S. suis infections in pigs. This
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is in part due to the multitude of capsular serotypes and subtypes (Vecht et al., 1996). Current
commercial vaccines are still primarily based on formalin-killed whole cell preparations that prevent
clinical disease but do not eliminate local tissue invasion or carriership (Holt et al., 1988; 1990).
Vaccination with live virulent and avirulent S. suis serotype 2 strains appears to confer good
protection in pigs, but this requires repeated immunizations (Holt et al., 1988; Busque et al., 1997).
Although the results with these vaccines are promising, their efficacy has only been evaluated after
a homologous serotype 2 challenge. At this time, it is not known whether whole cell vaccines can
elicit cross-protective immunity against S. suis.
Efficacy  studies in mice with live attenuated vaccines indicated that protection is probably
serotype-specific. The potential of temperature-sensitive mutants of S. suis serotypes 1/2, 1, 2 and
3 as vaccines was evaluated in mice (Kebede et al., 1990). All mutant strains provided protection
against challenge with a strain of homologous serotypes except for the S. suis serotype 1/2 mutant
which provided protection to challenge with serotypes 1 and 2 strains (Kebede et al., 1990). A
streptomycin-dependant mutant of S. suis serotype 1/2 was also tested as a vaccine. Homologous
and heterologous trials in mice resulted in complete protection against challenge with S. suis
serotypes 1 and 1/2 (Foster et al., 1994). However, only partial protection was observed against
challenge with S. suis serotype 2 strains. The results of these experiments should be interpreted with
caution as it has been demonstrated that murine models have only limited value for studying S. suis
infections (Vecht et al., 1997b). The protective efficacy of both the streptomycin-dependant mutant
and the temperature-sensitive mutant vaccine in pigs await further study.
5.2 Subunit vaccines
Little is known about antigens of S. suis which can be used in the development of subunit
vaccines. To obtain a broad protection, protective antigens that are conserved among serotypes need
to be identified. Jacobs et al. (1996) showed that a subunit vaccine based on purified suilysin
efficiently protected pigs against challenge with virulent S. suis serotype 2 strains. However, the
absence of suilysin in a substantial number of isolates recovered from diseased pigs limits the value
of this vaccine (Segers et al., 1998).
Attractive candidate antigens for use in a subunit vaccine are also the 136-kDa MRP protein and
the 110-kDa EF protein described above. Both antigens are recognised by convalescent sera of pigs
infected with virulent serotype 2 strains (Vecht et al., 1991). Further work needs to be done to
determine if MRP and EF can elicit protection against S. suis infections.
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In many bacteria with a polysaccharide capsule, antibodies directed against CPS are protective
against infection. The ability of CPS of S. suis serotype 2 to protect against infections is not well
established. Previous attempts to elicit an immune response in pigs by vaccination with purified
CPS have not been successful (Elliott et al., 1980). Only when CPS was used in combination with
Freund’s incomplete adjuvant, opsonising antibodies were observed against S. suis serotype 2
(Elliott et al., 1980). The protective efficacy of these antibodies has not been tested yet. Antibody
responses against CPS are probably not essential for full protection: Del Campo Sepulveda and
colleagues (1996) found that re-challenged pigs were completely protected against an experimental
S. suis infection even when CPS-specific antibody levels were very low. Furthermore, heat-killed
organisms have been demonstrated to elicit CPS-specific opsonic antibodies, yet failed to provide
protection against a homologous challenge with S. suis (Holt et al., 1990) suggesting that possibly
antibodies against heat-sensitive antigens are important to confer protection.
5.3 Passive and maternal immunity
Early studies showed that transfer of serum from convalescent pigs afforded complete protection
against subsequent S. suis serotype 2 infection (Elliott et al., 1966). Protection could also be
passively transferred to susceptible pigs by the inoculation of sera from pigs repeatedly
intravenously injected with live virulent S. suis serotype 2 strains (Holt et al., 1988). This indicates
that humoral immunity plays an important role in S. suis infections.
Potential protective components for a S. suis serotype 2 vaccine were identified in Western blot
analysis of different fractions of S. suis serotype 2, using sera from immune and non-immune pigs
(Holt et al., 1989; 1990). Six major surface antigens of 44, 78, 86, 94, 130 and 136 kDa were
identified (Holt et al., 1990). It was found that rabbit sera against the 94 kDa band protected mice
against challenge with a virulent strain of S. suis serotype 2 (Holt et al., 1990). However, the serum
raised against the 78 kDa protein inhibited the protective effect of the 94 kDa antiserum. Rabbit sera
raised against the 44 and 86 kDa proteins were tested negative with bactericidal tests for the
presence of opsonic antibodies to S. suis serotype 2 and none of these proteins was protective for
mice (Holt et al., 1990). However, differences between pig, rabbit and mouse IgG responses to S.
suis serotype 2 proteins showed that one must be careful in the interpretation of passive
immunization assays, since one protein may be immunogenic in one animal species but not in
another (Quessy et al., 1994). Moreover, whether the above described proteins, especially the 78 and
94 kDa proteins, were major surface antigens in serotypes other than serotype 2 was not reported.
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It would be of interest to test if these proteins contribute to protection against S. suis infections.
Maternal antibodies against S. suis serotype 2 can be transferred from vaccinated sows to their
piglets. However, sows responded poorly or not at all to vaccination with whole cell vaccines and
a good protection of their piglets was only obtained when titers of maternal antibodies reached a
certain level (Blouin et al., 1994). Amass et al. (2000) showed that sows, immunized with a S. suis
serotype 14 bacterin, provided only a partial protection against a homologous challenge in their
offspring. Maternal antibodies were presumable responsible for this protection.
6. Scope and outline of the thesis
At the start of the studies described in this thesis, several virulence-associated markers which
may have the potential to discriminate between virulent from less virulent or avirulent S. suis
isolates had been identified. These markers included CPS (Smith et al., 1999a), MRP and EF (Vecht
et al., 1991). The aim of the investigations described in this thesis was to test whether the described
markers could serve as the basis for diagnostic assays to detect S. suis infections and/or as antigens
to protect against the disease.
In previous work, MRP and EF were identified as markers of virulence in serotype 1 and 2
strains. In other serotypes the production of MRP and EF, and their potential importance for
bacterial virulence has not been investigated. Therefore, we started with determination of the
serotypes as well as MRP and EF phenotypes for a collection of S. suis strains isolated from
diseased pigs in seven European countries (Chapter 2). For the rapid and sensitive detection of pigs
carrying specific serotypes and virulence-associated phenotypes of S. suis, we developed PCR
methods including a PCR to detect virulent strains of S. suis type 2 and highly virulent strains of S.
suis type 1 in tonsillar specimens of pigs. This PCR was based on amplification of a fragment of the
epf gene encoding EF. The test was evaluated by comparing the results with those of a bacterial
examination of tonsillar specimens collected from pigs of herds known to be infected with S. suis
type 2 and herds without a S. suis history (Chapter 3). For the detection of pigs carrying strains
belonging to the most common isolated virulent serotypes and virulent-associated phenotypes,
multiplex PCR asays were developed. These assays were validated by comparing results with those
of bacterial examination of tonsillar specimens from pigs infected with S. suis strains of various
serotypes (Chapter 4).
For the development of protective vaccines, the efficacy of a MRP and EF vaccine applied in
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pigs challenged either with a homologous or heterologous S. suis serotype 2 strain (MRP+EF+) was
compared with the efficacy of a vaccine containing formalin-killed bacterin of S. suis serotype 2
(MRP+EF+). The effects of different adjuvants and their side-effects were also studied (Chapter 5).
Finally, in addition to the MRP and EF vaccines, we compared the efficacy of live and killed
vaccines based on a non-encapsulated mutant of S. suis serotype 2 in pigs with that of the parental
encapsulated strain (Chapter 6). All results and their contribution to the control of S. suis infections
were put in perspective in Chapter 7.
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Abstract
Streptococcus suis strains (n=411), isolated from diseased pigs in seven European countries were
serotyped using specific antisera against serotype 1 to 28, and were phenotyped on the basis of their
muramidase-released protein (MRP) and extracellular-factor protein (EF) production. Overall, S.
suis serotype 2 appeared to be most prevalent (32%), followed by serotype 9 (20%) and serotype
1 (12%). Serotype 2 was most frequently isolated in France, Italy and Spain, whereas serotype 9 was
most frequently isolated in Belgium, the Netherlands and Germany. In the United Kingdom
serotypes 1 and 14 were most frequently isolated. High percentages of S. suis serotype 1, 2, 1/2 and
14 strains, isolated from tissues associated with S. suis infections such as brain, serosae, joint, heart
and organs expressed the EF-protein, indicating that in these serotypes expression of EF is likely
to be associated with virulence. In contrast, strains belonging to serotype 7 and 9, isolated from
tissues associated with S. suis infections did not produce EF. These results strongly suggest that in
the serotypes 7 and 9 EF expression is not related to virulence. More than 80% of the S. suis
serotype 9 strains produced an MRP* protein, a high molecular variant of the 136-kDa MRP.
Expression of MRP* in serotype 9 strains is possibly associated with virulence.
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1. Introduction
Streptococcus suis is a pathogen responsible for a variety of infections in pigs such as meningitis,
arthritis, endocarditis, septicaemia and bronchopneumonia (Higgins et al. 1992; Kataoka et al. 1993;
Reams et al., 1994; Vecht et al., 1985). The economic impact of S. suis infections for the swine
industry is substantial (Chengappa et al., 1990). The prophylactic use of antibiotics in food and
drinking water has been unsuccessful in controlling the disease. Antibiotics are becoming less
effective because of an increase in resistance among S. suis isolates (Aarestrup et al., 1998b) and
are less accepted because of the public awareness of antimicrobial residues. In addition, the
development of effective vaccines is hindered by the number of virulent serotypes, by the lack of
knowledge of virulence factors and by differences in virulence not only among serotypes but also
within serotypes of S. suis.
So far, 35 serotypes of S. suis based on capsular antigens are described (Perch et al., 1983,
Gottschalk et al., 1989, 1991, Higgins et al., 1995). Worldwide S. suis serotype 2 is the most
frequently isolated serotype. However, the distribution varies with region and can change over time.
In Australia and the Netherlands, S. suis serotype 9 is most frequently isolated from diseased pigs,
whereas serotype 7 is the most prevalent serotype in Finland (Sihovenen et al., 1988; Gogolewski
et al., 1990; Jacobs et al., 1995). In Denmark, serotype 7 was 15 years ago the most common
serotype causing infections among diseased pigs. Recently, serotype 2 was most frequently isolated
in this country (Perch et al., 1983; Aarestrup et al., 1998a). In Scotland, serotype 14 was most
frequently isolated from diseased pigs (MacLennan et al., 1996).
Virulence can differ among various strains of S. suis. In our earlier work we showed that in S.
suis serotype 2 a correlation exists between the production of muramidase-released protein (MRP)
and extracellular-factor protein (EF) and virulence for pigs (Vecht et al., 1992). MRP+EF+ serotype
2 strains were mainly isolated from diseased pigs and are virulent for pigs. In contrast, MRP–EF–
serotype 2 strains were mainly isolated from the tonsils of healthy pigs and are nonvirulent.
MRP+EF* serotype 2 strains produce high molecular weight variants of EF and are weakly virulent
for young pigs.
Serotype 1 strains can also produce MRP and EF. Highly virulent S. suis serotype 1 strains
produced a 120 kDa-variant of MRP (MRPs) as well as EF. Serotype 1 strains that do not produce
MRP and EF appeared to be less virulent for young piglets, but were still capable of inducing illness
with the specific symptoms (Stockhofe-Zurwieden et al., 1996).
Different variants of the MRP-protein in S. suis serotype 2 strains were described (Vecht et al.,
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1991; Galina et al., 1996). Enlarged or reduced forms of MRP, respectively called MRP* (MW >
136kDa) and MRPs (MW < 136kDa) can compose phenotypes as MRP*EF–, MRPsEF–, MRP–EF*
and MRP+EF*. So far, the virulence of these strains has not been tested in animal models.
Although there is a strong correlation between MRP and EF and virulence, these proteins are
dispensable for causing disease. Isogenic mutants of S. suis serotype 1 and 2 impaired in expression
of MRP and EF were as virulent for pigs as the parent strains (Smith et al., 1996). Moreover, most
of the S. suis serotype 2 strains, isolated from diseased pigs in Canada, do not produce MRP and EF
(Gottschalk et al., 1998). Nevertheless, most of the S. suis serotype 2 strains isolated in America,
Austria, Germany and Spain showed the MRP+EF+ phenotype. (Awad-Masalmeh et al., 1999;
Galina et al., 1996; Luque et al., 1999; Salasia and Lämmler, 1995).
In serotypes other than serotypes 1 and 2 the production of MRP and EF, and a possible
correlation of their production with virulence, is unknown. Therefore, we performed serotyping and
we determined the production of MRP and EF of S. suis strains isolated from diseased pigs in seven
European countries. It has been suggested that S. suis is not a primary cause of pneumonia and
strains isolated from lungs may be less virulent than strains isolated from organs as brains, serosae,
heart and joints (Reams et al., 1995; Hoefling et al., 1998). Therefore, we compared the relationship
between MRP/EF phenotypes, serotypes of strains and their sites of isolation.
2. Materials and methods
2.1 S. suis isolates.
Four hundred and eleven strains of S. suis were obtained from seven European countries:
Belgium, UK, France, Italy, Germany, Spain and the Netherlands (Table 1). Strains were isolated
in the course of routine diagnostic procedures from tissues of diseased pigs.
Strains were kindly provided by Ing. J. Hommez, Provinciaal Verbond voor Dierenziekten-
bestrijding van West-Vlaanderen, Belgium; Dr. P. Heath, Veterinary Investigation Centre, Suffolk,
UK; Dr. H. Morvan, Laboratoire de Développement et d'Analyses, Ploufragan, France; Prof. Dr. V.
Sala, Institute of Infectious Diseases, Milan, Italy; Prof. Dr. G. Amtsberg, Institut für Mikrobiologie
und Tierseuchen, Tierärztliche Hochschule Hannover, Germany; Dr. M. Ganter, Außenstelle für
Epidemiologie der Tierärztliche Hochschule Hannover, Bakum, Germany; Prof. Dr. Ch. Lämmler,
Justus-Liebig Universität Giessen, Germany; Carmen Terradas Iglesias, Facultad de Veterinaria,
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Universidad de Cordoba, Spain. Dutch S. suis strains were isolated from diseased pigs at the Animal
Health Service, Boxtel. If known, the site of isolation and the age of the pigs were recorded.
Table 1
S. suis strains isolated from diseased pigs
Country Number of strains Period of isolation
Belgium 60 1994–1996
France 51 1994–1997
Germany 48 1997
Italy 48 unknown
Netherlands 78 1996
Spain 47 1991–1995
United Kingdom 79 1987–1996
2.2 Culture conditions and typing
A 1-day-old colony of each strain, grown on Columbia blood agar base (code CM 331; Oxoid,
Ltd., Inc., Columbia, Md) containing 6% horse blood, was incubated overnight at 37°C in Todd
Hewitt broth (code CM 189; Oxoid). Cultures were centrifuged at 4,000 g for 15 min. Aliquots of
the supernatants were stored at –20°C until use. All strains were typed as S. suis by biochemical
methods (Devriese et al., 1991). Serotyping was performed by slide agglutination with specific
rabbit antisera (ID-Lelystad) against the reference strains of serotypes 1 to 28 as described by
Gottschalk et al. (1993).
2.3 SDS-PAGE and Western blot analysis
Supernatants were analysed by using sodium dodecyl sulfate-polyacrylamide gel electrophoresis
as described by Laemmli (1970). Separating gels contained 6% polyacrylamide, stacking gels 4%.
After electrophoresis proteins were transferred to nitrocellulose filters by using a Multiphor II Nova
Blot system according to the recommendations of the manufacturer (Pharmacia LKB, Uppsala,
Sweden). The blots were either incubated with a 1:200 dilution of monoclonal antibodies against
MRP or EF (Vecht et al., 1992). After washing, bound mouse antibodies were visualized with a
1:1,000 dilution of rabbit-anti-mouse globulins conjugated to alkaline phosphatase (Zymed
laboratories, Inc., San Francisco, Calif.) and bromochloroindolyl phosphate (Sigma, St. Louis, Mo)
- Nitro Blue Tetrazolium (Merck, Darmstad, Germany) in phosphatase buffer (100 mM NaCl, 5 mM
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MgCl2, 100 mM diethanolamine [pH 9.5]) as substrate solution.
3. Results
3.1 Serotypes
Overall, most of the strains belonged to the serotypes 1/2, 1, 2, 3, 4, 5, 6, 7, 8, 9 and 14 (88%).
Thirty-seven strains were non-typable, 13 of these strains were polyagglutinable, 14
autoagglutinable and 10 strains could not be classified with the 28 antisera used (Table 2).
Table 2
Capsular serotypes of S. suis strains isolated from diseased pigs
Serotype No. (%) of strains isolated in
Belgium France Germany Italy Netherlands Spain United
Kingdom
Total
1 6 (10) 7 (15) 3 (4) 4 (9) 30 (38) 50 (12)
2 10 (16) 30 (59) 5 (10) 13 (27) 22 (28) 24 (51) 28 (35) 132 (32)
1/2 2 (3) 3 (6) 4 (8) 2 (3) 4 (9) 1 (1) 16 (4)
3 1 (2) 8 (17) 2 (4) 2 (4) 13 (3)
4 4 (8) 5 (10) 5 (10) 14 (3)
5 3 (6) 1 (2) 4 (1)
7 5 (8) 6 (12) 5 (10) 2 (4) 3 (4) 1 (2) 1 (1) 23 (6)
8 4 (7) 4 (8) 1 (2) 1 (2) 1 (2) 11 (3)
9 14 (23) 6 (12) 9 (19) 7 (15) 45 (58) 2 (4) 1 (1) 84 (20)
10 1 (2) 1 (1) 2 (1)
12 1 (2) 1 (0)
14 13 (17) 13 (3)
15 1 (1) 1 (0)
16 1 (2) 1 (0)
22 2 (3) 3 (4) 5 (1)
25 2 (3) 1 (2) 1 (2) 4 (1)
NT 13 (22) 1 (2) 7 (14) 6 (13) 7 (15) 3 (4) 37 (9)
Total 60 51 48 48 78 47 79 411
NT: Not typable isolates
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S. suis serotypes 2 (32%), 9 (20%) and 1 (12%) were most frequently isolated in the seven
European countries (Table 2). S. suis serotype 2 was most prevalent in France, Italy and Spain, while
serotype 9 was most prevalent in the Netherlands, Germany and Belgium. In the UK S. suis serotype
1 was most prevalent (38%) followed by serotype 2 (35%). S. suis serotype 14 strains were
exclusively isolated in the UK.
3.2 Serotypes and sites of isolation
 Sixty-six per cent of the strains was isolated from tissues typically affected by S. suis (brains,
serosae, heart, joints and parenchymateus organs like liver, kidney or spleen) while twenty per cent
of the strains was isolated from lungs (Table 3). Seven per cent of the strains was isolated from
Table 3
S. suis strains isolated from diseased pigs: serotypes and sites of isolation.
Serotype No. (%) of strains isolated from
Typical S. suis
tissuesa
Lung Other b Unknown Total
1 47 (94) 1 (2) 2 (4) 0 (0) 50
2 101 (77) 18 (14) 6 (4) 7 (5) 132
1/2 8 (50) 8 (50) 0 (0) 0 (0) 16
3 1 (8) 12 (92) 0 (0) 0 (0) 13
4 1 (7) 5 (36) 4 (29) 4 (29) 14
5 0 (0) 4 (100) 0 (0) 0 (0) 4
7 6 (26) 7 (30) 3 (13) 7 (30) 23
8 1 (8) 4 (33) 2 (17) 5 (42) 12
9 62 (74) 9 (11) 8 (10) 5 (6) 84
10 1 (50) 1 (50) 0 (0) 0 (0) 2
12 1 (100) 0 (0) 0 (0) 0 (0) 1
14 13 (100) 0 (0) 0 (0) 0 (0) 13
15 1 (100) 0 (0) 0 (0) 0 (0) 1
16 0 (0) 1 (100) 0 (0) 0 (0) 1
22 5 (100) 0 (0) 0 (0) 0 (0) 5
25 1 (25) 3 (75) 0 (0) 0 (0) 4
NT 22 (61) 10 (28) 4 (11) 0 (0) 36
Total 271 (66) 83 (20) 29 (7) 28 (7) 411
a brains, serosae, heart, joints, parenchymatous organs (liver, kidney, spleen)
b miscellaneous tissues as tonsils, lymph nodes, urinary tract, skin, trachea, nose, vagina, cervix or intestines
NT: Not typable isolates
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miscellaneous tissues such as tonsils, lymph nodes, urinary tract, skin, trachea, nose, vagina, cervix
and intestines. For seven per cent of the strains the site of isolation was unknown.
S. suis serotype 1, 2, 9, 14 and 22 strains were most frequently isolated from tissues commonly
involved in clinical disease, while serotype 3, 4, 5, 8 and 25 strains were mostly isolated from lungs.
Serotype 1/2 and 7 strains were isolated in similar proportions from both tissues typically affected
by S. suis and lungs.
Most of the strains isolated from tissues typically affected by S. suis were from brains (58%),
followed by joints (12% ) and organs: liver, kidney or spleen (8%) (results not shown). Compared
to serotype 2 and 9 strains, serotype 1 and 14 strains were more frequently isolated from the joints
(22% and 29% for serotypes 1 and 14 compared to 8 and to 10% for serotypes 2 and 9, respectively).
S. suis serotype 1/2 was as frequently isolated from brains as from organs (44% each).
3.3 Serotypes and age
The age of the pigs was known for 135 of the strains and varied between 0.5 and 20 weeks. Most
pigs (92%) were less then 10 weeks old (Table 4).
S. suis serotype 1 strains were predominantly isolated from 3-week-old pigs, while serotype 2,
7, 9 and 14 strains were mainly isolated from 6- to 8-week-old pigs. Serotype 22 strains were mainly
Table 4
S. suis strains isolated from diseased pigs: serotypes and age of pigs
Age (no. of weeks) of pigsSerotype No. of strains
Minimum Mean ± SD Median Maximum
1 29 0.5 3.8 ± 5.1 3 21
2 42 2 8.0 ± 3.6 8 18
1/2 2 7 8.5 ± 2.1 –a 10
7 4 4 8.0 ± 5.5 6 16
9 43 1 6.3 ± 1.9 7 9
10 1 6 – – 6
14 6 2.5 7.3 ± 4.3 6.5 14
22 4 1.5 4.6 ± 2.8 5 7
NT 4 5 10.8 ± 6.5 9 20
All 135 0.5 6.7 ± 3.9 6 21
a Not enough observations
NT: Not typable isolates
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isolated from 4.5-week-old pigs, serotype 1/2 strains from 8.5-week-old pigs and non-typable strains
from 10.8-week-old pigs.
3.4 Serotypes and phenotypes
MRP and EF phenotypes of the S. suis strains were determined by Western blot analysis using
monoclonal antibodies directed against MRP or EF. A high percentage of the serotype 1, 2 and 14
strains showed an EF-positive phenotype, either MRP+EF+, MRPsEF+ or MRP–EF+. (Table 5).
Among serotypes 1 and 1/2 EF*-producing strains were found. EF-negative strains (MRP*EF–,
MRPsEF– or MRP–EF–) were found in nearly all serotypes. Variants of MRP (MRP* or MRPs) were
found in nearly all serotypes. A high percentage (81%) of the serotype 9 strains belonged to the
MRP*EF– phenotype (Table 5).
Table 5
S. suis strains isolated from diseased pigs: serotypes and MRP/EF phenotypes
No. (%) of strains with phenotypeSerotype
MRP+EF+
MRPsEF+
MRP–EF+
MRP+EF*
MRPsEF*
MRP*EF–
MRPsEF–
MRP–EF– Total
1 33 (66) 2 (4) 3 (6) 12 (24) 50
2 91 (71) 0 (0) 32 (25) 6 (4) 129
1/2 3 (20) 4 (27) 6 (40) 2 (13) 15
3 0 (0) 0 (0) 4 (31) 9 (69) 13
4 0 (0) 0 (0) 3 (21) 11 (79) 14
5 0 (0) 0 (0) 1 (25) 3 (75) 4
7 0 (0) 0 (0) 1 (4) 22 (96) 23
8 0 (0) 0 (0) 1 (9) 10 (91) 11
9 0 (0) 0 (0) 68 (81) 16 (19) 84
10 0 (0) 0 (0) 1 (50) 1 (50) 2
12 0 (0) 0 (0) 0 (0) 1 (100) 1
14 11 (85) 0 (0) 1 (8) 1 (8) 13
15 1 (100) 0 (0) 0 (0) 0 (0) 1
16 0 (0) 0 (0) 1 (100) 0 (0) 1
22 0 (0) 0 (0) 1 (20) 4 (80) 5
25 0 (0) 0 (0) 0 (0) 4 (100) 4
NT 2 (5) 0 (0) 11 (30) 24 (65) 37
MRP+ = 136 kDa MRP; MRPs = lower molecular weight variant of MRP; MRP* = higher molecular weight variant of
MRP; EF+ = 110 kDa EF; EF* = higher molecular weight variant of EF
NT: Not typable isolates
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Table 6
S. suis strains isolated from diseased pigs: serotypes, MRP/EF phenotypesa and site of isolation
No. of strains with phenotypeSerotype
MRP+EF+
MRPsEF+
MRP–EF+
MRP+EF*
MRPsEF*
MRP*EF–
MRPsEF–
MRP–EF– Total
S. suis strains isolated from brains, serosae, heart, joints or organs:
1 32 (70) 2 (4) 3 (7) 9 (20) 46
2 76 (79) 0 (0) 15 (16) 5 (5) 96
1/2 3 (43) 3 (43) 1 (14) 0 (0) 7
3 0 (0) 0 (0) 1 (100) 0 (0) 1
4 0 (0) 0 (0) 0 (0) 1 (100) 1
7 0 (0) 0 (0) 0 (0) 6 (100) 6
8 0 (0) 0 (0) 0 (0) 1 (100) 1
9 0 (0) 0 (0) 50 (83) 10 (16) 60
10 0 (0) 0 (0) 0 (0) 1 (100) 1
12 0 (0) 0 (0) 0 (0) 1 (100) 1
14 11 (85) 0 (0) 1 (8) 1 (8) 13
15 1 (100) 0 (0) 0 (0) 0 (0) 1
22 0 (0) 0 (0) 1 (20) 4 (80) 5
25 0 (0) 0 (0) 0 (0) 1 (100) 1
NT 2 (9) 0 (0) 6 (27) 14 (64) 22
S. suis strains isolated from lungs:
1 0 (0) 0 (0) 0 (0) 1 (100) 1
2 9 (45) 0 (0) 11 (55) 0 (0) 20
1/2 0 (0) 1 (13) 5 (63) 2 (25) 8
3 0 (0) 0 (0) 3 (25) 9 (75) 12
4 0 (0) 0 (0) 2 (40) 3 (60) 5
5 0 (0) 0 (0) 1 (25) 3 (75) 4
7 0 (0) 0 (0) 0 (0) 7 (100) 7
8 0 (0) 0 (0) 1 (25) 5 (75) 4
9 0 (0) 0 (0) 8 (89) 1 (11) 9
10 0 (0) 0 (0) 1 (100) 0 (0) 1
16 0 (0) 0 (0) 1 (100) 0 (0) 1
25 0 (0) 0 (0) 0 (0) 3 (100) 3
NT 0 (0) 0 (0) 2 (20) 6 (80) 10
MRP+ = 136 kDa MRP; MRPs = lower molecular weight variant of MRP; MRP* = higher molecular weight variant of
MRP; EF+ = 110 kDa EF; EF* = higher molecular weight variant of EF
NT: Not typable isolates
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3.5 Serotypes, phenotypes and sites of isolation
S. suis serotype 2 strains which belonged to an EF-positive phenotype (either MRP+EF+,
MRPsEF+ or MRP–EF+) were frequently isolated from tissues typical for a S. suis infection (Table
6). The same results were obtained for serotype 1, 1/2 and 14 strains, isolated from tissues typically
affected by S. suis. Most of these strains had a MRP+EF+, MRPsEF+ or MRP–EF+ phenotype,
suggesting that also in these serotypes expression of EF seemed to be associated with virulence.
Different results were obtained for serotype 9 strains. Although serotype 9 strains were frequently
isolated from tissues typically affected by S. suis none of these strains produced EF. More than 80%
of the serotype 9 strains had a MRP*EF– phenotype, irrespective their site of isolation.
None of the serotype 7 strains, neither isolated from tissues associated with S. suis infections nor
isolated from lungs, produced EF. Therefore EF seemed not to be important in serotype 7 strains.
4. Discussion
We previously showed that a high percentage of virulent S. suis serotype 2 strains produce MRP
and EF (Vecht et al., 1991). In the present study we determined the serotypes and MRP/EF
phenotypes of a considerable number of S. suis strains isolated from diseased pigs in seven
European countries. It appeared that high percentages of S. suis serotype 1, 2, 1/2 and 14 strains
isolated from typical S. suis tissues (brains, serosae, joints, heart) or parenchymatous organs (liver,
kidney, spleen) of diseased pigs expressed EF, indicating that in these serotypes expression of EF
(either with or without MRP) is possibly associated with virulence. In contrast, a high percentage
of strains of serotypes 7 and 9, isolated from tissues typically affected by S. suis showed EF-negative
phenotypes (either with or without MRP). This suggests that in serotype 7 and 9 strains expression
of EF is not associated with virulence. Remarkably however, more than 80% of all S. suis serotype
9 strains produced a MRP* protein (higher molecular weight variant of the 136-kDa MRP). This
could suggest that in serotype 9 strains expression of MRP* is associated with virulence. Whether
MRP*EF– and MRP–EF– strains of serotype 9 differ in virulence has to be determined in an
experimental animal model. Among the 23 strains of serotype 7 investigated, only one produced an
MRP* protein. This suggests that expression of MRP in serotype 7 strains is not related to virulence.
No differences in phenotypes of S. suis serotype 2 were observed between strains isolated from
the seven European countries, suggesting that in Europe the production of MRP and EF is associated
with virulent strains of S. suis serotype 2. These results are in agreement with previous findings in
Australia, Europe and the United States (Vecht et al., 1991; Mwaniki et al., 1994; Salasia and
Lämmler 1995; Galina et al., 1996; Luque et al., 1999). In Canada, however, a correlation between
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the production of MRP, EF and virulence of S. suis serotype 2 strains was not found (Gottschalk et
al., 1998). None of the Canadian strains isolated from diseased pigs had an MRP+EF+ phenotype.
In this study, serotype 2 appeared to be the most prevalent serotype within the strains collected.
Moreover, not all serotypes seemed equally important in the various countries. Serotype 2 was the
most frequently isolated serotype in France, Italy and Spain. Earlier, serotype 2 was shown to be the
most frequently isolated serotype in Belgium, the Netherlands and Germany (Vecht et al., 1985;
Hommez et al., 1986; Estoepangestie et al., 1993). However, here we have shown that the
prevalence of serotype 9 increased in these countries during the last few years. In the Netherlands,
an increase in the number of serotype 9 strains has also been earlier reported (Jacobs et al., 1995).
Prior to these studies, S. suis serotype 9 was only shown to be a problem in Australia, where it was
recovered in high percentages from outbreaks of septicaemia and meningitis in weaned pigs
(Gogolewski et al., 1990).
Beside S. suis serotype 2 strains, serotype 1 and 14 strains were frequently isolated in the UK.
In fact, all S. suis serotype 14 strains were isolated from pigs in the UK. Because a one-way capsular
cross-reaction exists between S. suis serotypes 1 and 14 strains (Gottschalk et al., 1989) we assume
that these strains are closely related. A close relationship between serotype 1 and 14 strains could
be supported by our observation that all serotype 14 strains and almost 70% of the serotype 1 strains
isolated in the UK had the MRPsEF+ phenotype. Interestingly, three out of the four S. suis serotype
2 strains, which were isolated in the UK, had this characteristic MRPsEF+ phenotype. This is
suggestive for a clonal relationship between the serotype 1, 2 and 14 strains with the MRPsEF+
phenotype. Interestingly, the age distribution of pigs affected by S. suis serotype 1 and 14 strains
differed considerably. Serotype 1 strains were usually seen in 3-week-old pigs while serotype 14
strains were mostly isolated from 6.5-week-old pigs. Molecular fingerprinting experiments have to
be performed to study the genetic relation between the serotype 1, 2 and 14 strains with the
MRPsEF+ phenotype further.
In this study, S. suis strains were isolated from pigs until 21 weeks of age. As reported
previously, S. suis serotype 1 is mostly isolated from pigs at the age of 3 weeks while the strains of
the other serotypes were mostly isolated from 7- to 8-week-old pigs (Reams et al., 1994).
In summary, S. suis serotype 2 was overall the most isolated serotype in Europe although the
frequency of S. suis serotype 9 strains was emerging. In Belgium, Germany and the Netherlands
serotype 9 was the most frequently isolated serotype. The production of EF seemed to be important
in S. suis serotype 1, 2, 1/2 and 14 strains but not in serotype 7 and 9 strains. A high molecular
weight variant of MRP may be important for serotype 9 strains since more than 80% of these strains
produced this protein. Whether MRP*EF– and MRP–EF– strains of serotype 9 differ in virulence has
to be determined in an experimental animal model.
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Abstract
We developed a PCR assay for the rapid and sensitive detection of virulent Streptococcus suis
type 2 and highly virulent S. suis type 1 in tonsillar specimens from pigs. The PCR primers were
based on the sequence of the gene encoding the EF-protein of virulent S. suis type 2 strains
(MRP+EF+) and highly virulent S. suis type 1 strains (MRPsEF+) and of the EF* protein of weakly
virulent S. suis type 2 strains (MRP+EF*). The latter strains give rise to larger PCR products than
the virulent strains of S. suis type 1 and 2. A positive control template was included in the assay
to identify false negative results. The PCR was evaluated using tonsillar specimens from herds
known (or suspected) to be infected and herds without a S. suis history. The results obtained with
the PCR assay were compared with the results obtained with a newly developed bacteriological
examination. In this bacteriological examination we were able to identify the EF-positive strains
directly in the tonsillar specimens. From the 99 tonsils examined, 48 were positive in the PCR
and 51 negative. All specimens from which EF-positive S. suis strains were isolated were also
positive in the PCR assay. Three samples were positive in the PCR, but negative by
bacteriological examination. The results demonstrated that the PCR is a highly specific and
sensitive diagnostic tool for the detection of pigs carrying virulent strains of S. suis type 2 and
highly virulent strains of type 1. Application of the assay may contribute to the control of S. suis
infections.
PCR for EF-positive S. suis strains
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1. Introduction
Streptococcus suis type 2 is an important swine pathogen in nearly all countries with an extensive
pig industry. It is associated with meningitis, arthritis, endocarditis, septicaemia, pneumonia and
sudden death (Vecht et al., 1985; Reams et al., 1994). Most infections occur in piglets at the age of
3 to 12 weeks, especially after weaning (Lamont et al., 1980). At present 35 different capsular
serotypes of S. suis have been described (Perch et al., 1983; Gottschalk et al., 1989, 1991; Higgins
et al., 1995). In most European countries, S. suis serotype 2 is the most prevalent type isolated from
diseased pigs, followed by type 1 and 9. The bacteria colonizes the tonsil of both clinically affected
and healthy pigs (Arends et al., 1984). Subclinical carrier animals are the most important source
from which the bacteria are transmitted to sensitive young pigs (Clifton-Hadley et al., 1984). In
herds carrier rates can vary from 0 tot 100% (Arends et al.,1984; Van Leengoed et al.,1987;
Mwaniki et al.,1994), however, there is no correlation between carrier rate and disease level (Arends
et al., 1984; Van Leengoed et al., 1987).
S. suis type 1 and 2 strains can differ in virulence. Virulent S. suis type 2 strains possess a 136
kDa muramidase-released-protein and a 110 kDa extracellular factor (MRP+EF+), weakly virulent
strains produce MRP and an EF related protein (MRP+EF*), whereas non-virulent strains do not
produce MRP and EF (MRP–EF–) (Vecht et al., 1989, 1991, 1992). MRP, EF and EF* have been
characterized (Smith et al., 1992, 1993) and it appeared that the N-termini of EF and EF* proteins
are nearly identical. However, at their C-terminus EF* proteins contain several repeated amino acid
units which are absent in the smaller EF protein (Smith et al., 1993).
Strains of S. suis type 1 belong either to the MRPsEF+ or to the MRP–EF– phenotype. The
MRPsEF+ strains, which produce a MRP-protein of reduced size (molecular weight of about 120
kDa) and the 110-kDa EF protein are highly virulent for young pigs. MRP–EF– strains are less
virulent but can still induce disease (Stockhofe-Zurwieden et al., 1996; Vecht et al., 1996).
Although there is a strong correlation between MRP and EF and virulence, these proteins are
dispensable for causing disease. Isogenic mutant strains of S. suis type 1 and 2 were as virulent for
pigs as the parent strains (Smith et al., 1997b). Moreover, strains isolated from diseased pigs in
Canada do not express MRP and EF (Gottschalk et al., 1998). Nevertheless, in most European
countries as well as in the United States and Australia MRP+EF+ strains of S. suis serotype 2 were
the most prevalent type isolated from diseased pigs (Mwaniki et al., 1994, Salasia et al., 1995,
Galina et al., 1996). Therefore, this type is still considered as the “classical virulent phenotype”
(Chatellier et al., 1999). In this paper EF is used as a marker of virulence and the epf gene as a tool
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to discriminate between virulent and non-virulent S. suis type 2 strains.
A strategy to control disease by S. suis in pig herds is to eliminate pigs that carry virulent S. suis
strains. At present, conventional bacteriological methods are used to monitor herds for the presence
or absence of virulent S. suis type 2 strains. For this, bacteria are cultured on selective-elective
media from tonsillar swabs (Van Leengoed et al., 1987), followed by serological and biochemical
characterization of the isolated bacteria (Vecht et al., 1985; Devriese et al., 1991). Virulent, weakly
virulent and non-virulent strains are subsequently identified by detection of MRP and EF, either by
Western blot analysis or by enzyme-linked immunosorbent assays (Vecht et al., 1991, 1993). These
methods are very laborious, time-consuming and have a low sensitivity. In the present paper we
describe a PCR assay for the rapid and sensitive detection of virulent strains of S. suis type 2 and
highly virulent strains of S. suis type 1 in tonsillar specimens of pigs. This PCR is based on
amplification of a fragment of the epf gene encoding EF. The test is carried out in a 96-well
microplate format allowing large scale application. We evaluated the test with tonsillar specimens
collected from pigs of herds known to be infected with S. suis type 2 and herds without a S. suis
history.
The results showed that the PCR assay is a specific and sensitive diagnostic tool suitable for the
detection of pigs carrying virulent S. suis type 2 and highly virulent S. suis type 1 strains.
2. Materials and methods
2.1. Bacteria
Thirteen strains of S. suis type 2 and two strains of S. suis type 1 belonging to either phenotype
MRP+EF+, MRPsEF+, MRP+EF* or MRP–EF– were used in this study. From most of these strains
virulence was determined previously in newborn germfree pigs (Table 1A). S. suis type 2 MRP+EF*
strains were earlier categorized to five classes of EF-related proteins (Smith et al., 1993). Reference
strains of the S. suis serotypes 1/2, and 3 to 34 (Perch et al., 1983; Gottschalk et al., 1989; Higgins
et al., 1995), 19 other streptococcal species (Table 1B) and 38 non-streptococcal bacterial strains
(23 different species, Table 1C) were used to determine the specificity of the PCR.
E. coli strain JM101 was grown in Luria broth (Miller, 1987). Ampicillin was added as needed
to a final concentration of 50 µg/ml. All other bacterial strains were plated on Columbia blood agar
plates (code CM 331, Oxoid Ltd. Inc. Columbia Md) supplemented with 6% horse blood and grown
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Table 1
List of microorganisms
A. Streptococcus suis strains
Strain No. Serotype Phenotype Virulence in
pigsa
Reference
3 2 MRP+EF+ HV Vecht et al., 1992
10 2 MRP+EF+ HV Vecht et al., 1992
22 2 MRP+EF+ HV Vecht et al., 1992
D282 2 MRP+EF+ HV Vecht et al., 1992
3995 2 MRP+EF* (cat 1) NT Smith et al., 1993
3988 2 MRP+EF* (cat 2) NT Smith et al., 1993
2840 2 MRP+EF* (cat 3) NT Smith et al., 1993
3921 or 17 2 MRP+EF* (cat 4) WV Smith et al., 1993
1890 2 MRP+EF* (cat 5) NT Smith et al., 1993
12 2 MRP–EF– NV Vecht et al., 1992
16 2 MRP–EF– NV Vecht et al., 1992
25 2 MRP–EF– NV Vecht et al., 1992
T15 2 MRP–EF– NV Vecht et al., 1989
6388 1 MRPsEF+ HV Stockhofe-Zurwieden et al., 1996
6555 or NCTC 10237 1 MRP–EF– V Stockhofe-Zurwieden et al., 1996
B. Other streptococcal speciesb
Group Streptococcal species Group Streptococcal species
A Streptococcus pyogenes humanis D Streptococcus zymogenes
B Streptococcus agalactiae E Streptococcus group E
C Streptococcus equi G Streptococcus group G
Streptococcus equisimilis porcine L Streptococcus group L
Streptococcus dysgalactiae P Streptococcus group P
Streptococcus zooepidemicus Q Streptococcus group Q
D Enterococcus faecalis – Streptococcus milleri III
Enterococcus faecium – Streptococcus sanguis
Enterococcus liquefaciens – Streptococcus uberis
Streptococcus bovis
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Table 1 (continued)
C. Other bacterial speciesb
Actinobacillus pleuropneumoniae Haemophilus parasuis
Actinobacillus suis Klebsiella oxytoca
Actinobacillus viridans Klebsiella pneumoniae
Actinomyces pyogenes Listeria monocytogenes
Aeromonas hydrophila Micrococcus luteus
Bacillus cereus Micrococcus strain 3551
Bacillus licheniformis Mycobacterium avium serovar 2
Bacillus subtilis Mycoplasma hyopneumoniae
Bordetella bronchiseptica Mycoplasma hyorhinis
Brucella suis biotype I Mycoplasma hyosynoviae
Brucella suis biotype II Pasteurella multocida
Campylobacter coli Pasteurella vulgaris
Campylobacter faecalis Pseudomonas aeruginosa
Campylobacter jejuni Salmonella typhimurium
Candida albicans Serratia liquefaciens
Clostridium perfringens A toxic Staphylococcus aureus
Clostridium perfringens A non toxic Staphylococcus epidermidis
Erysipelothrix rhusiopathiae Staphylococcus hyicus hyicus
Escherichia coli Yersinia enterocolitica
a HV=highly virulent, WV=weakly virulent, V=virulent, NV=non-virulent, NT=not tested
b Reference: laboratory collection of the Institute of Animal Science and Health
overnight at 37°C in air with 5% CO2. Colonies were inoculated in Todd-Hewitt broth (code CM
189, Oxoid) and grown overnight at 37°C.
The S. suis strains were serotyped by slide-agglutination test with serotype-specific antibodies
(Vecht et al., 1985), the capsular reaction test (Higgins and Gottschalk, 1990) and the precipitation
test (Perch et al., 1983). The production of MRP and EF was measured by growing the strains
overnight in Todd-Hewitt broth at 37°C and analyzing the supernatants in the double antibody
sandwich ELISA's as described before (Vecht et al., 1993).
2.2. Preparation of tonsillar specimens.
Herds A and B had recent cases of meningitis in young piglets caused by S. suis type 2
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(MRP+EF+). Herds D and E had no history of meningitis in pigs. Herd C had recent cases of
meningitis in young piglets. However, in a previous bacteriological examination S. suis strains were
not isolated. Herds A, D and E are farrow-to-finish herds, herds B and C consisted of finishing pigs.
Tonsils from pigs were collected at a slaughterhouse. In the laboratory whole tonsils where
submerged in boiling water, sealed in poly ethylene bags and squeezed in a Stomacher (Laméris
Laboratorium B.V., Breukelen, The Netherlands). Glycerol was added to a final concentration of
15% and samples where stored at –70°C.
Hundred µl of this macerated tonsillar specimen were grown overnight at 37°C in 5 ml Todd-
Hewitt broth with 0.25% Streptococcus Selective Supplement (Oxoid) and 0.2 µg/ml cristalviolet.
From each sample 50 µl were dispensed into the wells of a 96-well MultiscreenTM plate (Millipore,
Bedford, MA.), each well fitted with a 0.65 µm DuraporeTM filter. The samples were processed and
DNA solutions were prepared as described previously (Reek et al., 1995; Kamp et al., 1996).
2.3. Bacterial examination.
Five-fold serial dilutions of the macerated tonsillar specimens were plated on Columbia blood
agar plates supplemented with 6% horse blood, 0.25% Streptococcus Selective Supplement (Oxoid)
and 0.2 µg/ml cristalviolet and incubated overnight at 37°C in air with 5% CO2. The next day two
plates containing approximately 100 to 200 separate colonies were selected. The colonies were lifted
onto sterilized GeneScreen Plus membranes (New-England Nuclear Corp., Boston, USA) and the
plates were further incubated for 18 hours. The filters were placed on fresh Columbia blood agar
plates with 6% horse blood and incubated for an additional 4 hours at 37°C. The bacteria on the
filters where lyzed (Sambrook et al., 1989) and the DNA on the filters was hybridized overnight
with the epf-specific probe. Colonies that hybridized where subcultured, characterized, serotyped
and phenotyped by using standard procedures (Devriese et al., 1991; Vecht et al., 1985, 1993).
2.4. DNA techniques and PCR.
Chromosomal DNA isolations and routine DNA techniques were performed as described by
Sambrook et al. (1989). Ribotype profiles were determined as described before (Smith et al., 1997a).
In addition to the serotyping by antibodies, S. suis serotype 1 and 2 strains were typed using
serotype-specific DNA probes derived from type 1 and 2 capsule operon (Smith et al. 1999).
DNA amplification was performed in microplates (Thermowell HTM; Corning Costar,
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Cambridge, MA. USA). As template 10 ng of purified chromosomal DNA from bacterial strains
or 25 µl of DNA solution from a clinical sample was used. The reaction mixtures (50 µl) contained
10 mM Tris.HCl, pH8.3, 2 mM MgCl2, 50 mM KCl, 0.2 mM of each of the four deoxynucleotide
triphosphates, 1 µM of each of the primers and 1 U of AmpliTaq Gold DNA Polymerase (Perkin
Elmer Applied Biosystems, Roche Molecular Systems, Branchburg, New Jersey).
The oligonucleotide primers were custom synthesized (Eurogentec, Belgium) and had the
following sequence: 5'-GCTACGACGGCCTCAGAAATC-3' and 5'-TGGATCAACCACTGGTGT
TAC-3'. They correspond to the positions 2407-2427 and 3032-3012 in the epf gene and to the
positions 2407-2427 and 5400-5380 in the epf* gene (Smith et al., 1993). Amplified fragments are
626 base pairs (bp) in length for EF+ strains and 1278, 1505, 2313, 2537 and 2993 bp for the five
classes of EF* strains.
PCR reaction mixtures were overlaid with two drops of mineral oil. DNA amplification was
carried out in a thermal cycler (OmnigeneTM; Hybaid, Teddington, Middlesex, UK) with a
microplate format heating block. The program used consisted of an incubation for 10 min at 95°C
and 40 cycles of 1 min at 94.8°C, 55 sec at 60°C and 2 min at 72°C, followed by an incubation for
10 min at 72°C.
To control failure of DNA amplification and to confirm the reliability of the PCR assay, each
sample was spiked with a positive control template. To construct the positive control template the
1180 bp-PstI fragment from pEF2-19 (Smith et al., 1993) was cloned into pKUN19 (Konings et al.,
1987). The resulting plasmid was linearized with EheI (1180 bp-PstI fragment contained an EheI
site), ligated to an HaeIII fragment of pKUN19 of about 400-bp and transformed to E. coli.
Amplification of this positive control template with the PCR primers results in a fragment of about
1000 bp. The optimal amount of positive control template to be included in the PCR reaction was
determined by titration against purified chromosomal DNA of a S. suis type 2 strain (MRP+EF+) so
that its amplification interfered as little as possible with the amplification of the target DNA.
2.5. Southern blotting and hybridization.
Twentyfive µl of the PCR reaction products were separated by electrophoresis on 2% agarose
gels and transferred to GeneScreen Plus membranes as described by Sambrook et al. (1989).
Strain 3 (MRP+EF+) of S. suis type 2 (Vecht et al., 1992) was used in a PCR to amplify the 626
bp epf-specific fragment. The fragment was purified from the amplification product with a “High
pure PCR product purification kit” (Boehringer Mannheim) and labeled with α-32P dCTP (3000
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Ci/mMol, Amersham Corp., Arlington Heights, USA) by use of a random primed labeling kit
(Boehringer GmbH, Germany) following the manufacturers protocol. After labeling, unincorporated
nucleotides were removed by Sephadex G-50 chromatography. Membranes with the PCR reaction
products were hybridized overnight at 65°C with the 32P-labeled epf-specific probe as recommended
by the manufacturer. After hybridization, membranes were washed twice in 40 mM Na-
Phosphatebuffer, pH 7.2, 5% sodium dodecyl sulfate (SDS), 1 mM EDTA, for 30 min. at 65°C and
twice in 40 mM Na-Phosphatebuffer, pH 7.2, 1% SDS, 1 mM EDTA, for 30 min. at 65°C.
3. Results
3.1. Primer selection and PCR conditions.
To set up an assay which specifically detects the virulent type 2 and highly virulent type 1 strains,
we selected primers, based on the epf and epf* genes. These genes are highly homologous, however
the epf* genes contain several repeated inserts. Primers were chosen in the regions flanking the site
where in the epf* variants additional sequences are present (see Fig. 1). As expected, this primer set
Fig. 1. Schematic presentation of genes encoding the EF protein and the EF* protein variants. The positions of the
primers ( ► and ◄), the site of the insert for the construction of the positive control template (∇) and the recognition sites
for the enzymes EcoRI (E), PstI (P), EheI (Eh) and HindIII (H) are indicated. The expected sizes of amplification
products are indicated in bp.
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f S. suis type 2 (Fig. 2A, lanes 1-5) and no PCR products were obtained with MRP–EF–
f both serotypes (Fig. 2A, lanes 11-15). PCR products of various sizes (1278, 1505, 2313,
93 bp) were obtained with the weakly virulent MRP+EF* strains of S. suis type 2 (Fig. 2A,
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lanes 6-10). Southern blot analysis of the PCR products with the epf-specific probe confirmed the
positive and negative PCR results (data not shown). To identify a failure of PCR, all samples were
spiked with a positive control template. The results (Fig. 2B) showed that in the absence of other
homologous template the positive control template is indeed amplified into a fragment of 1000 bp
demonstrating the amplifiability of the sample (Fig. 2B, lanes 11-15).
3.2. Sensitivity and specificity of the PCR assay.
We determined the sensitivity of the PCR assay with purified chromosomal DNA. The PCR
products obtained from as few as 25 fg of target DNA could easily be detected by eye on an agarose
gel stained with ethidium bromide (Fig. 3). Twentyfive fg DNA is the equivalent of approximately
14 S. suis cells (Pozzi et al., 1989). Fig. 3 also demonstrated the primer competition between target
DNA and positive control DNA, explaining the absence of a positive control PCR fragment in the
presence of a high concentration of target DNA.
To test the specificity of the assay, PCR reactions were performed with 10 ng chromosomal DNA
of the S. suis reference strains 1/2, 3-34, a panel of 19 streptococcal and of 38 non-streptococcal
strains (Table 1A, B, C). No amplification products were obtained with any of the strains examined
(results not shown). In addition, Southern blotting and hybridization experiments with the epf-
specific probe confirmed the negative PCR results. Therefore the PCR assay seems to be specific
for the detection of EF-positive S. suis strains.
Fig. 3. Sensitivity of the PCR assay on chromosomal DNA of an S. suis type 2 (MRP+EF+) strain. Samples were
separated on 2% agarose gel stained with ethidium bromide. The amount of target DNA tested in the PCR assays is
indicated in femtograms above the lanes. All samples contained equal amounts of positive control DNA. Lane MW
contain a molecular weight marker (phage λ DNA digested with EcoRI and HindIII).
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3.3. PCR and phenotype.
We next investigated whether the PCR assay could be used for the detection of EF-positive S.
suis strains in tonsillar samples. For that purpose, tonsils were collected from herds with a history
of infection by an EF-positive S. suis type 2 strain as well as from herds without a clinical S. suis
history. Samples were analyzed by PCR and the results were compared with the results of a
bacteriological examination on the same tonsillar specimens. Colonies hybridizing with the 626 bp
amplification product were isolated and characterized by determining their phenotype. The results
are summarized in Table 2, some examples are shown in Fig. 4, lanes 1-15. Of the 99 tonsillar
specimens examined, 48 were positive and 51 were negative in the PCR assay. All specimens from
which EF-positive S. suis strains were isolated were positive in the PCR assay (Table 2). Three
samples were positive in the PCR, but negative by bacteriological examination. Moreover, all PCR
positive specimens were collected from herds known (herds A and B) or suspected (herd C) to be
infected with EF-positive S. suis strains. All specimens collected from herds without a history of
S. suis problems were PCR negative. From none of these specimens we isolated EF-positive S. suis
strains.
Taken together, compared with bacteriological examination, the PCR assay identified 96 of 99
samples correctly. Therefore, the PCR assay on tonsillar specimens seems to be a highly reliable tool
to identify carriers of EF-positive S. suis strains.
Fig. 4. PCR products obtained directly on tonsillar specimens (I) and PCR products obtained on S. suis strains isolated
from tonsillar specimens (II) from pigs of five herds (A-E). Samples were separated on 2% agarose gel gel stained with
ethidium bromide. Herds A and B had a history of S. suis type 2 infection, herd D and E are free herds. Herd E is an SPF
herd. On herd C clinical signs of meningitis in piglets could not be confirmed by previous bacteriological examinations.
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3.4. PCR and serotype.
In addition to the EF-phenotype we determined the serotype of S. suis strains isolated from the
various tonsillar specimens (Table 3). Using the 626 bp amplicon as probe, EF-producing strains
of S. suis serotype 2 were present in samples collected from herds A, B and C (Table 3). In the PCR
test all these strains yielded the 626 bp amplicon. However, we also isolated EF-positive,
serologically untypable S. suis strains (herd B) and EF-positive S. suis strains of serotype 1/2 (herd
C). In the PCR assay all these strains were positive. Among the colonies hybridizing with the epf
-specific fragment, we also found EF-negative strains of various serotypes in samples from herds
A-D (Table 3). In the PCR test all these strains were negative.
Herd D had no S. suis history. Nevertheless, in the PCR assay fragments of about 2400 bp were
amplified, indicating the presence of S. suis strains expressing an EF* protein. Indeed, EF* producing
strains were isolated. These strains were serotyped as type 1 or were serologically untypable.
Table 2
Comparison of the PCR assay and bacteriological examination on tonsillar specimens.
Bacteriological examinationb
PCR Herda EF-positive S. suisc EF-negative S. suisd
Positive A 17 1
B 20 0
C 8 2
D 0 0
E 0 0
Total 45 3
Negative A 0 1
B 0 0
C 0 10
D 0 20
E 0 20
Total 0 51
a Herds A and B are clinically affected by S. suis type 2, herds D and E are free of S. suis type 2. Herd E is an SPF herd.
On herd C meningitis problems in piglets could not be confirmed by previous bacteriological examinations.
b Bacteriological examination was carried out as described in Materials and Methods.
c No. of samples from which a MRP+EF+ S. suis strain was isolated.
d No. of samples from which a MRP+EF* or MRP–EF– S. suis strain was isolated plus no. of tonsillar specimens which
were negative after bacteriological examination.
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Herd E had a specific pathogen free (SPF) status. All specimens collected from this herd were
negative in the PCR assay and we were unable to isolate any S. suis strain using the 626 bp EF
fragment as a probe.
3.5. Characterization of untypable S. suis strains.
So far, untypable strains and type 1/2 strains of S. suis expressing the EF protein as well as
untypable strains and type 1 strains of S. suis expressing the EF* protein have not been isolated. To
further characterize these strains we determined their ribotype profiles and hybridized them with
capsular polysaccharide probes specific for S. suis type 1 or S. suis type 2 (Smith et al., 1999). The
results (Table 4) showed that the EF-positive or EF* strains from one herd showed similar
properties, independent of their serotype, indicating that the S. suis strains, isolated from one herd,
are genetically closely related.
4. Discussion
We developed a PCR assay to detect virulent S. suis serotype 2 and highly virulent S. suis
serotype 1 strains. The PCR assay is highly specific and sensitive when tested on tonsillar specimens
of pigs. It is easy to perform and allows large-scale application, 96 samples can be processed
simultaneously. Compared to standard bacteriological assays, the PCR assay is much more rapid
to perform. Therefore, this assay may be an important diagnostic tool to detect pigs carrying virulent
S. suis type 2 and highly virulent S. suis type 1 strains. It may be applicable for epidemiological and
transmission studies and can contribute in efforts to control or eradicate S. suis infections.
Table 3
Serotypes and phenotypes of S. suis strains isolated from tonsillar specimens collected from the various herds.
S. suis serotypes isolated from herda
S. suis phenotype A B C D E
EF+ 2 2, UTb 1/2, 2 – –
EF* – – – 1, UT –
EF– 3, 8 8, 15 4, 5, 8, 15 1, 15 –
a Herds A and B are clinically affected by S. suis type 2, herds D and E are free of S. suis type 2. Herd E is a SPF herd.
On herd C meningitis problems in piglets could not be confirmed by previous bacteriological examinations.
b UT: serologically untypable S. suis strain.
PCR for EF-positive S. suis strains
55
So far, the PCR assay was carried out on specimens consisting of tonsillar tissues of pigs.
However, for routine detection of carriers, tonsillar swab specimens would be preferable as
sampling method. Our experience is that the PCR assay is also applicable on tonsillar swab
specimens, perhaps with a slightly lower sensitivity.
In the bacteriological examination we used the 626 bp amplified epf -specific fragment to identify
EF-positive S. suis colonies. All hybridizing strains were identified as being S. suis strains.
Surprisingly, S. suis strains of various serotypes (3, 4, 5, 8, 15), phenotypically EF-negative, still
hybridized with the epf-specific probe. Since all these strains were negative in the PCR, we presume
that a part of the epf gene, complementary to the probe, is present in these serotypes, but that the
regions required for primer annealing are probably absent or mutagenized.
In addition to EF-positive serotype 1 and 2 strains, EF-positive serotype 1/2 and EF-positive
serologically untypable strains were isolated. The fact that these strains possess a ribotype profile
that is associated with virulent (EF+) strains of S. suis type 2 and with highly virulent (EF+) strains
of S. suis type 1 (Smith et al., 1997a), indicates that these strains may also be virulent for pigs.
Moreover, these data suggest that all EF-positive strains are genetically closely related, irrespective
their serotype. The virulence of these strains needs to be determined.
In the clinical samples collected from herd D, EF*-positive type 1 strains were present as well
as EF*-positive untypable strains. These types were not detected before. It has been shown that EF*
strains of S. suis type 2 are weakly virulent (Vecht et al., 1992) and that they are associated with
Table 4
Properties of S. suis strains isolated from the tonsillar specimens collected from the various herds
S. suis strains isolated from herda
Properties Herd B Herd C Herd D
Serotype 2 UTb 1/2 2 1 UT
Phenotype MRP+EF+ MRP+EF+ MRP+EF+ MRP+EF+ MRP+EF* MRP+EF*
Rbotype profilec A A A A B B
Cps1Id – – – – + +
Cps2Je + + + + – –
a Herds A and B are clinically affected by S. suis type 2, herds D and E are free of S. suis type 2. Herd E is a SPF herd.
On herd C meningitis problems in piglets could not be confirmed by previous bacteriological examinations.
b UT: untypable S. suis strain.
c Ribotype patterns were determined as described before (Smith et al., 1997a).
d Hybridization with capsule polysaccharide probe specific for S. suis type 1 (Smith et al., 1999).
e Hybridization with capsule polysaccharide probe specific for S. suis type 2 (Smith et al., 1999).
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ribotype profile B (Smith et al., 1997a). Since the EF* strains of S. suis type 1 and untypable strains
found in this study also possess profile B, it is likely that they are genetically associated with each
other, irrespective of their serotype.
The serologically untypable EF-positive or EF*-positive strains of S. suis were not described
before. Hybridization studies using serotype-specific probes as well as ribotyping studies, showed
that the untypable strains and serotype 2 strains that were isolated from herd B, are closely related.
Moreover, the untypable strains that were isolated from herd D are closely related to the type 1 strain
isolated from the same herd. This suggests that these closely related strains, present on the same
herd, originated from each other or may have originated from a common ancestor.
When tested on clinical samples the results obtained with the PCR assay correlated completely
with the clinical history of the examined herds. PCR positive results were only obtained with
samples from herds known or suspected to be infected with virulent EF-positive strains. PCR
negative results were obtained with samples from herds without an S. suis history. PCR results were
confirmed by bacteriological examination.
On herd E, pigs were held under SPF-conditions. From this herd we were unable to isolate any
S. suis strain. This suggests that eradication of (virulent) S. suis strains may be achieved by
combining efficient management procedures with frequent monitoring using specific and sensitive
diagnostic tools as the currently developed PCR assay.
The data presented in this study confirmed that in the Netherlands there is a strong correlation
between virulence and EF-positive S. suis type 2 strains. Similar results were reported from
Germany, the United States and Australia: most of the S. suis type 2 strains isolated from diseased
pigs belonged to the phenotype MRP+EF+ (Vecht et al., 1991; Mwaniki et al., 1994; Salasia et al.,
1995; Galina et al., 1996). Recently, it was reported that most S. suis type 2 strains isolated from
diseased pigs in Canada were EF-negative (Gottschalk et al., 1998). Apparently, Canadian strains
differ from strains isolated in other countries. Therefore, the PCR assay described here cannot be
used for the detection of S. suis type 2 strains isolated in Canada.
Taken together, the PCR assay described here is a specific and sensitive diagnostic tool suitable
for the detection of pigs carrying virulent S. suis type 2 and highly virulent S. suis type 1 strains.
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SUMMARY
Multiplex PCR assays for the detection and identification of various Streptococcus suis strains in
tonsillar specimens of pigs were developed. In two separate reactions, five distinct DNA targets
were amplified. Three targets, based on the S. suis serotype 1 (and 14), 7 and 9 specific cps genes,
were amplified in Multiplex PCR I. Two other targets, based on the serotype 2 (and 1/2) specific
cps gene and the epf gene encoding the EF-protein of virulent serotype 2 and highly virulent
serotype 1 strains, were amplified in Multiplex PCR II. To identify false negative results, firefly
luciferase DNA and primers, based on the luc gene, were included in the assay. The Multiplex PCR
assays were evaluated using tonsillar specimens of pigs infected with S. suis strains .The results
obtained with the PCR assays were compared with the results obtained with a bacteriological
examination. Most (94%) of the results obtained with Multiplex PCR assays were confirmed by the
bacteriological examination. The PCR method seems to be more sensitive compared to the
bacteriological method since the remaining 6% of the samples were positive by PCR and negative
by bacteriological examination. No false positive results were obtained by PCR indicating that the
PCR method is highly specific for the detection of S. suis strains most frequently involved in clinical
disease in infected pig herds.
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INTRODUCTION
Streptococcus suis is an important agent of meningitis, arthritis, pericarditis, peritonitis, pneumonia
and sudden death in young piglets. Most infections occur when pigs are 3-12 weeks of age.
Especially after weaning the pigs are susceptible for infection (11). The disease has a worldwide
distribution and causes considerable losses to pig production (3). Attempts to control the disease are
still hampered by the lack of effective vaccines and sensitive diagnostic tools.
At present, 35 serotypes of S. suis based on capsular antigens are described (5, 6, 8, 14) with
serotypes 1/2, 1, 2, 7, 9 and 14 being among the most prevalent serotypes recovered from diseased
animals (28). S. suis colonizes the palatine tonsils of both healthy and diseased pigs (2, 12, 24).
Subclinical carrier pigs are known to be the source of infection for young sensitive pigs (9).
Detection of these carriers may lead to a better understanding of the epidemiology of S. suis
infections and may  be helpful in the development of effective control measures. At present, no
sensitive and specific methods are available for the detection of pigs carrying S. suis strains. The
bacteria can be cultured from tonsillar specimens by using traditional microbiological techniques.
However, tonsils are also colonized by nonvirulent S. suis strains and other streptococcal species,
which are difficult to distinguish on the basis of colony morphology. To meet this shortages,
serotype-specific isolation techniques using selective-elective media (24) or an immunomagnetic
separation technique (7) have been developed. However, so far their use is limited to serotype 2 and
1/2 strains. Moreover, these methods are very laborious, time-consuming and have a low sensitivity.
For a more convenient detection of specific serotypes and virulence-associated phenotypes of S.
suis, PCR procedures could be used. Recently, a PCR assay was described and successfully applied
to detect virulent S. suis serotype 2 and highly virulent serotype 1 strains in tonsillar specimens of
pigs (27). The PCR primers in this assay are based on the sequence of the epf gene encoding the EF-
protein, a marker of virulence in serotype 2 strains and highly virulent serotype 1 strains (23, 26).
In addition, we recently developed PCR assays for detection of S. suis serotype 1 (and 14), 2 (and
1/2), 7 and 9 strains in tonsillar specimens of pigs (21, 22). These assays are based on the capsular
polysaccharide biosynthesis loci (cps) of S. suis serotype 1, 2, 7 and 9 (19, 21, 22). However, the
latter PCRs were not optimized for maximum sensitivity nor evaluated for specificity. Moreover,
a large number of individual PCRs were required if single primer sets were used on large numbers
of clinical specimens. To reduce the number of tests we combined the single PCR assays to a set
of two Multiplex PCR assays. The tests were carried out in a 96-well microplate format, allowing
large scale application and were evaluated using tonsillar specimens from pigs infected with S. suis
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strains.
The results showed that the Multiplex PCR asays are specific and sensitive diagnostic tools suitable
for the detection of pigs carrying S. suis serotype 1 (and 14), 2 (and 1/2), 7 , 9 and virulent S. suis
serotype 2 and highly virulent S. suis serotype 1 strains.
MATERIALS AND METHODS
Bacteria and growth conditions. Reference strains of S. suis serotypes 1/2, 1 to 34 (5, 6, 8 ,14),
EF-positive strains of S. suis serotypes 1 (strain 6388) and 2 (strain 3), serotype 2 strains
belonging to the five different EF*-classes (20, 23, 26), 18 other streptococcal strains belonging
to the Lancefield groups A to E, G, L, P and Q, and 24 bacterial strains belonging to the genera:
Staphylococcus, Micrococcus, Aerococcus, Actinobacillus, Bordetella, Escherichia, Pasteurella,
Proteus, Salmonella, Serratia and a yeast, Cryptococcus (collection ID-Lelystad) were used in
this study.
Strains were plated on Columbia blood agar plates (code CM 331, Oxoid Ltd. Inc. Columbia Md)
supplemented with 6% horse blood and grown overnight at 37°C in air with 5% CO2. Colonies
were inoculated in Todd-Hewitt broth (code CM 189, Oxoid) and grown overnight at 37°C.
Tonsillar specimens. Tonsils from 38 pigs obtained from 28 farms were collected at the Animal
Health Service, Boxtel, The Netherlands and stored at –20°C. All pigs suffered from a S. suis
infection as confirmed by isolation of the bacteria from affected tissues.
Tonsillar specimens were prepared for PCR by the multiscreen method as described previously (27).
To evaluate the results obtained with the Multiplex PCR assays, S. suis serotype 1 (and 14), 2 (and
1/2), 7, 9, and EF-positive S. suis strains were directly isolated from the tonsillar specimens using
a bacteriological examination (27). To do this, tonsillar specimens were plated, colonies were lifted
onto sterilized GeneScreen Plus membranes (New-England Nuclear Corp., Boston, USA) and
hybridized with serotype-specific cps probes or an epf -specific probe (see below). Hybridizing
colonies were subcultured, characterized and serotyped by standard procedures (4, 25).
PCR conditions. Oligonucleotide primers used in the Multiplex PCR assays for the detection of
S. suis serotype 1 (and 14), 2 (and 1/2), 9 and EF-positive S. suis strains were as described before
(22, 27), except for the reverse primer in the serotype 2-specific PCR. The new primer has the
sequence: 5'-CATTTCCTAAGTCTCGCACC-3' and corresponds to the positions 14027-14008 in
the cps2J  gene (22). The primers used for the detection of serotype 7 strains correspond to the
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positions 3185-3206 and 3726-3705 in the serotype-7-specific cps gene (21). The sequences were
5’-GAATCAATCCAGTCAGTGTTGG-3’ and 5’-CTAATTCGATACGAAGCTAAAC-3’.
In Multiplex PCR I, primers specific for serotype 1 (and 14), 7, and 9 strains were combined.
Amplified fragments are 441, 541, and 388 bp in length, respectively. In Multiplex PCR II,
primers specific for serotype 2 and EF-positive strains were combined. In this PCR, amplified
fragments are 236 and 626 bp in lenght, respectively.
To control failure of DNA amplification and to confirm the reliability of the PCR assays, each
sample was spiked with a positive control template. For this, the pGL2-Basic Vector (Promega,
Madison, Wis.) encoding the firefly luciferase gene (luc) was used. Oligonucleotide primers,
amplifying a part of the luc gene, correspond to the positions 723-744 and 1672-1651 on the pGL2-
Basic Vector and had the sequences 5’-CGTCAGATTCTCGCATGCCAGA-3’ and 5’-
TTGCGTCGAGTTTTCCGGTAAG-3’. This resulted in a PCR product of 949 bp.
As template for PCR we used 1 ng of purified chromosomal DNA (16) from bacterial strains or 25
µl of clinical sample prepared for PCR as described above. The reaction mixtures (50 µl) contained
10 mM Tris.HCl, pH8.3, 2 mM MgCl2, 50 mM KCl, 0.2 mM of each of the four deoxynucleotide
triphosphates, 0.4 µM of each of the primers and 1.5 U of AmpliTaq Gold DNA Polymerase (Perkin
Elmer Applied Biosystems, Roche Molecular Systems, Branchburg, New Jersey).
PCR mixtures were overlaid with two drops of mineral oil. DNA amplification was carried out in
microplates (Thermowell HTM; Corning Costar, Cambridge, MA. USA) in a DNA thermal cycler
(OmnigeneTM; Hybaid, Teddington, Middlesex, UK). The program used for Multiplex PCR I
consisted of an incubation for 10 min at 95°C and 40 cycles of 0.45 min at 94.8°C, 1.10 min at 60°C
and 3 min at 72°C, followed by an incubation for 10 min at 72°C. The program used for Multiplex
PCR II consisted of an incubation for 10 min at 95°C and 40 cycles of 0.45 min at 94.8°C, 1.10 min
at 63°C and 1.20 min at 72°C, followed by an incubation for 10 min at 72°C. Twenty µl of the PCR
products were separated by electrophoresis on 2% agarose gels, stained with ethidium bromide (0.25
µg/ml), and photographed under UV light.
Hybridization. Reference strains of S. suis serotypes 1, 2, 7 and 9, and strain 3 (MRP+EF+) were
used in individual PCR assays to amplify serotype 1, 2, 7, and 9-specifc cps fragments and an epf
-specific fragment, respectively. These fragments were purified from the amplification products with
a “High pure PCR product purification kit” (Roche) and labelled with α-32P dCTP (3000 Ci mmol-
1, Amersham Corp. Arlington Heights, Ill.) by use of a random primed labelling kit (Roche). The
DNA on the blots was hybridized at 65°C with appropriate DNA probes, as recommended by the
supplier of the GeneScreen Plus membranes. After hybridization, the membranes were washed twice
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with a solution of 40 mM sodium phosphate (pH 7.2) – 1 mM EDTA – 5% sodium dodecyl sulfate
(SDS) for 30 min at 65°C and twice with a solution of 40 mM sodium phosphate (pH 7.2) – 1 mM
EDTA – 1% SDS for 30 min at 65°C.
DNA sequence analysis. DNA sequences were determined on a ABI Prism 3700 DNA Analyzer
System (Perkin Elmer Applied Biosystems). Samples were prepared by use of a ABI Prism Bigdye
terminator cycle sequencing ready reaction kit (Perkin Elmer Applied Biosystems).
RESULTS
Specificity of the Multiplex PCR assays. To test the specificity of the Multiplex PCR assays,
PCRs were performed on the various S. suis reference strains and on a panel of 18 streptococcal and
24 non-streptococcal strains. As shown in Figs 1A and B, PCR products of the predicted sizes were
obtained on chromosomal DNAs (1 ng) of the S. suis serotype 1/2, 1, 2, 7, 9, 14 as well as on EF-
expressing strains. Multiplex PCR II amplified a fragment of about 2400 bp in chromosomal DNA
of S. suis serotype 14 strain (Fig 1B, lane 8). This indicates the presence of a S. suis strain
expressing an EF* protein. Multiple amplification products were observed in a mixture of
chromosomal DNA of the above mentioned eight strains (Figs. 1A and B, lane 10). No
amplification products were obtained on any of the other S. suis serotypes nor on any of the other
strains examined (results not shown). This indicates that the Multiplex PCR assays were highly
specific for the detection of S. suis serotype 1, 2, 1/2, 7, 9, 14 and EF-positive S. suis strains.
Moreover, the Multiplex PCR assays were capable to detect several S. suis serotypes and phenotypes
simultaneously from a mixture of chromosomal DNAs.
As expected, in the negative control (without chromosomal S. suis DNA) an amplification product
of the internal positive control was detected (Figs. 1A and B, lane 9). No interference was observed
between the internal positive control primerset with chromosomal DNA (1 ng) of the S. suis
reference strains and vice versa between the S. suis primersets and internal positive control DNA
(1 ng) (results not shown).
We also used Multiplex PCR II on chromosomal DNA of EF*-producing serotype 2 strains. In
addition to the serotype 2-specific cps PCR products, epf* PCR products of various sizes (1278,
1505, 2313, 2537, 2993-bp) were expected (27). However, a faint amplification product was
obtained on chromosomal DNA of the strain expressing the smallest EF* protein, whereas no
amplification products could be detected in the other EF*-producing strains. Apparently, the
Multiplex PCR II was not able to efficiently detect EF*-producing strains.
 Multiplex PCR assays
65
FIG. 1. PCR products obtained in Multiplex PCR I (A) or Multiplex PCR II (B) with purified chromosomal DNA
(1 ng) of eight S. suis strains spiked with 10 fg of pGL2-Basic Vector. Samples were separated on 2% agarose gel stained
with ethidium bromide. Lane designations are indicated. S. suis serotype 1/2, strain 5209 (lane 1); S. suis serotype 1,
strain 5210 (lane 2); S. suis serotype 2 (MRP+EF*), strain 5211 (lane 3); S. suis serotype 7, strain 5216 (lane 4); S. suis
serotype 9, strain 5218 (lane 5); S. suis serotype 14, strain 5223 (MRP–EF*) (lane 6); S. suis type 1 (MRPsEF+), strain
6388 (lane 7); S. suis type 2 (MRP+EF+), strain 4005 (lane 8); negative control (without S. suis DNA) (lane 9); mixture
of chromosomal DNA (1ng) of strains in lanes 1 to 8 (lane 10); MW contains DNA molecular weight marker VIII
(0.019-1.11kbp; Roche); the sizes (in bp) of the PCR products are indicated on the left.
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Sensitivity of the Multiplex PCR assays. The sensitivity of the Multiplex PCR assays was
determined using chromosomal DNA of S. suis serotype 1, 2, 7, 9 and an EF-positive serotype 2
strain. In both Multiplex PCR assays, 10 fg of chromosomal DNAs of the various serotypes and
phenotypes was sufficient to amplify a fragment which could easily be detected by eye on an agarose
gel (Figs. 2 A and B).
Evaluation of the Multiplex PCR assays. We subsequently analyzed tonsillar specimens by
Multiplex PCR assays and a bacteriological examination (27) to compare both tests. The results are
summarized in Table 1 and several examples are shown in Figs. 3 A and B. All tonsillar specimens
bacteriologically positive for a specific serotype/phenotype were also positive in the corresponding
PCR. Moreover, tonsils negative in the Multiplex PCR for a specific serotype/phenotype were also
negative for this particular serotype/phenotype using the bacteriological method. Some samples
which tested positive in the Multiplex PCR, tested bacteriological negative (3 out of 17 for serotype
7, 4 out of 28 for serotype 9 and 6 out of 18 for serotype 2 (and 1/2)). This could suggest that,
especially for serotype 2 (and 1/2), the PCR method is more sensitive compared to the
TABLE 1. Comparison of Multiplex PCR assays and bacteriological examination1 for 38 tonsillar specimens from
diseased pigs
No. (%) of tonsillar specimensMultiplex PCR result2
PCR + /
Bacterial
examination +
PCR + /
Bacterial
examination –
PCR –/
Bacterial
examination –
PCR – /
Bacterial
examination +
Serotype 1 (or 14)3 14(3) 0(0) 37(97) 0(0)
Serotype 2 (or 1/2)3 125(31) 6(16) 20(53) 0(0)
EF-positive 5(13) 0(0) 33(87) 0(0)
Serotype 7 14(37) 3(8) 21(55) 0(0)
Serotype 9 28(74) 4(10) 6(16) 0(0)
Total 60(31) 13(7) 117(62) 0(0)
1 Bacteriological examination was carried out as described in Materials and Methods.
2 Serotypes as identified by Multiplex PCR I (S. suis serotype 1 (and 14), 7 and 9 strains), and Multiplex PCR II (S. suis
serotype 2 (and 1/2) and EF-positive S. suis strains).
3 Similar PCR products were amplified in S. suis serotype 1 and 14 strains, and in serotypes 2 and 1/2 strains due to
common capsular genes (18).
4 S. suis serotype 14 strain as detected by bacteriological examination.
5 S. suis serotype 1/2 (7/12) and EF-positive S. suis serotype 2 strains (5/12) as detected by bacteriological examination.
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FIG. 2. Sensitivity of Multiplex PCR I (A) and II (B) on a mixture of chromosomal DNAs of S. suis serotype 1, 7
and 9 (A) or on a EF-positive S. suis serotype 2 strain (B). Samples were separated on 2% agarose gel stained with
ethidium bromide. The amount of target DNA tested in the PCR assays is indicated above the lanes. All samples
contained 10 fg of positive control DNA. Lane MW contains DNA molecular weight marker VIII (0.019-1.11kbp;
Roche); the sizes (in bp) of the PCR products are indicated on the left.
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bacteriological examination. To corroborate this and to exclude false positive PCR results we
repeatedly tested the samples both by PCR and by bacteriological examination. The same results
were obtained. Moreover, the specificity of the serotype 2-PCR product of samples, which could
not be confirmed bacteriologically, was further examined by sequence analysis and cross-
hybridization experiments. All fragments showed the expected serotype 2-specific sequence and
hybridized specifically with the serotype 2-specific probe (data not shown). From these data we
conclude that the PCR assays are more sensitive than the bacteriological examination.
Comparison of serotypes isolated from tonsils and affected tissues of diseased pigs. We next
compared the results of the serotypes found by PCR in tonsillar specimens of diseased pigs and the
serotypes of the strains isolated from the affected tissues of the same pigs. Table 2 shows that in
89% (34/38) of the cases a S. suis strain in the tonsils belonged to the same serotype as the disease-
causing strain. For some serotypes a positive correlation between clinical illness and carrier state
could be found. Four out of 5 pigs carrying EF-positive S. suis serotype 2 strains and most of the
pigs (27/32) carrying a serotype 9 strain were also clinically ill due to such a strain. Such a
correlation was not found in EF-negative serotype 2 (and 1/2) and 7 strains. One and 2 pigs suffered
from serotype 1/2 and 7 infections, respectively, whereas 13 and 17 pigs carried these bacteria on
their tonsils. This could indicate that compared to the EF-positive serotype 2 and serotype 9 strains,
EF-negative serotype 2 (and 1/2) and 7 strains are less virulent.
TABLE 2. S. suis strains isolated from affected tissues compared with the strains as detected by Multiplex PCR assays
on tonsils of 38 diseased pigs
S. suis No. of pigs in which bacteria were
isolated from
affected tissues
detected by
PCR on tonsils
isolated from
affected tissues and detected
by PCR on tonsils
Serotype 1 (or 14) 1 0 0
Serotype 2 (or 1/2) 1 13 1
EF-positive 4 5 4
Serotype 7 2 17 2
Serotype 9 29 32 27
NT1 1 0 0
Total 38 61 34
1 NT = Non Typable
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FIG. 3. PCR products in Multiplex PCR I (A) and Multiplex PCR II (B) obtained directly on tonsillar specimens
collected from diseased pigs carrying serotype 1 (and 14), 2 (and 1/2), 7, 9 and EF-positive S. suis strains as detected
by bacteriological examination. PCR products obtained with tonsillar specimen collected from pigs carrying: S. suis
serotype 1/2 (lane 1); S. suis serotype 7 (lane 2); S. suis serotype 9 (lane 3); S. suis serotype 7 and 9 strains (lane 4); S.
suis serotype 7 and 14 strains (lane 5); S. suis serotype 1/2 and 9 strains (lane 6); S. suis serotype 2 (EF-positive
phenotype) and 7 strains (lane 7); S. suis serotype 2 (EF-positive phenotype) and 9 strains (land 8); S. suis serotype 1/2,
7 and 9 strains (land 9). All samples contained 10 fg of positive control DNA. Lane MW contains DNA molecular weight
marker VIII (0.019-1.11kbp; Roche); the sizes (in bp) of the PCR products are indicated on the left.
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Multiple serotypes in tonsillar specimens of pigs. In 66% (25/38) of the tonsillar specimens
examined, two or more S. suis strains were identified by the Multiplex PCR assays on the same
tonsillar specimen (Table 3). Most frequently, a combination of serotypes 9 and 2 (and 1/2) (18%)
and serotypes 9 and 7 (16%) strains were detected by the Multiplex PCR assays. In 5 (13%) of the
tonsillar samples, the Multiplex PCR assays identified S. suis strains belonging to three different
serotypes, namely serotypes 2 (or 1/2), 7 and 9.
DISCUSSION
We previously showed that a PCR, based on the epf gene, specifically detects virulent strains of S.
suis serotype 2 and highly virulent strains of S. suis serotype 1 (27). In addition, PCR assays on the
serotype-specific cps genes of S. suis serotype 1, 2, 7 and 9 specifically identified S. suis serotype
1 (and 14), 2 (and 1/2), 7 and 9 strains (21, 22). In the present study, we improved the diagnostic
value of these PCR methods by using a multiplex based approach. In two separate reactions we
TABLE 3. Multiple serotypes of S. suis strains in tonsillar specimens of diseased pigs as detected by Multiplex PCR
assays
S. suis1No. of S. suis
strains on tonsillar
specimens
No. (%) of
specimens Serotype 1
(or 14)
Serotype 2
(or 1/2)
EF-positive Serotype 7 Serotype 9
One 11(29) –2 – – – +3
1(3) – – – + –
1(3) – + – – –
Two 7(18) – + – – +
6(16) – – – + +
3(8) – +4 +4 – +
2(5) – +4 +4 + –
1(3) – + – + –
1(3) + – – + –
Three 5(13) – + – + +
1 S. suis serotype 1 (and 14), 7 and 9 strains were detected by Multiplex PCR I and S. suis serotype 2 (and 1/2) and EF-
positive S. suis strains were detected by Multiplex PCR II.
2 –, negative result
3 +, positive result
4 Tonsillar specimens which contained an EF-positive serotype 2 strain
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could easily identify serotypes 1 (and 14), 7 and 9 (Multiplex PCR I) as well as serotype 2 (and 1/2)
and EF-positive S. suis strains (Multiplex PCR II). Evaluation of the Multiplex PCR assays using
tonsillar specimens of diseased pigs showed that both assays were highly specific and sensitive. The
bacteriological examination confirmed most (94%) of the results obtained with Multiplex PCR
assays. The PCR method seemed to be more sensitive compared to the bacteriological method.
Thirteen out of 73 samples positive by PCR were negative by bacteriological examination. Low
levels of bacterial cells (live or dead) in the tonsillar specimens may explain the differences in
results obtained with both methods.
S. suis strains producing an EF* protein, yielded in Multiplex PCR II only the serotype 2 products,
although larger products of various sizes were expected (27). Apparently, in the Multiplex PCR the
epf* gene was far less efficiently amplified, compared to the 236-bp amplicon of the serotype 2 -
specific cps gene. Since the frequency of S. suis strains isolated from diseased pigs which produce
the EF* protein is very low (28), detecting of strains producing an EF* protein in the Multiplex PCR
is a not a necessity.
In the bacteriological examination we isolated serotype 1/2 and 14 strains which hybridized
specifically with the serotype 2 and 1 probe, respectively. In early studies it was shown that serotype
1/2 strains cross-react in agglutination tests with antiserum against serotype 1 and serotype 2 strains
(13). For serotype 1 and 14 strains a one-way capsular cross-reaction in agglutinationtests was
described (6).
A positive correlation between carriership and clinical illness was observed for S. suis serotype 9
and EF-positive strains and not for serotype 7 and EF-negative serotype 2 (or 1/2) strains. This could
indicate that, compared to serotype 9 and EF-positive strains, serotype 7 and EF-negative serotype
2 (or 1/2) are less virulent. This idea corresponds well with the observation that in The Netherlands
serotype 9 and EF-positive strains were more frequently isolated from diseased pigs than serotype
7 and EF-negative serotype 2 (or 1/2) strains (28). Moreover, our data confirmed earlier studies
which indicated that EF-negative serotype 2 and 1/2 strains, belonging to these serotypes, are
possibly less or nonvirulent for pigs compared to EF-positive serotype 2 strains (26, 28). A role for
EF in the virulence of S. suis serotype 7 strains is not very likely. In recent studies, all serotype 7
strains, isolated from diseased pigs, were EF-negative, suggesting that EF cannot play a role in
virulence of serotype 7 strains (1, 28). Whether the serotype 7 strains, detected by the Multiplex
PCR assays in this study, are less virulent compared to serotype 9 or EF-positive serotype 2 strains
or whether these strains are totally nonvirulent is unknown. Experimental infections in pigs will be
necessary to examine the virulence of the serotype 7 strains.
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Multiple S. suis serotypes were found on tonsils of diseased pigs. Earlier, it was found that pigs can
be infected with multiple serotypes of S. suis (15, 17). These findings may account in part for the
difficulty in disease control by vaccines. At present, for the control of the disease by vaccines,
autogenous bacterins are used. It seemed that these vaccines only confer protection against challenge
with a strains of a homologous serotype (10). It can be hypothesized that a bacterin vaccine prepared
from one serotype may suppress clinical disease caused by that certain serotype but that new
outbreaks may occur caused by S. suis strains belonging to other serotypes. Therefore, identification
of specific strains, not only those involved in clinical disease in infected herds but also those
involved in the carrier state, may be needed to provide adequate control measures. The currently
developed Multiplex PCR assays can contribute to such an approach.
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ABSTRACT
The efficacy of a muramidase-released-protein (MRP) and extracellular factor (EF) vaccine in
preventing infection and disease in pigs challenged either with a homologous or a heterologous
Streptococcus suis serotype 2 strain (MRP+EF+) was compared with the protective capacity of a
vaccine containing formalin-killed bacterin of S. suis serotype 2 (MRP+EF+). The enhancement of
the immune response by different adjuvants (a water-in-oil emulsion [WO] and an aluminium
hydroxide-based adjuvant [AH]) and their side-effects were also studied. The MRP and EF were
purified by affinity chromatography. Pigs were vaccinated twice at three weeks and six weeks of age
and challenged intravenously with virulent S. suis serotype 2 strains (MRP+EF+) at eight weeks of
age. At challenge, the pigs vaccinated with MRP+EF/WO had high anti-MRP and anti-EF titres and were
protected as effectively as pigs vaccinated with WO-formulated vaccines with bacterin. Eight of the
nine pigs survived the challenge and almost no clinical signs of disease were observed. The titres
obtained with the MRP+EF/AH vaccine were low and only two of the five pigs were protected. Pigs
vaccinated with either MRP or EF were less well protected; three of the four pigs died after challenge
but the clinical signs of disease were significantly less severe than those observed in the placebo-
vaccinated pigs. The protective capacity of the bacterin/AH vaccine was very low and the mortality
among these pigs was as high as in the placebo-vaccinated pigs (80 per cent). Post mortem
histological examination revealed meningitis, polyserositis and arthritis in the clinically affected
pigs. The results demonstrate that a subunit vaccine containing both MRP and EF, formulated with
the WO adjuvant, protected pigs against challenge with virulent S. suis serotype 2 strains.
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INTRODUCTION
Streptococcal meningitis, polyserositis and polyarthritis, is a severe, often fatal disease of young pigs
at weaning, and is usually caused by Streptococcus suis serotype 2 (Vecht and others 1985, Higgins
and others 1992, Reams and others 1994). S. suis strains can be differentiated by serotype on the
basis of their capsular polysaccharides. At present, 35 serotypes are known (Perch and others 1983,
Gottschalk and others 1989, 1991, Higgins and others 1995). The virulence of most serotypes is
unclear. Strains of serotypes 2 and 1 are considered to be the most virulent serotypes, but strains of
some other serotypes, such as serotype 7, 9, and 14 have also been associated with disease
(Sihovenen and others 1988, Jacobs and others 1995, MacLennan and others 1996).
The economic impact of S. suis infections in the swine industry is substantial (Chengappa and
others 1990), and the prophylactic use of antibiotics in food and drinking water has so far been
unsuccessful in controlling the disease. Furthermore, antibiotics are becoming less effective because
of an increase in resistance among S. suis isolates and their use is unpopular because of the public
awareness of antimicrobial residues (Aarestrup and others 1998).
Little is known about the protective antigens of S. suis. Whole-cell vaccines with live avirulent
or killed virulent S. suis serotype 2 cells protected against challenge with a strain of a homologous
serotype (Holt and others 1988, 1990, Busque and others 1997). However, vaccination with whole
cells did not induce protection against challenge with a strain of a heterologous serotype (Kebede
and others 1990). Jacobs and others (1996) showed that a vaccine based on the purified 54 kDa
suilysin protected against a homologous challenge but the absence of this haemolysin from a
substantial number of isolates obtained from diseased pigs limits the usefulness of this vaccine
(Segers and others, 1998).
In previous work, the authors identified two proteins, the 136 kDa muramidase-released protein
(MRP) and the 110 kDa extracellular factor protein (EF), as markers of virulent S. suis serotype 1 and
2 strains (Vecht and others 1992). The MRP is a membrane-associated protein and EF is an
extracellular protein. Both are transported across the bacterial membrane and are major antigens
recognised by convalescent sera of infected pigs (Vecht and others 1992).
This paper describes the results of studies of the efficacy of MRP and EF vaccines in preventing
infection and disease in pigs challenged with a homologous or a heterologous S. suis serotype 2
strain (MRP+EF+), in comparison with the protective capacity of a vaccine containing formalin-
killed bacterin of S. suis serotype 2 (MRP+EF+).
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MATERIALS AND METHODS
Bacterial strains
Strains 4005 (3) and 3881 (10) of S. suis serotype 2, both belonging to the phenotype MRP+EF+,
were used. Both strains were field isolates, isolated from pigs suffering from meningitis and were
virulent for newborn germ-free pigs (Vecht and others 1992).
Adjuvants
Two adjuvants, a water-in-oil emulsion (Specol; ID-Lelystad) (WO) and a 2 per cent aluminium
hydroxide gel (Alhydrogel; Superfos Bisosector) (AH) were used.
Antigens
For the preparation of the vaccine, MRP and EF were purified by affinity chromatography. A two liter
culture of strain 4005, grown in Todd-Hewitt broth (code CM 189; Oxoid Ltd) was centrifuged at
4000 g for 15 minutes. The supernatant was cleared from remaining cells by filtration under air-
pressure through 0.2 µm-filters (Millipore). Monoclonal antibodies MRP3, or EF2 (ID-Lelystad) were
coupled separately to cyanogen bromide-activated Sepharose 4B in accordance with the instructions
of the supplier (Pharmacia). After appropriate washing the bound proteins were eluted with glycine-
hydrochloric acid buffer (0.1 M, pH 2.8) and the pH of the fractions was immediately increased to
7.0 by 1M sodium hydroxide. The fractions were measured with the MRP or EF double antibody
sandwich (DAS) ELISA for the detection of MRP and EF proteins as described by Vecht and others
(1993). Fractions positive for MRP and EF were pooled and dialysed overnight against physiological
saline. The purified proteins gave single bands in silver-stained sodium dodecyl sulfate-
polyacrylamide gels. The quantities of proteins were measured with the bicinchoninic acid protein
assay reagent (Pierce), using bovine serum albumin (BSA) as standard. Approximately 100 µg of
MRP and 240 µg of EF was obtained per litre of culture.
For preparation of the whole-cell vaccine, strain 4005 was incubated overnight at 37°C in 100
ml Todd-Hewitt broth. The culture contained about 1x109 colony-forming units (cfu)/ml. Fifty ml
were centrifuged at 4000 g for 15 minutes. Pellets were washed twice in phosphate-buffered-saline
(PBS: 136.89 mM sodium chloride, 2.68 mM potassium chloride, 8.1 mM sodium hydrogen
phosphate, 2.79 mM potassium hydrogen phosphate, pH 7.2.) and resuspended in 2.5 ml PBS. To
this suspension, 250 µl 3 per cent formalin was added and it was maintained at 4°C overnight. The
next day, the suspension was checked for the absence of live bacteria by plating on 6 per cent
Columbia horse blood agar base (code CM 331, Oxoid). To remove formalin, the cells were washed
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twice with physiological saline and resuspended in physiological saline to a final count of
approximately 1x109 cells/ml.
Vaccine preparation
WO or AH was used as adjuvant. For the preparation of emulsions in WO adjuvant, four parts of the
water phase containing the antigen were mixed with five parts of WO (Bokhout and others 1981).
For the vaccinations with AH adjuvant, 1.25 mg metallic aluminium was used per dose, according
to the manufacturer’s instructions. The antigens and AH were stirred for 4 hours at 4°C. To control
adsorption, 1 ml of the mixture was centrifuged in an Eppendorf centrifuge at 10,000 rpm for three
minutes, and the supernatants were analysed for the absence of the antigens either by MRP and EF
DAS ELISA (Vecht and others 1993) or spectrophotometrically by using an Ultrospec 3000
spectrophotometer (Pharmacia Biotech) at wavelengths of 250 to 650 nm.
For the preparation of placebo-vaccines, antigen solutions were replaced by a physiological saline
solution.
Vaccination
Fifty-five three-week-old pigs, crossbreeds of Yorkshire and Dutch landrace, were obtained from
the specified pathogen-free herd of the ID-Lelystad for two experiments. In both experiments the
pigs were allotted to six treatment groups each consisting of four or five pigs. Pigs were separated
and housed in boxes at the animal facilities of the ID-Lelystad.
Priming-vaccinations of pigs were given at the age of three weeks. Each dose contained 50 µg
MRP, 50 µg EF or 1x109 formalin-killed whole cells, either separately or in combination, and they
were administered intramuscular, divided over two injection sites, in both upper hind legs. Three
weeks later the pigs were boosted intramuscularly in the neck with the same dose of vaccines
without adjuvants.
Challenge
Two weeks after the second vaccination, the pigs were challenged intravenously in the ear vein with
1x107 cfu of the homologous S. suis serotype 2 strain 4005 (experiment 1) or the heterologous S.
suis serotype 2 strain 3881 (experiment 2). The inocula were prepared as described by Vecht and
others (1992). The pigs were monitored twice daily for the following clinical signs of disease: fever,
disorders of the nervous system, lameness, inappetence and depression. Blood samples were taken
once a week before the challenge and three times a week after the challenge to monitor the immune
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response. White blood cells were counted, using a semi-cell bloodcounter (Sysmex, model F 800;
Charles Goffin Medical Systems). The number of neutrophils was calculated after a differential
count of Giemsa-stained blood smears. For animal welfare reasons, pigs that were moribund or
showed nervous signs were killed by an intravenous injection of pentobarbiturate, exsanguinated
and examined postmortem. Tissue specimens from the central nervous system (CNS), serosae, and
joints were examined bacteriologically and histologically as described by Vecht and others (1992).
Lesions resulting from the injections of the vaccines were recorded.
The experiments were approved by the ethical committee of the Institute for Animal Science and
Health in accordance with Dutch law on animal experiments.
Antibodies against MRP and EF
The sera were tested for antibodies against MRP and EF by an indirect ELISA. Each well of the
polystyrene microtitre plates was coated for 18 hours at 37°C with 30 ng of MRP for the indirect MRP
ELISA or with 25 ng of EF for the indirect EF ELISA. Pig sera in two-fold dilutions from 1:5 to
1:5120 in PBS containing 0.05 per cent Tween 80 were added and the plates were incubated for 1
hour at 37°C. Serum from a gnotobiotic pig which had survived an infection with the virulent S. suis
serotype 2 strain 4005 (MRP+EF+) was used as positive control. As a conjugate, monoclonal
antibody mouse anti-swine immunoglobulin IgL labelled with horseradish peroxidase (ID-Lelystad)
was used. After incubation for one hour at 37°C, the substrate 5-aminosalycylic acid with hydrogen
peroxidase was added. After incubation for two hours at room temperature, the absorbance at 450
nm was read. Titres were expressed as the reciprocal of the 2log of the highest dilution showing an
absorbance of more than 50 per cent of the positive control.
Statistical analysis
Data concerning mortality and pathological lesions of the various groups were analysed
simultaneously by the nonparametric Fisher-Freeman-Halton exact test. When there was overall
significance, Fisher’s exact test was used to make pair-wise comparisons between the various
groups. In a similar manner, the antibody titres against MRP and EF, the clinical signs of disease,
fever and the number of leucocytes were subjected to exact median tests for simultaneous
comparisons, followed by exact pair-wise permutation tests. The last test was only used if there was
overall significance. The significance level was set at 95 per cent.
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RESULTS
Antibody titres against MRP and EF
All the pigs vaccinated with the MRP and EF vaccines with WO as adjuvant developed high anti-MRP
and -EF titres (Table 1). At the time of challenge average antibody titres against MRP ranged from
6208 to 23,170 and against EF from 7131-13,308. The titres obtained after vaccination with
MRP+EF/AH were much lower; at the time of challenge, the average antibody titre against MRP was
388 and against EF it was 1522.
Pigs vaccinated with the bacterin vaccines developed low anti-MRP titres only. In the pigs
vaccinated with bacterin/WO they started to develop after the booster administration to an average
anti-MRP titre of 158 at the time of challenge. No anti-EF titres could be detected in this group neither
before nor after challenge. In the bacterin/ AH group, none of the pigs had anti-MRP or anti-EF titres
at the time of challenge.
As expected, none of the pigs vaccinated with the placebo vaccines had developed antibodies
against MRP or EF at the time of challenge.
TABLE 1: Effect of vaccination with various Streptococcus suis serotype 2 vaccines on mean 2log antibody titres against
muramidase-released protein (MRP) and extracellular factor (EF) in pigs at the time of challenge
Experiment* Antigens Adjuvant Antibody titre against MRP (2log) Antibody titre against EF (2log)
Mean SEM Antilog Mean SEM Antilog
1 MRP WO 13.8a 1.1 14,263 0.0 0.0 0
EF WO 0.0 0.0 0 12.8a 1.3 7,131
MRP+EF WO 13.5a 0.9 11,585 13.3a 0.8 10,086
MRP+EF WO 12.6a 1.7 6,208 13.1a 0.8 8,780
+ bacterin
Placebo WO 0.0 0.0 0 0.0 0.0 0
Placebo No adjuvant 0.0 0.0 0 0.0 0.0 0
2 MRP+EF WO 14.5b 1.3 23,170 13.7b 1.8 13,308
MRP+EF AH 8.6c 1.3 388 10.6c 1.5 1,552
Bacterin WO 7.3b 1.6 158 0.0 0.0 0
Bacterin AH 0.0 0.0 0 0.0 0.0 0
Placebo WO 0.0 0.0 0 0.0 0.0 0
Placebo AH 0.0 0.0 0 0.0 0.0 0
* In experiment 1 pigs were challenged with the homologous S. suis serotype 2 strain 4005 (MRP+EF+) and in experiment 2 with the
heterologous S. suis serotype 2 strain 3881 (MRP+EF+).
a Significantly different from group placebo/WO, experiment 1
b Significantly different from group placebo/WO, experiment 2
c Significantly different from group placebo/AH, experiment 2
WO Water-in-oil emulsion, AH Aluminium hydroxide based adjuvant
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Protection
Two weeks after the second vaccination, the pigs were challenged intravenously in the ear vein with
1x107 cfu of the homologous S. suis serotype 2 strain 4005 (experiment 1) or the heterologous S.
suis serotype 2 strain 3881 (experiment 2). Seventeen of the 19 pigs vaccinated with the placebo
vaccines died one to four days after the challenge as a result of the infection or had to be killed for
animal welfare reasons (Table 2). In these groups, specific clinical signs of disease, such as
TABLE 2: Results of the vaccination of pigs with muramidase-released protein (MRP), extracellular factor (EF) and/or
bacterin of Streptococcus suis serotype 2 followed by a homologous or heterologous S. suis serotype 2 challenge
Experiment* Antigens† Adjuvant Number
of pigs
Mortality‡ Clinical signs of
disease (%)¥
Number
of pigs
Mean number
of days after
challenge§
Specific# Non-specific≠
Fever
index
(%)¶
Leucocy-
tosis index
(%)∆
1 MRP WO 4 3 5.0 15a 21a 38a 65
EF WO 4 3 2.6 38a 43 65 28
MRP+EF WO 4 1a 3 16a 11a 19a 31
MRP+EF WO 4 1a 2 13a 17a 16a 25
+ bacterin
Placebo WO 5 5 2 60 70 75 80
Placebo No adjuvant 5 5 2.4 46 84 77 100
2 MRP+EF WO 5 0b NA 1b 4b 7b 28b
MRP+EF AH 5 2 3.5 13c 31 36c 65
Bacterin WO 5 0b NA 0b 3b 1b 5b
Bacterin AH 5 4 2.8 37 56 86 90
Placebo WO 4 3 3.3 31 54 76 88
Placebo AH 5 4 3.3 34 57 78 90
* In experiment 1 pigs were challenged with the homologous S. suis serotype 2 strain 4005 (MRP+EF+) and in experiment
2 with the heterologous S. suis serotype 2 strain 3881 (MRP+EF+).
† MRP and EF were purified from S. suis serotype 2 strain 4005 (MRP+EF+). Bacterin was prepared from S. suis serotype
2 strain 4005 (MRP+EF+)
‡ Number of pigs that died owing to infection or had to be killed for animal welfare reasons
§ Mean number of days after challenge on which pigs died owing to infection or had to be killed for animal welfare
reasons
¥ Individual mean percentages were calculated by the number of observations/number of all observations per animal.
Group means were then calculated by total of individual means/number of pigs per group
# Nervous signs and/or lameness on at least one joint
≠ Inappetence and/or depression
¶ Percentage of observations of pigs with a body temperature >40°C
∆ Percentage of observations of pigs in which the concentration of granulocytes was >1010/litre
a Significantly different from group placebo/WO, experiment 1
b Significantly different from group placebo/WO, experiment 2
c Significantly different from group placebo/AH, experiment 2
NA Not applicable, WO Water-in-oil emulsion, AH Aluminium hydroxide based adjuvant
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lameness and nervous signs, were frequently recorded. Non-specific clinical signs of disease, such
as depression, recumbency and lack of appetite were also frequently observed. The pigs’ body
temperatures and leucocyte counts were also increased. In contrast, WO-formulated vaccines
containing both MRP and EF conferred a high degree of protection. Compared with the placebo-
vaccinated pigs, mortality was significantly (P<0.05) lower, and 11 of the 13 pigs survived the
challenge, both with the homologous and with the heterologous serotype 2 strain. The clinical signs
of disease and the increase in body temperatures were also significantly (P<0.05) reduced. Vaccines
containing either MRP or EF were less protective than the vaccine containing both proteins (Table
2, experiment 1), and most of the pigs in these groups did not survive the challenge. However,
compared with the pigs in the placebo-vaccinated groups, the pigs vaccinated with either MRP or EF
showed significantly (P<0.05) fewer specific clinical signs of disease and had lower fever and
TABLE 3: Lesions observed in pigs after vaccination with muramidase-released protein (MRP), extracellular factor (EF)
and/or bacterin of Streptococcus suis serotype 2 followed by a homologous or heterologous S. suis serotype 2 challenge
Experiment* Antigens Adjuvant Number
of pigs
Number of pigs with lesions
Meningitis† Polyserositis‡ Polyarthritis§ Total¥
Number of pigs
with lesions at
site of injection
1 MRP WO 4 2 0 2 3 2
EF WO 4 3 3 2 3 2
MRP+EF WO 4 1 1 1a 2 4
MRP+EF WO 4 1 1 1a 1a 2
+ bacterin
Placebo WO 5 4 5 5 5 5
Placebo No adjuvant 5 4 4 5 5 2
2 MRP+EF WO 5 0 0b 0 0b 3
MRP+EF AH 5 1 1 1 2 3
Bacterin WO 5 0 0b 0 0b 3
Bacterin AH 5 2 4 2 4 4
Placebo WO 4 3 3 3 4 4
Placebo AH 5 1 5 3 5 0
* In experiment 1 pigs were challenged with the homologous S. suis serotype 2 strain 4005 (MRP+EF+) and in experiment 2 with
the heterologous S. suis serotype 2 strain 3881 (MRP+EF+).
† Meningitis was characterised by inflammation of cerebrum, cerebellum, pons, mesencephalon and medulla oblongata
‡ Polyserositis was characterised by inflammation of peri- and epicardium, thoracic pleura and peritoneum
§ Polyarthritis was characterised by inflammation of carpal, tarsal, knee, elbow, shoulder and hip joints
¥ Total number of pigs with lesions: several pigs developed more than one lesion
a Significantly different from group placebo/WO, experiment 1
b Significantly different from group placebo/WO, experiment 2
WO Water-in-oil emulsion, AH Aluminium hydroxide based adjuvant
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lower leucocyte counts. The MRP+EF/AH vaccine conferred a low degree of protection; only three
of the five pigs survived the challenge with the heterologous S. suis type 2 strain, but, compared
with the placebo-vaccinated pigs, the specific clinical signs of disease and the fever were
significantly (P<0.05) lower (Table 2, experiment 2). Eight of the nine pigs vaccinated with WO -
formulated vaccines containing bacterin were protected against a challenge with the homologous
or heterologous serotype 2 strain; mortality in these groups was significantly (P<0.05) lower than
in the placebo-vaccinated groups, and there were fewer specific or non-specific signs of disease
(P<0.05) and a lower level of fever. In contrast, a bacterin/AH vaccine conferred less protection; four
of the five pigs vaccinated with this vaccine died two to four days after challenge, and specific signs
of disease were observed as often as in the placebo-vaccinated pigs.
Postmortem results confirmed the clinical findings. Histological examination revealed
meningitis, polyserositis and arthritis in the placebo-vaccinated pigs, in four of the five pigs
vaccinated with bacterin/AH, and in three of the five pigs vaccinated with EF/WO (Table 3). In
contrast, the pigs vaccinated with MRP+EF/WO, bacterin/WO and MRP+EF+bacterin/WO had
significantly (P<0.05) fewer lesions and bacteria were isolated from the lesion sites less frequently.
Lesions were observed at the injection site in the pigs of all groups, except for those vaccinated
with the AH-formulated placebo vaccine. They ranged in severity from being less than 1 cm3 in size
and involving connective tissue only, to being more than 1 cm3, with necrosis, microabscesses or
granulomas (Table 3).
DISCUSSION
These results show that vaccines containing MRP+EF/WO protected pigs against challenge with either
a homologous or heterologous S. suis serotype 2 strain with the phenotype MRP+EF+. The
MRP+EF/WO vaccine was as protective as a bacterin/WO vaccine. All but one of the pigs vaccinated
with MRP+EF/WO survived the challenge and few specific clinical signs of disease were observed.
The MRP/WO or EF/WO vaccines were much less protective; three of the four vaccinated pigs died
after challenge. However, compared with the placebo-vaccinated pigs, the pigs vaccinated with
MRP/WO or EF/WO showed significantly fewer clinical signs of disease. These data are in accordance
with the results of Jacobs and others (1996) who described a vaccine which contained most of the
extracellular antigens produced by a S. suis serotype 2 strain, with EF being the most abundant
protein. However, the vaccine only partially protected pigs against challenge with a virulent S. suis
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type 2 strain.
The protection observed with the MRP and/or EF vaccines was associated with the levels of anti-
MRP and anti-EF antibodies. The MRP+EF/WO vaccine induced high antibody titres and protected pigs
effectively against challenge with either homologous or heterologous S. suis serotype 2 strains. On
the other hand, the vaccine with MRP+EF/AH induced lower antibody titres and the pigs were less
well protected. In contrast, no association between anti-MRP and anti-EF titres and protection was
observed with the bacterin vaccines. Pigs vaccinated with bacterin/WO had low antibody titres
against MRP and EF but nevertheless appeared to be completely protected against challenge. It seems
likely that other antigens than MRP and EF are responsible for this protection, for example capsular
antigens, as has been suggested by Kebede and others (1990).
WO adjuvant was superior to AH adjuvant in its capacity to stimulate an immune response after
vaccination with MRP and EF and to confer protection against challenge with virulent S. suis serotype
2 strains. Similarly, Ripley (1983) showed that an oil-based adjuvant produced a significant antibody
response with killed bacterins, whereas only a transient increase in antibodies was observed after
vaccination with an AH-formulated vaccine. However, it appeared that both WO and AH adjuvants
caused serious lesions at the injection sites, and a suitable alternative adjuvant or a refinement of
WO is therefore desirable.
Holt and others (1990) found that a vaccine containing bacterin without an adjuvant protected
as well as bacterin formulated either with Freund's incomplete adjuvant or with aluminium
hydroxide gel as an adjuvant. However, the same experiments showed that the protective response
of bacterin was stimulated when the size of the inoculum was increased from 1010 to 1011 killed
organisms. In this study, the bacterin contained 109 killed cells, and a strong potentiating adjuvant
like WO seemed to be necessary to obtain protection.
Whole-cell vaccines are probably serotype-specific, because protection was achieved only against
a strain of a homologous serotype, and the vaccines failed to protect against other serotypes (Kebede
and others 1990; Foster and others 1994). Subunit vaccines based on proteins conserved among
serotypes may be more useful in veterinary practice if they protect against challenge with strains of
heterologous serotypes. Jacobs and others (1996) suggested that suilysin, a thiol- activated
haemolysin from S. suis serotype 2, could be such a cross-protection factor. Vaccination challenge
experiments in pigs indicated that this vaccine protected against challenge with a homologous
serotype. However, the haemolysin is absent from quite a number of strains of S. suis, isolated from
diseased pigs in the field. This implies that other vaccine components will be necessary to provide
protection against all field strains (Jacobs and others 1996, Segers and others 1998). A 52 kDa
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immunoglobulin-binding protein (IBP), which has recently shown to be identical to a 60 kDa heat-
shock protein that is produced by various serotypes, could be another candidate for a subunit vaccine
(Serhir and others 1993; Benkirane and others 1997, 1998). The protective value of this protein has
not been tested.
In Europe, the USA and Australia, most of the S. suis serotype 2 strains isolated from diseased
pigs produce MRP and EF (Mwaniki and others 1994, Galina and others 1996, Wisselink and others
2000). In these countries an MRP+EF vaccine could therefore be of great value. However, most of
the S. suis serotype 2 strains isolated from diseased pigs in Canada appeared to be MRP and EF
negative (Gottschalk and others 1998). Apparently, Canadian strains differ from strains isolated in
other countries. The proteins MRP and/or EF are not only produced by serotype 2 strains. High
percentages of European S. suis serotype 1, 1/2, and 14 strains, isolated from tissues associated with
S. suis infections such as brain, serosa, joint, heart and other organs of diseased pigs, expressed MRP
and EF, and more than 80 per cent of the S. suis serotype 9 strains produced an MRP* protein, a high
molecular variant of the 136 kDa MRP. (Wisselink and others 2000). In addition to serotype 2 strains,
strains of serotypes 1, 1/2, 7, 9 and 14 are frequently isolated from diseased pigs. Further work is
needed to determine whether MRP and EF are involved in the protection of pigs infected with strains
of other serotypes producing MRP and/or EF.
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Abstract
The protective efficacy of a live and killed non-encapsulated isogenic mutant of Streptococcus
suis serotype 2 was determined in pigs, and compared with the efficacy of the capsulated wild-type
strain. SPF pigs were vaccinated twice intramuscularly at four and seven weeks of age with a dose
of 1X109 formalin-killed CFU of the wild-type (WT-BAC), formalin-killed non-encapsulated
mutant (CM-BAC) or live non-encapsulated mutant (CM-LIVE) strain. After two weeks, vaccinated
pigs and non-vaccinated controls were challenged intravenously with 1X107 CFU of the
homologous, wild-type S. suis serotype 2 strain. Protection was evaluated by clinical,
bacteriological, serological and post-mortem examinations. All pigs vaccinated with WT-BAC were
completely protected against challenge with the homologous serotype. Pigs vaccinated with CM-
BAC were partially protected. Although all pigs vaccinated with CM-BAC survived the challenge,
four out of five pigs developed clinical signs of disease for several days. Compared to the WT-BAC
and CM-BAC, the CM-LIVE vaccine was less protective. Two out of five pigs vaccinated with CM-
LIVE died in the course of the experiment and all of them developed specific clinical signs of
disease for several days. The protective efficacy of the vaccines could be associated with serum
antibody titers. Antibody titers against cells of wild-type and non-encapsulated mutant strains as
well as against muramidase-released proteins (MRP) were high in pigs vaccinated with WT-BAC
and CM-BAC. Pigs vaccinated with CM-LIVE showed lower antibody titers. Antibody titers against
purified capsular polysaccharides (CPS) of S. suis serotype 2 were only found in pigs vaccinated
with WT-BAC. These findings indicate that CPS and other bacterial components of WT-BAC are
probably essential for full protection against homologous challenge.
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1. Introduction
Streptococcus suis serotype 2 is a major cause of meningitis, polyserositis, arthritis, septicaemia
and sudden death in young pigs (Vecht et al., 1985; Reams et al., 1994). At present, 35 serotypes
of S. suis are described (Perch et al., 1983; Gottschalk et al., 1989; 1991; Higgins et al., 1995). In
Europe, S. suis serotype 2 is the most prevalent capsular serotype isolated from diseased pigs,
followed by serotypes 9 and 1 (Wisselink et al., 2000).
The development of effective vaccines is hampered by the number of virulent serotypes, by the
lack of knowledge of virulence factors and by variation in virulence not only between serotypes but
also between strains belonging to a single serotype (Vecht et al., 1992; Stockhofe et al., 1996).
Killed whole-cell vaccines seem to induce significant protection against challenge with a strain
of a homologous serotype, but this protection is probably serotype-specific (Kebede et al., 1990;
Foster et al., 1994). Live virulent and avirulent S. suis serotype 2 strains also confer good protection
against a homologous challenge, but this requires repeated immunizations (Holt et al., 1988; Busque
et al., 1997). In addition to killed whole-cell and live vaccines, a number of different subunit
vaccines has been developed. Jacobs and others (1996) showed that a vaccine containing purified
suilysin, a thiol- activated haemolysin from S. suis serotype 2, protected pigs against challenge with
the homologous strain. However, the absence of suilysin in a substantial number of isolates
recovered from diseased pigs hampers the use of this vaccine (Segers et al., 1998). Recently, we
showed that a vaccine containing muramidase-released proteins (MRP) and extracellular factor
(EF), two virulence markers of S. suis serotype 2, protected pigs against challenge with a
homologous and heterologous S. suis serotype 2 strain (Wisselink et al., 2001). The protective
efficacy against other serotypes remains to be investigated.
Previous attempts to stimulate an immune response by vaccination with purified CPS were not
successful (Elliott et al., 1980). Only when CPS was used with Freund’s incomplete adjuvant,
opsonizing antibodies were observed against S. suis serotype 2. The protective effect of this
antibody is not known. In addition, it was found that besides antibodies to CPS, antibody responses
against other bacterial components are required to confer full protection against challenge with S.
suis serotype 2 (Holt et al., 1990; Del Campo Sepúlvida et al., 1996). However, in these studies,
whole-cell vaccines of fully encapsulated S. suis serotype 2 strains were used and so far, the
contribution of CPS and other bacterial components in protection remains unclear.
Recently, we isolated and characterized non-encapsulated isogenic mutants of a virulent S. suis
serotype 2 strain (Smith et al., 1999). These mutants were highly sensitive to ingestion by porcine
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lung macrophages and appeared avirulent in young germfree pigs. The non-encapsulated bacteria
however, were still able to replicate in the host and pigs became carriers (Smith et al., 1999).
Here, we describe the protective properties of a non-encapsulated mutant in pigs against
challenge with a virulent, homologous S. suis serotype 2 strain. Therefore, the protective capacity
of live and killed vaccines based on the non-encapsulated mutant strain was determined and
compared with the protective efficacy of a vaccine containing formalin-killed cells of the fully
encapsulated wild-type strain. The results showed that, as expected, formalin-killed cells of a wild-
type strain conferred complete protection against mortality and morbidity after challenge with a
homologous strain. Formalin-killed cells of the non-encapsulated mutant conferred complete
protection against mortality. However, only partial protection against morbidity was observed. The
live vaccine conferred only partial protection, both against mortality and morbidity.
2. Materials and methods
2.1 Bacterial strains
Two strains, the wild-type strain 10 of S. suis serotype 2, and its isogenic non-encapsulated
mutant strain 10cps∆EF, were used in this study (Vecht et al., 1992, Smith et al. 1999).
2.2 Preparation of the killed vaccines
For preparation of the whole-cell vaccines, strains were incubated overnight at 37°C in 100 ml
Todd-Hewitt broth (code CM 189; Oxoid). The next day, bacteria were diluted tenfold in fresh,
prewarmed Todd-Hewitt. Log-phase cultures were prepared, suspended in phosphate-buffered-
saline (PBS: 136.89 mM NaCl, 2.68 mM KCl, 8.1 mM Na2HPO4, 2.79 mM KH2PO4, pH 7.2.) and
adjusted to an optical density of 1 (600 nm). Formalin-killed cells were prepared as described before
(Wisselink et al., 2001). The vaccines contained about 109 CFU/ml.
A water-in-oil emulsion, (Specol; ID-Lelystad) (WO) was used as adjuvant (Table 1). For
preparation of emulsions in the WO adjuvant, four parts of the water phase containing the antigens
were mixed with five parts of WO (Bokhout et al., 1981). In the placebo-vaccine, the antigen
solution was replaced by a physiological saline solution.
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2.3 Preparation of the live vaccine
To prepare a vaccine containing live cells of the non-encapsuled mutant, strain 10cps∆EF was
incubated overnight at 37°C in 100 ml Todd-Hewitt broth. The next day, bacteria were diluted
tenfold in fresh, prewarmed Todd-Hewitt. Log-phase cultures were prepared, suspended in Todd-
Hewitt and adjusted to an optical density of 1 (600 nm) corresponding to approximately ~ 109
CFU/ml.
CoVaccine Adjuvant (CoVaccine, Lelystad, The Netherlands), a nonmineral oil-in-water
emulsion, was used as adjuvant in the live vaccine. CoVaccine Adjuvant was prepared with Todd-
Hewitt broth instead of PBS as the aqueous phase. The vaccine was prepared by mixing one volume
of the CoVaccine Adjuvant with one volume of live bacteria.
2.4 Viability of the live vaccine
To evaluate the viability of S. suis strain 10cps∆EF in CoVaccine Adjuvant, ten ml of the vaccine
were incubated for three days at ambient temperature. Tenfold dilutions of the vaccine were plated
on six per cent Columbia horse blood agar base (code CM 331, Oxoid) and incubated overnight at
37°C. The next day the numbers of CFU were determined.
2.5 Vaccination
Twenty pigs, crossbreeds of Yorkshire and Dutch landrace (three-weeks-old) were obtained from
the specified pathogen-free (SPF) herd kept at ID-Lelystad. Pigs were allotted to four treatment
groups of five animals. Pigs were separated and housed in boxes at the animal facilities of the ID-
Lelystad.
Priming-vaccinations of pigs were done at the age of three weeks. Pigs received per dose 1x109
formalin-killed whole cells of either the wild-type or the non-encapsulated mutant strain. Priming-
vaccinations were administered intramuscularly, divided over three injection sites, in the neck and
in the upper hind- and foreleg. Three weeks later the pigs were boosted with the same vaccine, via
the same route.
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2.6 Challenge
Two weeks after the second vaccination all pigs were challenged intravenously with 1x107 CFU
of the virulent, wild-type S. suis serotype 2 strain 10 via the ear vein. Inocula were prepared as
described before (Vecht et al., 1992). Pigs were monitored twice a day for clinical signs of disease
such as fever, depression, loss of appetite, lameness and central nervous signs. Blood samples were
collected once a week, immediately before challenge, and three times a week after challenge. White
blood cells were counted using a semi-cell bloodcounter (Sysmex, model F 800; Charles Goffin
Medical systems BV, Tiel, The Netherlands). The number of neutrophils was calculated after
differential count of Giemsa-stained blood smears. To monitor for the presence of S. suis serotype
2, we used a PCR-assay based on the epf gene (Wisselink et al., 1999). Tonsillar swabs were
collected weekly before challenge and three times a week after challenge. Swabs were grown
overnight at 37°C in five ml Todd-Hewitt broth with 0.25% Streptococcus Selective Supplement
(Oxoid) and 0.2 µg/ml cristalviolet. From each sample, 50 µl were processed and used in the PCR
assay as described previously (Reek et al., 1995; Wisselink et al., 1999). For animal welfare reasons,
pigs that were moribund or showed disorders of the nervous system were immediately euthanized
by intravenous injection of pentobarbiturate followed by exsanguination and necropsy. Tissue
specimens from the central nervous system (CNS), serosae, and joints were examined
bacteriologically and histologically as described before (Vecht et al., 1992). Tissue lesions resulting
from the injections with vaccines were recorded. To examine colonization of the live vaccine at the
injection sites, these sites were examined bacteriologically.
The experiments were approved by the ethical committee of the ID-Lelystad in accordance with
Dutch law on animal experiments.
2.7 Immune response
To monitor the immune response, blood samples were collected prior to the vaccinations and
immediately prior to challenge. Sera were tested in indirect ELISAs. For the detection of antibodies
against the wild-type and non-encapsulated mutant strains, wells of polystyrene microtiter plates
(Greiner BV, Alphen aan den Rijn, The Netherlands) were coated for 18 h at 37°C with 1x107
formalin-killed cells of the wild-type (WT-ELISA) or of the non-encapsulated mutant strains (CM-
ELISA). Fifty µl of twofold serum dilutions from 1:10 to 1:5120 in PBS containing 0.05% Tween
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80, were added and plates were incubated for 1 h at 37°C. Serum of a gnotobiotic pig, which
survived an earlier infection with the virulent S. suis serotype 2 strain 4005, was used as positive
control (Vecht et al., 1992).
For the detection of antibodies against purified CPS of S. suis serotype 2, an indirect ELISA was
used as described by Del Campo Sepúlvida et al. (1996). Purified CPS was kindly provided by Dr.
E. Altman (NRC, Ottawa, Ont., Canada). Each well of the polystyrene microtiter plates was coated
for 18 h at 37°C with 0.1 µg purified CPS of S. suis serotype 2 suspended in 50 mM NaHCO3, pH
9.6. As negative and positive controls anti-S. suis serotype 1 and 2 hyperimmune rabbit sera were
used, respectively (Vecht et al., 1985).
The indirect anti-MRP and anti-EF ELISAs were performed as described before (Wisselink et
al., 2001).
As conjugate in the indirect ELISAs, MAb anti-swine IgL (ID-Lelystad, Lelystad, The
Netherlands), conjugated with HRPO, or swine anti-rabbit IgG, conjugated with HRPO (Nordic,
Tilburg, The Netherlands) was used. After incubation for 1 h at 37°C, the substrate 3,3’,5,5’-
tetramethylbenzidine (TMB) with H2O2 was added to each well. After incubation for 10 min at
roomtemperature the reaction was stopped by the addition of sulphuric acid. The plate was read by
use of an Bio-Kinetics ELISA reader (Bio-Tek Instruments INC, Winooski, VT) at 450 nm. Optimal
dilutions of coating antigens and peroxidase conjugated MAb anti-swine IgL were determined by
checkerboard titrations in preliminary studies.
Antibody titers were expressed as the 2-log of the regression coefficient of the optical density vs.
serum concentration. Per group of five animals, geometric mean and STDEV was calculated.
2.8 Statistical analysis
Data concerning mortality, morbidity and post-mortem results were analyzed simultaneously by
the nonparametric Fisher-Freeman-Halton exact test. In case of overall significance, the Fisher’s
exact test was performed to make paired comparisons between the experimental groups vs. the
placebo-vaccinated group. In a similar manner antibody titers against the wild-type strain, against
the non-encapsulated mutant strain, against MRP and EF, clinical signs of disease, fever and number
of leucocytes were subjected to exact median tests for simultaneous comparisons, followed by exact
paired permutation tests. The latter test was only performed in case of overall significance. A P
value <0.05 was considered to be significant.
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3. Results
3.1 Antibody titers
All pigs vaccinated with WT-BAC or CM-BAC developed high antibody titers against formalin-
killed wild-type cells, against formalin-killed non-encapsulated mutant cells as well as against the
membrane protein MRP (Figs. 1 A, B, C). Compared to titers of placebo-vaccinated pigs,
significantly (P<0.05) higher titers were already observed three weeks after the priming-vaccination.
At the day of challenge mean antibody titers ranged from 14.5 to 16.7 2-log units. Pigs vaccinated
with WT-BAC or CM-BAC did not develop titers against EF (Fig. 1D).
Compared to the bacterin vaccinated pigs, CM-LIVE vaccinated pigs developed lower antibody
titers against formalin-killed wild-type and non-encapsulated mutant cells as well as against MRP
(Figs. 1 A, B, C). Especially at the time of the second immunization the mean antibody titer in CM-
LIVE vaccinated pigs was lower than in WT-BAC and CM-BAC vaccinated pigs. However, at this
time, titers in the CM-LIVE vaccinated pigs against formalin-killed non-encapsulated mutant cells
and MRP were significantly (P<0.05) higher than the placebo-vaccinated pigs. At the time of
challenge, titers against formalin-killed wild-type and non-encapsulated mutant cells and against
MRP were significantly (P<0.05) higher in the CM-LIVE vaccinated pigs than in the placebo-
vaccinated pigs. In a previous experiment we showed that the non-encapsulated mutant strain was
avirulent, but could replicate in the host. If so, expression of EF and the development of anti-EF
antibodies in CM-LIVE vaccinated pigs could be expected. However, no anti-EF antibodies were
detected in CM-LIVE vaccinated pigs (Fig. 1D).
Four out of five pigs vaccinated with WT-BAC developed antibodies against purified CPS of S.
suis serotype 2. Titers ranged from 1.9 to 4.8 2-log units at the time of the second immunization and
ranged on the day of challenge from 3.0 to 9.0 2-log units (Fig. 1 E). Compared to the placebo-
vaccinated pigs, the mean anti-CPS titer in the WT-BAC vaccinated pigs was significantly (P<0.05)
higher at the time of challenge. As expected, in sera from pigs vaccinated with CM-BAC and CM-
LIVE, no anti-CPS antibodies could be detected. Rabbit hyperimmune sera to S. suis serotype 1 and
2 were used as negative and positive control, respectively. A titer of 9.7 2-log units was found in
rabbit hyperimmune serum to S. suis serotype 2, while a titer of 0.4 2-log units was obtained with
S. suis serotype 1 serum.
None of the placebo-vaccinated pigs developed antibodies against the wild-type strain, the non-
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Fig. 1. Antibody titers in sera from pigs after vaccination with CM-LIVE () and CM-BAC (), WT-BAC () and
placebo (X). Arrows indicate the time of first immunization (week 4) and booster immunization (week 7). Antibody titers
were measured by indirect ELISAs against formalin-killed wild-type cells (A), formalin-killed non-encapsulated mutant
cells (B), MRP (C), EF (D), and purified CPS of S. suis serotype 2 (E).
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encapsulated mutant strain, purified CPS of S. suis serotype 2, MRP and EF. There was no change
in the antibody response throughout the period following the vaccination.
3.2 Viability of the live vaccine strain
The numbers of CFU of the non-encapsulated mutant strain in CoVaccine Adjuvant modified
in Todd-Hewitt decreased in 24 h at ambient temperature from 1.3 X 109 to 7.5 X 108 CFU/ml. The
next two days colony counts were nearly stable at 7.3 and 4.2 X 108 CFU/ml, respectively. This
indicates that the CoVaccine Adjuvant hardly affected (factor 3) the viability of the non-capsulated
mutant strain.
3.3 Efficacy of live and killed vaccines
All placebo-vaccinated pigs were severely affected after challenge (Table 1). All pigs had to be
killed for animal welfare considerations within two days after the challenge due to the infection.
Specific S. suis clinical signs of disease as central nervous signs and lameness were found in 87%
Table 1
Vaccination of pigs with S. suis serotype 2 non-encapsulated mutant and wild-type strains followed by a challenge with
a wild-type S. suis serotype 2 strain
Antigens Adjuvant Clinical signs of
disease (%)d
Vaccine
S. suis straina
Mortalityb Morbidityc
Specifice Non-
specificf
Fever
index
(%)g
Leucocy-
tosis index
(%)h
CM-BAC 10cps∆EF Formalin-killed WO 0/5i 4/5 15 i 29 i 42 i 20
CM-LIVE 10cps∆EF Live CoVaccine adjuvant 2/5 5/5 30 i 27 i 46 i 0
WT-BAC 10 Formalin-killed WO 0/5 i 0/5 i 0 i 0 i 0 i 40
Placebo NA NA WO 5/5 5/5 87 100 80 60
a Strain 10 is the wild-type strain, and strain 10cps∆EF is an isogenic non-encapsulated mutant strain (Smith et al. 1999)
b Number of pigs per group that died due to infection or had to be killed for animal welfare reasons
c Number of pigs with specific symptoms
d Individual mean percentages were calculated by number of observations/number of all observations per animal. Group means
were then calculated by total of individual means/number of pigs per group
e Nervous signs and/or lameness on at least one joint
f Inappetence and/or depression
g Percentage of observations of pigs with a body temperature >40°C
h Percentage of observations of pigs in which the concentration of granulocytes was >1010/liter
i Significantly different from Placebo-vaccinated group
NA: Not applicable; WO: Water-in-oil emulsion
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of the observations after challenge (Table 1). The incidence of non-specific clinical signs of disease
was also high and all animals became anorexic, depressed and feverish (temperature above 40°C)
within one day after challenge. In contrast, WT-BAC was highly effective in protecting pigs against
a challenge with the wild-type strain. All pigs in this group survived and no specific or non-specific
clinical signs of disease were recorded. Body temperatures of these pigs never exceeded 40°C and
leucocyte counts remained low until the end of the experiment.
CM-BAC also conferred protection against challenge with the virulent wild-type strain.
Mortality, specific and non-specific clinical signs of disease in CM-BAC vaccinated pigs were
significantly (P<0.05) lower as in the placebo-vaccinated pigs. Moreover, pigs had a significantly
(P<0.05) lower fever and leucocytosis index. However, four out of five pigs developed lameness
for one or more days.
Compared to the other vaccines used, CM-LIVE seemed to be less protective. Two of the five
CM-LIVE vaccinated pigs developed neurological signs of disease and had to be killed. However,
no severe illness occurred in the three other pigs and clinical signs of disease as well as fever index
was significantly (P<0.05) lower compared to the placebo-vaccinated pigs.
At necropsy, four out of five placebo-vaccinated pigs had meningitis and all had polyserositis and
polyarthritis, with most joints affected (Table 2). S. suis serotype 2 could frequently be isolated from
the CNS, the serosae and the joints. In contrast, pigs vaccinated with WT-BAC showed no
Table 2
Post-mortem results recorded in vaccinated pigs after challenge with a virulent S. suis serotype 2 strain
Antigens No. of pigs with lesions at
CNSb Serosaec Jointsd
Vaccine
S. suis straina
Adjuvant No. of
pigs
Pte Bacf Pt Bac Pt Bac
Immunization
siteg
CM-BAC 10cps∆EF Formalin-killed WO 5 0h 0h 0h 0h 5 0h Major lesions
CM-LIVE 10cps∆EF Live CoVaccine adjuvant 5 2 1 0h 0h 5 2 Minor lesions
WT-BAC 10 Formalin-killed WO 5 0h 0h 0h 0h 0h 0h Major lesions
Placebo NA NA WO 5 4 4 4 4 5 5 Major lesions
a Strain 10 is the wild-type strain, and strain 10cps∆EF is an isogenic non-encapsulated mutant strain (Smith et al. 1999)
b Cerebrum, cerebellum, pons, mesencephalon and medulla oblongata
c Peri- and epicardium, thoracic pleura and peritoneum
d Carpal, tarsal, knee, elbow, shoulder and hip joints
e Pathologic lesions
f Isolation of S. suis at necropsy
g Immunization sites were examined at necropsy and evaluated for the extent of abscess formation
h Significantly different from Placebo-vaccinated group
NA: Not applicable; WO: Water-in-oil- emulsion
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pathological lesions and no S. suis bacteria were isolated. None of the pigs vaccinated with CM-
BAC showed pathological lesions in the CNS and the serosae and no S. suis bacteria were isolated
from these sites. All CM-BAC vaccinated pigs showed pathology at the joints with signs of serous
or fibroserous inflammation. However, no S. suis bacteria could be isolated from the affected joints.
Two out of five pigs vaccinated with CM-LIVE had pathology in the CNS and from one of these
pigs S. suis could be recovered from the CNS. All pigs had signs of serous or fibroserous
inflammation at the joints. From two of these pigs, S. suis could be reisolated from the joints.
Severe lesions at the immunization sites were found in all pigs vaccinated with WO formulated
vaccines. Necrosis, abscesses and granulomas of connective tissue were seen. Minor lesions with
extra connective tissue reaction were observed in pigs vaccinated with the CoVaccine Adjuvant
formulated vaccine. No bacteria could be recovered at necropsy from the injection sites of the CM-
LIVE vaccinated pigs, indicating that the bacteria were not able to colonise at these sites.
Tonsillar swabs were obtained for the detection of EF-positive S. suis serotype 2 strains by PCR.
At the start of the experiment no EF-positive strains were detected by PCR on the tonsillar swabs
(results not shown). One week after the second immunization two out of five CM-LIVE vaccinated
pigs were PCR-positive, indicating that in these two pigs bacteria of the live vaccine colonized the
tonsil. However, at the day of challenge these two pigs were PCR-negative again. Two to five days
after the challenge all pigs became positive in the PCR assay.
4. Discussion
In the present study we evaluated the protective efficacy of a non-encapsulated mutant of S. suis
serotype 2. The results showed that a CM-BAC vaccine protected pigs against challenge with a
strain of a homologous serotype. However, compared to the WT-BAC vaccinated pigs this
protection was not complete. All CM-BAC vaccinated pigs survived the challenge with the virulent
wild-type S. suis serotype 2 strain, but four out of five pigs showed clinical signs of disease during
a few days. Full protection was obtained with the WT-BAC vaccine. All pigs survived the challenge
and no clinical signs of disease were seen throughout the whole observation period after challenge.
Because the wild-type and the isogenic non-encapsulated mutant strains only differ in expression
of CPS, these data indicate that CPS and other bacterial components are probably essential for full
protection against homologous challenge. Antibody titers induced by the two bacterin vaccines
supported this hypothesis. WT-BAC and CM-BAC induced identical antibody levels against
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formalin-killed wild-type and non-encapsulated mutant cells as well as against MRP, a membrane
protein. However, only WT-BAC induced antibodies against CPS. Although present in low levels,
CPS antibodies seem to play a role in protection against challenge after vaccination with WT-BAC.
The protection obtained with CM-BAC was not complete. Earlier Holt et al., (1990) showed that
the protective immunity of a killed vaccine was enhanced when the size of the inoculum was
increased to 1010 or 1011 organisms. Since we used 109 cells in our experiment the protective
efficacy of CM-BAC could probably be enhanced by using inocula with a higher number of cells.
Compared to WT-BAC and CM-BAC, CM-LIVE seemed to be less protective. Two out of five
CM-LIVE vaccinated pigs died in the course of the experiment and all pigs showed clinical signs
of disease for one or more days. The difference in protection between CM-LIVE and CM-BAC
could be associated with the various levels of antibody responses against formalin-killed wild-type
and non-encapsulated mutant cells as well as against MRP. Antibody titers were consistently higher
in WT-BAC and in CM-BAC vaccinated pigs than in CM-LIVE vaccinated pigs. Since we used
CoVaccine Adjuvant as adjuvant in CM-LIVE, and WO as adjuvant and in WT-BAC and in CM-
BAC, we can not exclude that WO and CoVaccine Adjuvant also have an effect on antibody levels
and protection in our treatment groups.
No antibody titers against EF, an extracellular protein, were detected in the CM-LIVE vaccinated
pigs. To obtain antibodies against EF, replication of the non-encapsulated mutant strain in the host
is required. PCR analysis on tonsillar swabs for the presence of EF-positive S. suis strains showed
that two out of five CM-LIVE vaccinated pigs became carriers. This implies that, at least in two
pigs, the bacteria were able to colonize the host after intramuscular vaccination. However, the levels
of bacteria were apparently not sufficient to trigger an anti-EF immune response. This idea was
supported by the observations that only two out of five CM-LIVE vaccinated pigs were PCR-
positive at only one point of time. Moreover, no differences in protection were seen between carrier
and non-carrier pigs.
The present study shows that protective levels of antibody did not prevent the establishment of
carriers. In accordance with findings of Holt et al. (1988), we found that pigs, even if they were
protected against challenge, became carriers.
Previous studies showed that the capsule is an important virulence factor for S. suis serotype 2
(Charland et al., 1998; Smith et al., 1999). So far, the role of capsule in protection is not so clear.
Attempts to stimulate an immune response by vaccination with purified CPS were not successful
(Elliott et al., 1980). Moreover, it was suggested that besides antibodies to CPS, antibody responses
against other cellular components contribute to protection (Holt et al., 1990; Del Campo Sepúlveda
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et al., 1996). On the other hand, Jacobs et al. (1996) and Wisselink et al. (2001) showed that subunit
vaccines based on purified proteins efficiently protected pigs against challenge with virulent S. suis
serotype 2 strains. These data indicate that the capsule is not strictly required to obtain full
protection.
In many bacteria with an outer polysaccharide capsule, antibodies directed against CPS are
protective against infection. For example, CPS vaccines have been licensed for Neisseria
meningitidis and Streptococcus pneumoniae (Gotschlich et al., 1969; Kass, 1981). However, it is
well known that polysaccharides are T-cell independent immunogens and are poorly immunogenic
in children younger than 2 years owing to the immature status of their immune systems (Douglas
et al., 1983). For that reason, these vaccines do not work well in young children. Similarly, this may
explain why young pigs develop low levels of antibodies directed against CPS. The current
pneumococcal and meningococcal vaccine strategies concentrate on the use of conjugate vaccines,
in which CPS are linked to a highly immunogenic carrier protein thereby switching the immune
response against polysaccharides from T-cell independent to T-cell dependent. Consequently, the
antibody response towards the polysaccharides is increased and a memory response is provided. So
far, conjugated CPS vaccines have never been tested in S. suis. It would be of interest to test the
protective capacity of such conjugate vaccines against challenge with S. suis strains in vaccination
challenge experiments.
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1. Introduction
Streptococcus suis continues to be an economically important pig pathogen that is mainly
associated with meningitis, arthritis and septicaemia (Staats et al., 1997). Effective control of the
disease is still hampered due to a lack of effective vaccines and a lack of rapid and reliable
diagnostic assays. Development of such assays, is complicated by the diversity in behaviour of the
pathogen, in particular with respect to its virulence. Thirty-five different serotypes (types 1/2 and
1 through 34) of S. suis have been described (Perch et al., 1983; Gottschalk et al., 1989; 1991;
Higgins et al., 1995). In addition, virulent and avirulent subtypes of distinct serotypes have been
isolated ( Vecht et al., 1991, 1996; Stockhofe-Zurwieden et al., 1996). Therefore, research has been
focused on the identification of virulence-associated markers which might be useful to distinguish
virulent from less virulent or avirulent strains. Candidates for such markers are serotype-specific
capsular polysaccharides (CPS) (Smith et al., 1999a), the muramidase-released protein (MRP) and
the extracellular protein factor (EF) (Vecht et al., 1991). The aim of the investigations described in
this thesis, was to test whether these virulence-associated markers could be used in diagnostic assays
for the detection of S. suis infections and/or for use in vaccines to protect against the disease. This
chapter discusses the significance of the results for the control of S. suis infections in pigs.
2. Epidemiology
Virulence can differ among strains of S. suis. We previously demonstrated for S. suis serotypes
1 and 2, that bacterial virulence is associated with the production of MRP and EF (Vecht et al.,
1992). In this thesis we determined the serotypes and MRP/EF phenotypes of a considerable number
of S. suis strains (n=411) isolated from diseased pigs in seven European countries (Chapter 2).
2.1 Prevalence of serotypes
Serotype 2 was the most prevalent isolated serotype in strains isolated from diseased pigs in
seven European countries, followed by serotype 9 and serotype 1 (Chapter 2). However, not all
serotypes seemed equally distributed in the various countries. Serotype 2 was the most frequently
isolated serotype in France, Italy and Spain (Chapter 2). In previous studies on S. suis strains isolated
from disease pigs in Belgium, Germany and the Netherlands (Hommez et al., 1984; Vecht et al.,
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1985; Estoepangestie and Lammler, 1993) serotype 2 was the most often recorded serotype.
Nowadays, serotype 9 has emerged as the most prevalent serotype in these countries (Chapter 2).
The high prevalence of serotype 9 strains isolated from diseased pigs in the Netherlands confirms
earlier findings by Jacobs et al. (1995). In a recent study among S. suis strains, isolated from
diseased pigs in Germany, the importance of serotype 9 strains in infections caused by S. suis was
confirmed (Allgaier et al., 2001).
In the United Kingdom serotype 1 was the most prevalent serotype followed by serotype 2 and
14 (Chapter 2). S. suis infections caused by S. suis serotype 14 were for the first time reported in
1996 in the UK by Heath et al. (1996) and confirmed by MacLennan et al (1996). Nowadays nearly
50 per cent of the S. suis isolates belong to this serotype (Heath and Hunt, 2001).
Differences in prevalence of serotypes over time were also found in the Scandinavian countries
where serotype 7 was in 1983 the most predominant isolate (Perch et al., 1983). Fifteen years later,
serotype 2 was the most commonly isolated serotype from diseased pigs (Aarestrup et al., 1998).
In conclusion, although strains belonging to serotype 2 were the most prevalently isolated strains
from diseased pigs in seven European countries, it seemed that strains belonging to serotypes 1/2,
1, 7, 9 and 14 were increasingly involved in clinical disease (Chapter 2).
2.2 Phenotyping
The results of the phenotyping showed that, in accordance with earlier studies, strains of serotype
2 with the phenotype MRP+EF+ were frequently isolated from organs with lesions typical for S. suis
infections (Chapter 2) (Vecht et al., 1992). This was also the case for S. suis serotype 1 strains with
the phenotype MRPsEF+ (Chapter 2), (Stockhofe-Zurwieden et al., 1996). In this thesis, an
association between MRP and EF phenotypes and virulence was also found for serotype 14 and
serotype 1/2 strains. High percentages of these strains, isolated from pigs with a history of clinical
disease, showed an MRP- and/or EF-positive phenotype (Chapter 2). This suggests that also within
S. suis serotype 1/2 and 14 the expression of MRP and EF is associated with virulence. Different
results were obtained with serotype 9 strains. Although serotype 9 strains were frequently isolated
from tissues with lesions typical for S. suis infections, none of the strains produced EF. More than
80 per cent of the serotype 9 strains had the MRP*EF‾ phenotype, independent whether these strains
were isolated from organs with lesions typical for S. suis infection, or from lungs with pneumonic
lesions. None of the serotype 7 strains, neither those isolated from lesions typical for S. suis
infections nor those isolated from lungs with pneumonic lesions, produced MRP or EF. This
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suggests that in strains belonging to serotypes 7 or 9 and isolated from cases with a history of
clinical disease, EF expression is not related to virulence. In serotype 9 strains expression of MRP*
is possibly associated with virulence. The absence of EF in S. suis serotype 7 and 9 strains has been
confirmed in a study of S. suis strains isolated from German pigs with clinical disease (Allgaier et
al., 2001). Furthermore, similar to our results, it was found that a high percentage of S. suis serotype
9 strains expressed a MRP* protein.
So far, the association of MRP and EF with virulence was confirmed after challenging pigs with
S. suis serotype 1 and 2 strains only (Vecht et al., 1992; Stockhofe-Zurwieden et al., 1996). To proof
the importance of MRP and/or EF in the serotype 1/2, 9 and 14 strains more challenge experiments
in pigs are needed.
2.3 Prevalence of MRP+EF* strains
In previous work, we noticed that certain serotype 2 strains exhibited the phenotype MRP+EF*
(Vecht et al., 1991). Here, we demonstrate this feature for serotype 1 and 1/2 strains (Chapters 2 and
3). Similar results have been reported by Luque et al (1999), who S. suis serotype 1, 2, 1/2 and 14
strains with the phenotype MRP+EF* isolated from diseased pigs. Earlier, it was found that S. suis
type 2 strains with the phenotype MPR+EF* were weakly-virulent for pigs (Vecht et al., 1992). The
fact that serotype 1 strains with the phenotype MRP+EF* posses a ribotype identical to that of
MRP+EF* positive serotype 2 strains (Chapter 3) suggests that these strains are genetically closely
related, irrespective of their serotype. Whether the above mentioned Spanish S. suis serotype 1/2 and
14 strains, that share the phenotype MRP+EF*, also share ribotypes is unknown.
Interestingly, serotype 2 strains with the phenotype MRP+EF* were not detected in the
epidemiological survey among European S. suis isolates (Chapter 2). Earlier, these strains seemed
to be more important. More than a decade ago, over 10 per cent of S. suis serotype 2 strains isolated
from diseased pigs in the Netherlands showed the phenotype MRP+EF* (Vecht et al., 1991). In
addition, the S. suis serotype 2 reference strain, originally described by de Moor in 1963 showed the
MRP+EF* phenotype.
2.4 Association of MRP and EF with virulence
Earlier, we found that serotype 2 strains with the phenotype MRP+EF+ were more virulent for
young pigs than serotype 2 strains with the phenotype MRP+EF*(Vecht et al., 1992). Therefore, EF
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is probably a better virulence marker for S. suis serotype 2 infections than MRP. The potential role
of MRP as virulence marker was, among other evidence, based on the finding that strains isolated
from human patients were most often MRP+EF* positive (Vecht et al., 1991). Importantly, neither
MRP nor EF played a crucial role in the pathogenesis of S. suis serotype 1 and 2 infections. Isogenic
mutants of virulent serotype 1 and 2 strains, lacking the MRP and/or EF proteins, were as virulent
as the wild-type strain after experimental infection of new-born germfree pigs (Smith et al., 1996;
1997b). The strong association of MRP and EF with virulence could be explained by the fact that
synthesis of these proteins could merely be coincidence. Another explanation is that multiple factors
are involved in virulence of S. suis strains. This implies, that in the absence of MRP and EF,
particular functions can possibly be fulfilled by alternative factors which can take over their
functions so that loss of virulence is not observed in the mutant strains. The presence of such
alternative factors could also explain why a high association of MRP and EF with virulence is
observed in several countries all over the world but not in all countries (Salasia and Lammler, 1995;
Galina et al., 1996; Gottschalk et al., 1998; Awad-Masalmeh et al., 1999; Chatellier et al., 1999;
Luque et al., 1999; Allgaier et al., 2001). In Canada nearly all serotype 2 strains isolated from acute
cases of septicaemia and/or meningitis in pigs were MRP and/or EF negative (Gottschalk et al.,
1998; Chatellier et al., 1999). Interestingly, comparison of genotypic features by using different
molecular typing methods such as ribotyping or pulsed-field gel electroforese suggested a clonal
relationship of S. suis serotype 1 and 2 strains with the phenotype MRP+EF+ (Mogollon et al., 1991;
Smith et al., 1997a; Staats et al., 1998; Chatellier et al., 1999; Allgaier et al., 2001). Apparently,
some clones of virulent strains have been successful in spreading over several countries all over the
world, excluding Canada.
In conclusion, the data suggests that MRP and EF can be considered as markers for virulent
serotype 2 and highly virulent serotype 1 strains, although their contribution to virulence can be
disputed.
3. Prevention and control
Management factors such as more intensive production and control of other pig diseases play an
important role in the outcome of S. suis infections (Clifton Hadley et al., 1986; Akkermans and
Vecht, 1994; Amass et al., 1996b). Mixing and moving of pigs as well as overcrowding, poor
ventilation, excessive temperature fluctuations seem to be the most important stress factors involved
in the development of S. suis infection in susceptible pigs (Clifton Hadley et al., 1986; Dee et al.,
1993). Disease control still depends on minimising these stress factors, on feed medication, and on
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hygienic measures (Clifton Hadley et al., 1986). Different production techniques as medicated or
segregated early weaning were used to improve the health status of pigs and to eliminate the virulent
S. suis strains (Clifton Hadley et al., 1986; Amass et al., 1995; 1996a). The efficacy of these
methods is questionable. Despite optimisation of management and environment of pigs, some
animals still become healthy carriers or even develop clinical disease. To better control S. suis
infections, a strategy based on preventive vaccination could be considered. We therefore tested the
protective efficacy of several experimental vaccines, including one containing MRP and EF, against
challenge with virulent S. suis serotype 2 strains (discussed later). Another strategy to control the
disease is to prevent the transmission of virulent S. suis strains from infected carriers to susceptible
pigs. This strategy requires detection and elimination of pigs carrying the virulent strains. For such
an approach, highly sensitive diagnostic methods are needed to detect virulent S. suis strains in
clinical specimens. We therefore developed sensitive and specific diagnostic assays, based on PCR.
Both strategies, vaccination and detection followed by elimination of carriers, can be applied
separately or in combination.
3.1 Diagnostic assays based on PCR
S. suis can be detected on the palatine tonsils of both healthy and diseased pigs (Arends et al.,
1984; Van Leengoed et al., 1987; Mwaniki et al., 1994). Carrier pigs without any signs of disease
are known to be a source of infection for young sensitive pigs (Higgins et al., 1990). For the
detection of carriers of six major serotypes and two virulence-associated phenotypes of S. suis we
developed and evaluated rapid and sensitive diagnostic methods, based on PCR. First, we developed
a PCR assay, based on the epf gene, for the detection of virulent strains of S. suis serotype 2 and
highly virulent strains of S. suis serotype 1 (Chapter 3). Second, for the detection of pigs carrying
strains belonging to the most common isolated virulent serotypes and virulent-associated
phenotypes, Multiplex PCR tests have been developed in which five distinct DNA targets were
amplified (Chapter 4). Three targets, based on the S. suis serotype 1 (and 14), 7 and 9 specific cps
genes, were amplified in Multiplex PCR I. Two other targets, based on the serotype 2 (and 1/2)
specific cps gene and the epf gene encoding the EF-protein of virulent serotype 2 and highly virulent
serotype 1 strains, were amplified in Multiplex PCR II. The evaluation of these PCR assays for use
on tonsillar specimens of diseased pigs demonstrated that the assays were highly specific and
sensitive. Taken together, these assays will allow more reliable epidemiological studies of
colonisation by and transmission of the pathogen and may facilitate control and eradication
programs.
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The PCR assays are suitable for large scale detection of S. suis strains of various serotypes and
phenotypes (Chapters 3 and 4). Target DNA for use in these PCR assays was isolated and purified
from clinical samples by the “Multiscreen method” (Reek et al., 1995; Kamp et al., 1996). In this
method, DNA is isolated from clinical samples that are processed in wells of microplates, so that
96 samples can be prepared simultaneously (Reek et al., 1995; Kamp et al., 1996). We further
improved the diagnostic value of the PCR assays by using a multiplex-based approach so that we
could readily identify in two separate reactions five separate target DNAs (Chapter 4). For the
detection of the amplification products obtained by these PCR methods, we used agarose gel
electrophoresis. This is not well suited for rapid screening of large numbers of samples because of
the limited number of samples that can be analysed per gel and the time required for loading and
running gels. To overcome these limitations, fluorogenic PCR-based TaqMan or LightCycler
systems could be used. These systems enable simultaneous amplification and detection in a closed-
tube system. Continuous real-time PCR monitoring permits the rapid throughput of large numbers
of specimens in a highly standardised format. The advantages of these systems are that no post
amplification manipulations are required. Direct scanning of the emission spectra of the PCR
products results in significant time savings, and minimizes the risk of contamination between
samples. Development of a fluorogenic based PCR system could be of a great value for the detection
pigs carrying virulent strains of S. suis.
The PCR assays for the detection of serotype 1 (and 14), 2 (and 1/2), 7 and 9 strains in tonsillar
specimens of pigs are based on the serotype-specific cps loci of S. suis serotype 1, 2, 7 and 9. For
S. suis serotype 2, the CPS was recognised as an important virulence factor (Smith et al., 1999a).
However, the CPS is probably not the only major virulence factor as considerable differences in
virulence have been found for serotype 2 strains. S. suis serotype 2 strains, which appeared virulent,
weakly-virulent or avirulent for young pigs (Vecht et al., 1992) were all fully encapsulated after
growth in vitro or in vivo (Smith et al., 2001). This finding implies that diagnosis solely on the basis
of the presence of the serotype 2-specific cps sequence is not sufficient for the detection of virulent
S. suis serotype 2 strains. To identify pigs carrying virulent serotype 2 strains an additional marker
of virulence is necessary. The PCR, based on the epf gene encoding the EF protein of virulent
serotype 2 strains, appeared to be suitable for identifying pigs carrying these strains (Chapters 3 and
4).
In addition to EF-positive serotype 2 strains, EF-positive serotype 1, 1/2, 14 and 15 were isolated
from pigs suffering from a S. suis infection (Chapter 2). In tonsillar specimens of pigs carrying these
strains, the PCR will amplify an epf-specific fragment (Chapter 3). For serotype 1 strains also an
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association between virulence and the expression of EF was observed (Stockhofe-Zurwieden et al.,
1996; Vecht et al., 1996). EF-negative serotype 1 strains were less virulent for young pigs than EF-
positive serotype 1 strains but were still able to induce disease. Whether in the serotypes 1/2 and 14
expression of EF is associated with virulence is at present unknown. Epidemiological data suggested
that, as in the serotypes 1 and 2, also in the serotypes 1/2 and 14 strains, expression of EF is
associated with virulence (Chapter 2). Moreover, ribotype patterns of serotype 1, 2 and 1/2 strains
that express EF were identical (Chapter 3) (Smith et al., 1997a; Chatellier et al., 1999). This
suggests that EF-positive strains of serotype 1, 2 and 1/2 are genetically closely related. However,
since only a limited number of strains and serotypes was tested, a larger study with more strains is
necessary to confirm this relationship.
Virulence can differ among strains of S. suis. For serotype 1 and 2 an association between
virulence and the expression of EF is observed. At present, it is not known whether strains of
serotypes other than serotypes 1 and 2 also show a variation in virulence. Especially, serotype 7 and
9 strains deserve attention. Both serotypes were frequently isolated from organs of pigs suffering
from meningitis, septicaemia and pneumonia (Chapter 2) (Orr et al., 1989; Gogolewski et al., 1990;
Aarestrup et al., 1998; Allgaier et al., 2001). Both serotypes were also frequently isolated from
tonsillar specimens of clinically healthy pigs, apparently without causing disease (Monter Flores et
al., 1993; Wisselink et al., 2000). Whether these tonsillar strains can be considered as virulent is not
clear. Pigs may carry a variety of S. suis strains in their tonsils without an apparent relationship with
a specific pathological condition (Devriese et al., 1994; Higgins and Gottschalk, 1999). For effective
control of S. suis infections in pigs more knowledge is required about the virulence of serotype 7
and 9 strains. Experimental infections in pigs with serotype 7 and 9 strains, isolated from diseased
animals and from tonsils of healthy pigs, are necessary.
The Multiplex PCR assays detected multiple S. suis serotypes on tonsils of diseased pigs. Earlier,
it was found that pigs can be infected with multiple serotypes of S. suis (Sihvonen et al., 1986;
Reams et al., 1996). These findings may account in part for the difficulty in disease control by
vaccines. For the control of the disease by vaccines, in the Netherlands autogenous bacterins are
used. However, it seemed that these vaccines only confer protection against challenge with a strains
of a homologous serotype (Kebede et al., 1990). It can be hypothesised that a bacterin vaccine
prepared from one serotype may suppress clinical disease caused by that certain serotype but that
new outbreaks may occur caused by S. suis strains belonging to other serotypes. Therefore,
identification of specific strains, not only those involved in clinical disease in infected herds but also
those involved in the carrier state, may be needed to provide adequate control measures. The
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currently developed Multiplex PCR assays will contribute to such an approach.
At present, the Multiplex PCR assays identified most virulent S. suis serotypes and virulence
associated phenotypes (Chapter 4). If desired, it would also be possible to extend the assays to the
detection of other serotypes by isolation of the serotype-specific cps genes of the S. suis serotype
of interest (Smith et al., 1999b). Subsequently, PCR assays could be developed and evaluated by
using the strategy as described in Chapters 3 and 4.
For evaluating the PCR assays, a sophisticated bacteriological method was developed (Chapters
3 and 4). Using the amplicons of the single PCR assays as probe we were able to isolate the S. suis
bacteria directly from the clinical specimens. Although the sensitivity of this bacteriological method
was lower than the sensitivity of the PCR assays (Chapter 4), this method appeared to be a valuable
method for the selective isolation of S. suis bacteria from tonsils of carrier animals. Moreover,
viable bacteria could be recovered with this technique, which may also facilitate testing of
antimicrobial sensitivity and virulence.
3.2 Prevention of transmission
The PCR assays, described in this thesis (Chapters 3 and 4) can be used for the development of
programs based on prevention of transmission of the S. suis bacteria. Before such an approach is
feasible, epidemiological studies under field and experimental conditions are necessary and a
number of questions needs to be answered.
A first question concerns the type of tissue sample required to detect reliable carrier pigs. For the
detection of carriers, whole tonsils, slices of frozen tonsils or deep tonsil scrapings obtained from
dead pigs can be used as well as tonsil biopsies or tonsillar swabs obtained from live pigs (Arends
et al., 1984; Clifton Hadley et al., 1984a; 1984b; Van Leengoed et al., 1987; Moreau et al., 1989;
Mwaniki et al., 1994). However, it is not clear which type of sample is preferable. Arends et al.
(1984), found that S. suis serotype 2 was confined to the tonsillar crypt lumen of pigs aged 4 to 6
months, whereas Williams et al. (1973) found these organisms also in adjacent lymphoid tissue after
experimental infection of 10-day-old-pigs. Since the whole tonsil of pigs contains the deeper
tonsillar crypts, this type of sample may be used for maximum sensitivity of the test. However, for
routine detection of carriers, tonsillar swab specimens from live animals would be preferred as
sampling method. So far, the PCR assays described in this thesis (Chapter 3 and 4) were carried out
on tonsillar specimens sampled from dead pigs. Our experience is that the PCR assay is applicable
on tonsillar swab specimens of live pigs, perhaps with a slightly lower sensitivity (Swildens et al.,
2000). Nevertheless, additional experiments are necessary in which carrier rates in whole tonsils
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should be compared with those in tonsillar swabs and tonsillar biopsies.
A second question is whether sows and/or weaned pigs should be sampled and monitored for the
detection of virulent S. suis strains in a herd. Sows will presumably infect their own litters orally or
nasally (Clifton Hadley et al., 1986; Robertson and Blackmore, 1989; Amass et al., 1997) but the
bacteria are also readily transmitted between weaned pigs (Clifton Hadley et al., 1986; Mogollon
et al., 1990). Therefore, more knowledge about the epidemiology of the infection in a herd is needed
and more research is necessary to identify carrier animals.
A third question is whether at present pig herds do exist or can be obtained and maintained that
are completely free from S. suis infection. On one hand it was found that depopulation and
restocking with clean pigs ensured eradication of the infection caused by S. suis serotype 2 (Clifton
Hadley et al., 1986). In addition, Mills (1996) described the procedures that were used to establish
a pure-bred minimal-disease herd from gilts found to be carriers of a virulent strain of S. suis
serotype 2. On the other hand, preliminary results of PCR analysis for the detection of S. suis strains
in tonsils of pigs revealed that some serotypes, especially serotype 9 strains were endemically
present in pig herds (Wisselink et al., 2000). In addition, medicated and segregated early-weaning
technologies did not eliminate S. suis infections in weaned pigs (Clifton Hadley et al., 1986; Amass
et al., 1995; 1996a). Probably because pigs were already colonised during birth or in the first hours
of life (Robertson and Blackmore, 1989; 1991; Dee et al., 1993).
In conclusion, we developed and evaluated PCR procedures for the detection of six major
serotypes and two virulence-associated phenotypes of S. suis in tonsillar specimens of pigs. These
PCR assays can be used in epidemiological and transmission studies. Therefore, these tests may
facilitate control and eradication programs. Further research is necessary to test the feasibility of a
program, based on the prevention of transmission from carrier pigs to susceptible pigs by eradication
of carrier pigs. Preliminary PCR results, obtained on tonsillar specimens of pigs (Chapter 4),
indicated that serotype 9 strains are endemically present in Dutch pig herds. For control in these
herds, preventive vaccination can be carried out.
3.3 Vaccination
Another strategy to prevent disease caused by S. suis is by the use of vaccines. Vaccination of
piglets against a homologous S. suis serotype 2 infection with a whole cell bacterin vaccine seems
feasible as method of prevention since results obtained in vaccination/challenge studies with such
a vaccine were quite promising (Chapters 5 and 6) (Holt et al., 1990). However, inconsistent results
from experimental field trials and poor disease control in the field with the use of bacterins have
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been reported (Ripley, 1983; Holt et al., 1990; Reams et al., 1996). Exact reasons for vaccine failure
in the field are unknown but possible explanations are the lack of cross-reactivity between and
within serotypes (Kebede et al., 1990) and the presence of multiple serotypes in a single herd
(Chapter 4) (Reams et al., 1996). To meet these shortages we will aim to develop vaccines with the
potential of cross-protection. To my opinion, the components of an ideal S. suis vaccine are all
immunogenic and cross-protective between all virulent serotypes. Subunit vaccines, based on
antigens, conserved among serotypes, could meet these requirements. Attractive candidates for use
in a subunit vaccine are the 136-kDa MRP protein and the 110-kDa EF protein. Earlier, these
proteins were identified as markers of virulent S. suis serotype 1 and 2 strains (Vecht et al., 1991;
Stockhofe-Zurwieden et al., 1996). The protective capacity of vaccines containing purified MRP
and EF proteins was tested in pigs vaccinated twice at three weeks and six weeks of age and
challenged intravenously with homologous or heterologous virulent S. suis serotype 2 strains at eight
weeks of age.
3.4 Subunit vaccines based on MRP and EF
MRP and EF were purified from culture supernatant of a virulent S. suis serotype 2 by affinity
chromatography and used in vaccines (Chapter 5). The results of these experiments demonstrated
that vaccines containing both proteins protected piglets efficiently against challenge with either a
homologous or heterologous S. suis serotype 2 strain, while vaccines containing only one of these
proteins were less protective (Chapter 5). Apparently the combination of both proteins is necessary
to obtain full protection.
The protection observed with the MRP and/or EF vaccines was associated with the levels of anti-
MRP and anti-EF antibodies. The vaccine with MRP and EF, formulated with a water-in-oil
emulsion, induced high antibody titers and protected pigs effectively against challenge with either
homologous or heterologous S. suis serotype 2 strains. On the other hand, the vaccine with MRP
and EF, formulated with aluminium hydroxide gel, induced lower antibody titers and the pigs were
less well protected.
So far, it is unknown how the anti-MRP and anti-EF antibodies protect against disease caused
by S. suis serotype 2. It can be speculated that the antibodies act as opsonins, stimulating
phagocytosis and killing of the bacteria. In this process, a role for anti-MRP antibodies is more
likely than for anti-EF antibodies. MRP is a membrane-associated protein and EF is an extracellular
secreted protein (Vecht et al., 1991). Therefore, antibody-mediated attachment to mononuclear
leucocytes followed by uptake of bacteria seemed more likely for MRP than for EF. No results of
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laboratory experiments are available to proof these suggestions. More information about the possible
biological functions of the MRP and EF proteins is needed to understand their protective effect.
Whether a vaccine containing MRP and EF could confer a cross protective immune response
against other serotypes than serotype 2 is unknown. Highly virulent S. suis serotype 1, 2, 1/2 and
14 strains possess both proteins, which indicates that MRP and EF have potential to confer
protection against infection with these serotypes. This potential may be lower for strains belonging
to serotypes that produce one of these proteins. Especially, protection obtained by MRP could be
of interest since strains which express variants of MRP (MRP* or MRPs) were found in nearly all
serotypes. For example, serotype 9, which is at present the most prevalent serotype in the
Netherlands expresses only a MRP* protein, an enlarged variant of the 136-kDa MRP (Chapter 2).
Since this MRP* protein is detected in Western blots by mouse monoclonal anti-MRP antibodies,
by rabbit polyclonal anti-MRP antibodies and by swine convalescent anti-S. suis serotype 2
antibodies, this MRP* protein is immunologically related to the MRP proteins, which are expressed
by virulent serotype 2 and highly virulent serotype 1 strains. Therefore, a vaccine containing MRP
has potential to protect against S. suis serotype 9 infections. However, within serotype 2 we obtained
a partial protection after vaccination with MRP only (Chapter 5). Whether this is also the case for
S. suis serotype 9 infections is unknown.
Serotype 7 strains were also frequently isolated from diseased pigs (Chapter 2). However, a role
for MRP or EF in protection against S. suis serotype 7 infections is not very likely because nearly
all serotype 7 strains, isolated from diseased pigs, were MRP- and EF-negative. Therefore, to confer
protection against S. suis serotype 7 vaccines additional vaccine components need to be added to
a subunit vaccine based on MRP and EF.
For application in the field, a subunit vaccine, based on MRP and EF can be of a great value. In
total, MRP and/or EF were detected in 79 per cent of all S. suis strains isolated from typical S. suis
tissues (brains, serosae, joints, heart) or parenchymatous organs (liver, kidney, spleen) of diseased
pigs (Chapter 2). For protection against these infections there is potential for MRP and/or EF to
afford protection. Further work is needed to determine whether MRP and EF are involved in the
protection of pigs infected with strains of other serotypes producing MRP and/or EF.
3.5 Killed non-encapsuled mutant and immunity
Killed whole cell vaccines induced significant protection against challenge with a strain of a
homologous serotype (Chapters 5 and 6). However, it is not clear whether the CPS and other
bacterial components are both necessary to obtain a full protection. To determine the contribution
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of CPS to protection of a whole cell vaccine, we compared the protective efficacy of two vaccines
in pigs: namely a bacterin based on a non-encapsulated mutant (CM-BAC) of S. suis serotype 2
(Smith et al., 1999a) and a bacterin based on the fully encapsulated wild-type strain (Chapter 6). The
results demonstrated that, as expected, the formalin-killed cells of WT-BAC induced complete
protection in pigs against mortality and morbidity after challenge with a homologous strain. The
formalin-killed cells of CM-BAC induced complete protection against mortality, but only partial
protection against morbidity was observed. Because the mutant and the wild-type strains only
differed in the expression of CPS, CPS and other bacterial components are probably essential for
full protection against homologous challenge. The levels of antibody titers induced by the two
bacterin vaccines support this hypothesis. WT-BAC and CM-BAC induced identical antibody levels
against formalin-killed wild-type and non-encapsulated mutant cells as well as against MRP, the
membrane-associated protein. However, only the fully-encapsulated wild WT-BAC induced
antibodies against CPS. Although present in low levels, anti-CPS antibodies seem to play a role in
protection against challenge after vaccination with WT-BAC. These findings indicate that CPS and
other bacterial components of WT-BAC are probably essential for full protection against
homologous challenge.
The protection obtained with CM-BAC was not complete. Earlier Holt et al., (1990) showed that
the protective immunity of a bacterin vaccine was enhanced when the size of the inoculum was
increased to 1010 or 1011 organisms. Since we used 109 cells in our experiment the protective
efficacy of CM-BAC could probably be enhanced by using inocula with a higher number of cells.
3.6 Live non-encapsulated mutant and immunity
The use of a live vaccine may be an alternative approach to vaccine development. Live bacterial
vaccines usually induce more durable and efficacious responses than inactivated vaccines.
Advantages of a live vaccine are a more natural presentation of protective antigens and the ability
to stimulate both humoral immunity as well as cellular immunity (Ellis, 1999). Also, the organism
may produce protective antigens or immunomodulatory compounds in vivo which are not produced
in vitro (Mekalanos, 1994) Therefore, it could be of interest to test the protective capacity of a live
vaccine. We therefore used a non-encapsulated isogenic mutant of a virulent S. suis serotype 2 strain
(CM-BAC) which has attenuated virulence, but was still able to colonise young germfree pigs
(Smith et al., 1999a). Protection experiments in pigs with this mutant were not very promising
(Chapter 6). The results indicated that intramuscular administration of the mutant strains provides
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only partial protection to challenge with the virulent wild-type strain. Two out of five pigs died in
the course of the experiment and all pigs showed clinical signs of disease for one or more days.
Apparently the live vaccine failed to confer a complete protective immunity. This might be
explained by the fact that the mutant is not able to replicate in the host. Another explanation is that
the mutant is able to replicate but due to rapid phagocytosis (Smith et al., 1999a), only present is at
low levels. The absence of carriership, except for two pigs at only one point of time, supports these
explanations. Also, no antibodies against EF, an extracellular protein were detected. To obtain
antibodies against EF, replication of the non-encapsulated mutant strain in the host is required.
Apparently, levels of viable bacteria were too low to trigger an immune response against this
protein. Taken together, it seemed that the non-encapsulated mutant serotype 2 strain is over-
attenuated, leading to poor protection, such that it no longer replicates sufficiently to function as a
vaccine.
At present, besides the non-encapsulated mutant strain of S. suis serotype 2, only a few other
isogenic mutants of S. suis serotype 2 were described. Isogenic mutant strains of a virulent S. suis
serotype 2 strains, lacking MRP and/or EF or suilysin were generated and characterised. Results of
experimental infections in pigs showed that these mutants were hardly attenuated in their disease-
causing capacity (Smith et al., 1996; 1997b; Allen et al., 2001). For developing a live vaccine, it is
clear that other factors, which are essential in the disease process need to be identified.
In conclusion
In this thesis, we showed that the Multiplex PCR assays are specific and sensitive diagnostic
tools suitable for the detection of pigs carrying S. suis serotype 1 (and 14), 2 (and 1/2), 7 ,9 and
virulent serotype 2 and highly virulent serotype 1 strains. They may be applicable for
epidemiological and transmission studies and can contribute in efforts to control or eradicate S. suis
infections. Results of the vaccination/challenge experiments demonstrate that a subunit vaccine
containing both MRP and EF, protects pigs against challenge with virulent S. suis type 2 strains. The
epidemiological study revealed that high percentages of serotype 1, 1/2, 9 and 14 produce MRP
and/or EF (or variants thereof). This could suggest that a MRP/EF vaccine can protect pigs against
challenge with serotypes other than serotype 2. Further experiments need to be done to confirm this.
Further research is also necessary to develop strategies to control and/or eliminate disease caused
by S. suis. The in this thesis developed diagnostic PCR asays and MRP/EF vaccine may facilitate
this research.
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Streptococcus suis is an important pig pathogen which is mainly associated with meningitis,
arthritis and septicaemia. Most infections occur in piglets at the age of 3 to 12 weeks, especially
after weaning. Control of the disease is hampered by the lack of effective vaccines and the lack of
reliable diagnostic tests with high specificity and sensitivity. The development of these tools is
complicated by the number of existing serotypes, by the fact that we still lack knowledge of the
factors responsible for virulence and protection, and by the fact that strains of various serotypes as
well as individual strains within a single serotype may vary in virulence. Therefore, research focused
on the identification of virulence-associated markers that discriminate between virulent and less
virulent or avirulent isolates, has gained considerable interest in recent years. The aim of the
investigations described in this thesis, was to test whether these virulence-associated markers could
be used in diagnostic assays for the detection of S. suis infections and/or for use in vaccines to
protect against the disease.
Epidemiology
Virulence can differ in strains of S. suis. Earlier, we showed that in S. suis serotype 1 and 2, a
correlation exists between the production of muramidase-released protein (MRP) and extracellular-
factor protein (EF) and virulence for pigs. Biochemical studies have demonstrated that MRP is
predominantly present in protoplast supernatants and therefore may be associated with
peptidoglycan. Because EF appeared only in culture supernatant, it is considered to be a protein that
is secreted. So far, an association between virulence and the production of MRP and EF was only
studied for serotype 1 and 2 strains. Whether these proteins could be used as indicators of the
virulence of other S. suis serotypes was unknown. Therefore, we determined the serotypes and
MRP/EF phenotypes of a considerable number of S. suis strains (n=411) isolated from diseased pigs
in seven European countries (Chapter 2). Overall, S. suis serotype 2 strains appeared to be most
prevalent (32%), followed by serotype 9 (20%) and serotype 1 (12%) strains. Serotype 2 was most
frequently isolated from strains of France, Italy and Spain, whereas serotype 9 was most frequently
isolated in Belgium, the Netherlands and Germany. In the United Kingdom serotype 1 was most
frequently isolated. High percentages of S. suis serotype 1, 2, 1/2 and 14 strains, isolated from
tissues associated with S. suis infections, expressed the EF-protein. This indicates that in these
serotypes expression of EF is likely to be associated with virulence. In contrast, strains belonging
to serotype 7 and 9, isolated from tissues associated with S. suis infections did not produce EF.
These results strongly suggest that in the serotypes 7 and 9 EF expression is not related to virulence.
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More than 80 per cent of the S. suis serotype 9 strains produced an MRP* protein, a high molecular
variant of the 136-kDa MRP. Expression of MRP* in serotype 9 strains is possibly associated with
virulence.
Diagnostic PCR assays
S. suis can be detected on the palatine tonsils of both healthy and diseased pigs. Carrier pigs
(probably the sow) without any signs of disease are known to be a source of infection for young
sensitive pigs. A strategy to control the disease is to prevent the transmission of virulent S. suis
strains. This strategy requires detection and elimination of pigs carrying the virulent strains. For such
an approach, highly sensitive diagnostic methods are needed to detect virulent S. suis strains in
clinical specimens. We therefore developed sensitive and specific diagnostic assays, based on PCR
(Chapters 3 and 4). For the rapid and sensitive detection of pigs carrying virulent strains of S. suis
type 2 and highly virulent strains of S. suis type 1 in tonsillar specimens of pigs a PCR assay was
described (Chapter 3). This PCR was based on amplification of a fragment of the epf gene encoding
the EF protein of virulent S. suis type 2 strains (MRP+EF+) and highly virulent S. suis type 1 strains
(MRPsEF+). The test was evaluated using bacterial examination of tonsillar specimens collected
from pigs of herds known to be infected with S. suis type 2 and herds without a S. suis history. The
results demonstrated that the PCR is a highly specific and sensitive diagnostic tool for the detection
of pigs carrying virulent strains of S. suis type 2 and highly virulent strains of type 1.
In addition to virulent serotype 2 strains, serotype 1, 1/2, 7, 9 and 14 strains are also frequently
isolated from diseased pigs. For the detection of pigs carrying these strains, Multiplex PCR tests
have been developed in which five distinct DNA targets were amplified (Chapter 4). Three targets,
based on the S. suis serotype 1 (and 14), 7 and 9 specific capsular polysaccharide (cps) genes, were
amplified in Multiplex PCR I. Two other targets, based on the serotype 2 (and 1/2) specific cps gene
and the epf gene encoding the EF-protein of virulent serotype 2 and highly virulent serotype 1
strains, were amplified in Multiplex PCR II. The evaluation of these PCRs for use on tonsillar
specimens of diseased pigs demonstrated that the assays were highly specific and sensitive. The
Multiplex PCR assays are easy to perform and allows large-scale application, 96 samples can be
processed simultaneously. Compared to standard bacteriological assays, the PCR assays are much
more rapid to perform. Therefore, this assay may be an important diagnostic tool to detect pigs
carrying the most frequent isolated serotypes and virulence-associated phentoypes of S. suis. It may
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be applicable for epidemiological and transmission studies and can contribute in efforts to control
or eradicate S. suis infections.
Vaccines
Another strategy to prevent disease caused by S. suis is by the use of vaccines. Killed whole-cell
vaccines seem to induce significant protection against challenge with a strain of a homologous
serotype, but this protection is probably serotype-specific. Therefore, we will aim to develop
vaccines with the potential of cross-protection. The components of an ideal S. suis vaccine are all
immunogenic and cross-protective between all virulent serotypes. Subunit vaccines, based on
antigens, conserved among serotypes, could meet these requirements. MRP and/or EF are candidates
for use in a subunit vaccine. Both are produced by several virulent serotypes and both are recognised
by convalescent sera of pigs infected with virulent serotype 2 strains. Therefore, we determined the
efficacy of MRP and EF vaccines applied in pigs challenged either with a homologous or
heterologous S. suis serotype 2 strain (MRP+EF+) (Chapter 5). MRP and EF were purified by affinity
chromatography. Pigs were vaccinated twice at three weeks and six weeks of age and challenged
intravenously with virulent S. suis serotype 2 strains (MRP+EF+) at eight weeks of age. At challenge,
pigs vaccinated with MRP and EF had high anti-MRP and anti-EF titers and were protected against
infection and disease. Pigs vaccinated with either MRP or EF were less well protected. Apparently
the combination of both proteins is necessary to obtain full protection. The results demonstrated that
MRP and EF are attractive candidates for a subunit vaccine to protect pigs against disease caused
by S. suis serotype 2 strains. Further work is needed to determine whether MRP and EF are involved
in the protection of pigs infected with strains of other serotypes, as serotypes 1, 1/2, 9 and 14 which
produce variants of MRP and/or EF.
In many bacteria with a polysaccharide capsule, antibodies directed against CPS are protective
against infection. The ability of anti-CPS antibodies of S. suis serotype 2 to protect against infections
is not well established. Therefore, the protective efficacy of an avirulent, non-encapsulated isogenic
mutant of S. suis serotype 2 was determined in pigs, and compared with the efficacy of the
capsulated wild-type strain. SPF pigs were vaccinated twice intramuscularly at four and seven weeks
of age with formalin-killed cells of the wild-type (WT-BAC), formalin-killed cells of the non-
encapsulated mutant (CM-BAC) or with the live non-encapsulated mutant (CM-LIVE) strain. After
two weeks, vaccinated pigs and non-vaccinated controls were challenged intravenously with the
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homologous, wild-type S. suis serotype 2 strain. The results demonstrated that, as expected, the
formalin-killed cells of WT-BAC induced complete protection in pigs against mortality and
morbidity after challenge with a homologous strain. The formalin-killed cells of CM-BAC induced
complete protection against mortality, but only partial protection against morbidity. The CM-LIVE
vaccine induced only partial protection, both against mortality and morbidity. The protective
efficacy of the vaccines could be associated with serum antibody titers. WT-BAC and CM-BAC
induced identical antibody levels against formalin-killed wild-type and non-encapsulated mutant
cells as well as against MRP. However, only the fully-encapsulated wild WT-BAC induced
antibodies against CPS. Although present in low levels, anti-CPS antibodies seem to play a role in
protection against challenge after vaccination with WT-BAC. These findings indicate that CPS and
other bacterial components of WT-BAC are probably essential for full protection against
homologous challenge.
In conclusion
In this thesis, we showed that the Multiplex PCR assays are highly sensitive and specific
diagnostic tools for the detection of S. suis strains most frequently involved in clinical disease in
infected pig herds. In addition, we showed that a subunit vaccine containing both MRP and EF
protected pigs efficiently against a homologous challenge. Therefore, the PCR assays and the
MRP/EF vaccine can be used for the development of programs to control disease caused by S. suis.
To control S. suis infections, strategies based on preventive vaccination and/or based on
prevention of transmission by detecting carrier pigs could be considered. Further research is
necessary to test the feasibility of these strategies. The in this thesis developed diagnostic PCR
assays and MRP/EF vaccine may facilitate this research.
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Streptococcus suis is een belangrijke oorzaak van zenuwverschijnselen, kreupelheid en sterfte
bij biggen. De infectie, die vooral bij biggen van speenleeftijd (rond 6 weken) problemen
veroorzaakt, is wereldwijd verspreid. Met name in landen met een intensieve veehouderij is de
ziekte een economisch belangrijke schadepost. S. suis is soms ook verantwoordelijk voor infecties
bij de mens, met onder andere hersenvliesontsteking als gevolg. De risicogroep blijkt vooral te
bestaan uit mensen uit de beroepsgroep zoals varkenshouders en slachters.
Bestrijding van de ziekte bij het varken wordt belemmerd door het ontbreken van effectieve
vaccins en van diagnostische testen met een hoge sensitiviteit en specificiteit. Eén reden daarvoor
is de diversiviteit binnen S. suis. Momenteel zijn er van S. suis 35 verschillende serotypes
beschreven. Bovendien kunnen binnen serotypes ook weer subtypes onderscheiden worden. Zo
zijn van S. suis serotype 2, één van de meest frequent voorkomende serotypes, ziekmakende
(virulente) en onschuldige (avirulente) subtypes beschreven. De virulente subtypes veroorzaken
ziekte en sterfte bij jonge biggen terwijl de avirulente dat niet doen. Om virulente S. suis bacteriën
te onderscheiden van avirulente is het onderzoek er op gericht geweest ziekteverwekkende
eigenschappen (virulentiefactoren) of met virulentie geassocieerde kenmerken te identificeren.
Het doel van het onderzoek beschreven in dit proefschrift was om te testen of deze kenmerken
van virulentie gebruikt kunnen worden als basis voor diagnostische testen om S. suis infecties te
kunnen detecteren en/of voor het gebruik in vaccins om biggen te beschermen tegen de ziekte.
Epidemiologie
Uit eerder onderzoek is gebleken dat de verschillen in virulentie binnen serotype 2 stammen
geassocieerd zijn met het voorkomen van een tweetal eiwitten in deze stammen. Eén van deze
eiwitten heeft een molecuulgewicht van 136 kDa en wordt wel MRP (muramidase-released
protein) genoemd. Dit eiwit ligt aan het oppervlak van de bacterie en wordt ook uitgescheiden
door de bacterie. Een ander eiwit met een molecuulgewicht van 110 kDa wordt enkel
uitgescheiden door de bacterie en werd daarom EF (extracellular factor) genoemd. Uit
vervolgonderzoek bleek dat de productie van deze eiwitten ook bij S. suis serotype 1 stammen
geassocieerd is met virulentie. Hoogvirulente serotype 1 stammen produceren zowel MRP als EF
terwijl minder virulente serotype 1 stammen deze beide eiwitten niet produceren. Of deze beide
eiwitten ook geassocieerd zijn met virulentie in andere, veel voorkomende serotypes was niet
bekend. Daarom werd een epidemiologisch onderzoek uitgevoerd waarin S. suis isolaten (n=411)
geïsoleerd uit zieke biggen afkomstig uit 7 Europese landen werden geserotypeerd en werden
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gefenotypeerd op basis van hun MRP en EF productie (Hoofdstuk 1). Serotype 2 (32%) werd het
meest frequent geïsoleerd, gevolgd door de serotypes 9 (20%) en 1 (12%). De frequentie van
vóórkomen van de serotypes bleek te verschillen tussen landen. In Frankrijk, Italië en Spanje
werd serotype 2 het meest frequent geïsoleerd uit zieke biggen, terwijl in België, Duitsland en
Nederland serotype 9 het meest geïsoleerd werd. S. suis isolaten afkomstig van zieke biggen uit
Engeland bleken meestal tot serotype 1 te behoren. Omdat serotype 2 in België, Duitsland,
Nederland en Engeland ruim 10 jaar geleden het meest geïsoleerd werd uit zieke biggen geven
deze resultaten aan dat er in de loop van de tijd een verschuiving van serotype kan optreden.
Uit de MRP en EF fenotypering bleek dat een hoog percentage van serotype 1, 2, 1/2 en 14
stammen geïsoleerd uit organen zoals hersenen, gewrichten en serosae, EF produceerde. Deze
bevindingen geven aan dat in deze serotypes de productie van EF waarschijnlijk geassocieerd is
met virulentie. Daarentegen bleek geen van de serotype 7 en 9 stammen, geïsoleerd uit hersenen,
gewrichten en serosae, EF te produceren. In deze serotypes is EF daarom waarschijnlijk niet van
belang. Meer dan 80% van de serotype 9 stammen bleek een MRP* eiwit te produceren. Het
MRP* eiwit heeft een hoger molecuulgewicht dan het 136 kDa MRP eiwit. Omdat het MRP*
eiwit in Western blot testen reageert met monoclonale muis antilichamen en polyclonale konijnen
antilichamen gericht tegen het 136 kDa MRP eiwit is het immunologisch hieraan gerelateerd. Dit
MRP* eiwit zou geassocieerd kunnen zijn met virulentie in serotype 9 stammen. Experimentele
infectieproeven in biggen zijn echter nodig om dit te bevestigen.
Diagnostiek op basis van PCR
S. suis kan zich latent ophouden in de tonsil (de amandelen) en op het neusslijmvlies van
zowel volwassen als jonge, gezonde varkens. Deze dieren zijn dus dragers. Via deze dragers
(hoogstwaarschijnlijk de zeug) wordt de infectie overgedragen op jonge biggen. Deze jonge
biggen zijn vaak rond de speenleeftijd extra vatbaar voor de infectie. Het voorkómen van
transmissie van de bacterie door dragers te identificeren en vervolgens te elimineren zou een
belangrijk middel kunnen zijn om de ziekte te bestrijden. Voor de identificatie van dragers kan
gebruik gemaakt worden van conventionele bacteriologische technieken. Bacteriën worden
daarvoor gekweekt uit tonsilswabs op selectieve-electieve media. Determinatie gebeurt
vervolgens met biochemische en serologische technieken. Om de virulente stammen te kunnen
onderscheiden van de avirulente dient het MRP en EF fenotype bepaald te worden met Western
blot analyse of ELISA technieken. Echter, deze methoden zijn arbeidsintensief en ongevoelig. Om
de diagnostiek van dragers te verbeteren zijn testen op basis van de polymerase chain reaction
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(PCR) ontwikkeld (Hoofdstukken 3 en 4). De PCR heeft bewezen een eenvoudige, snelle en zeer
gevoelige methode te zijn om verschillende bacteriën in klinische monsters aan te kunnen tonen.
In hoofdstuk 3 is een PCR methode beschreven om virulente serotype 2 en hoog virulente
serotype 1 stammen te kunnen detecteren. Op basis van de DNA sequenties van het epf gen, dat
codeert voor het EF eiwit van virulente serotype 2 en hoog virulente serotype 1 stammen, werden
primers geselecteerd. De PCR werd gevalideerd op tonsillen afkomstig van bedrijven waar
recentelijk infecties, veroorzaakt door serotype 2 stammen van het fenotype MRP+EF+, waren
vastgesteld en bedrijven zonder een dergelijke historie. De resultaten van de PCR op deze
tonsillen werden vergeleken met de resultaten van een uitgebreid bacteriologisch onderzoek op
dezelfde tonsillen. In dit bacteriologisch onderzoek werd het PCR product gebruikt om de EF-
positieve stammen direct uit het tonsilmateriaal te isoleren. Uit de vergelijking bleek dat deze
PCR een snelle en betrouwbare methode is om virulente serotype 2 en hoog virulente serotype
1 stammen in klinisch materiaal aan te tonen.
Behalve virulente serotype 2 stammen worden ook frequent andere serotypes, als serotype 1,
1/2, 7, 9 en 14 geïsoleerd uit zieke biggen. Om dragers van deze stammen te identificeren werden
eerder al PCR testen ontwikkeld. Deze PCR testen zijn gebaseerd op de serotype 1, 2, 7 of 9
specifieke kapselgenen. Behalve deze serotypes kunnen daarmee ook dragers van serotype 1/2
en 14 stammen aangetoond worden. Dit vanwege homologie tussen het DNA dat codeert voor
de serotype-specifieke kapselgenen van de serotypes 1 en 14 en de serotypes 2 en 1/2. Hoofdstuk
4 beschrijft de ontwikkeling van Multiplex PCR testen op basis van de serotype 1, 2, 7 en 9
specifieke kapselgenen en het epf gen. In twee aparte reacties kunnen we hiermee dragers
detecteren van serotype 1 (en 14), 7 en 9 stammen (Multiplex PCR I) en van serotype 2 (en 1/2)
en EF-positieve stammen (Multiplex PCR II). De Multiplex PCR testen werden gevalideerd op
tonsillen afkomstig van biggen geïnfecteerd met S. suis. Daarvoor werden de resultaten van de
Multiplex PCR testen vergeleken met de resultaten van een uitgebreid bacteriologisch onderzoek,
uitgevoerd op dezelfde tonsillen. Uit deze vergelijking bleek dat de Multiplex PCR een snelle en
betrouwbare methode is om dragers te detecteren van de belangrijkste serotypes en fenotypes van
S. suis. Deze testen zijn daarom geschikt om gebruikt te worden voor epidemiologisch onderzoek
en het ontwikkelen van bestrijdingsprogramma’s. De Multiplex PCR testen zijn geschikt om op
grote schaal gebruikt te worden omdat 96 monsters tegelijk kunnen worden getest. Uit
vervolgonderzoek zal moeten blijken of het mogelijk is om de basis van detectie en eliminatie
van dragers de ziekte in het veld te bestrijden.
Chapter 9
136
Vaccins
Vaccins worden veelvuldig gebruikt om jonge biggen te beschermen tegen ziekte na infectie
met S. suis. Vaccins op basis van afgedode S. suis bacteriën blijken goed te beschermen tegen een
infectie veroorzaakt door een S. suis bacterie van hetzelfde (homologe) serotype maar niet tegen
een ander (heteroloog) serotype. Onderzoek is er daarom op gericht vaccins te ontwikkelen die
bescherming bieden tegen alle virulente serotypes. Daartoe dienen vaccins immuniteit
opwekkende componenten (antigenen) te bevatten die voorkomen in alle virulente serotypes.
MRP en/of EF komen in aanmerking om in een dergelijk vaccin gebruikt te worden. Beiden
worden door meerdere virulente serotypes geproduceerd. Bovendien blijken biggen, die een
infectie met virulente S. suis serotype 2 stammen hebben doorgemaakt, hoge antistoftiters tegen
deze beide eiwitten te ontwikkelen. Daarom werden experimenten uitgevoerd waarin de
beschermende werking van MRP en EF vaccins in jonge biggen tegen ziekte en sterfte,
veroorzaakt door S. suis, werd bepaald (Hoofdstuk 5). MRP en EF werden middels
affiniteitschromatografie opgezuiverd. SPF biggen werden intramusculair gevaccineerd op de
leeftijd van 3 en 6 weken; een intraveneuze besmetting (challenge) werd uitgevoerd op de leeftijd
van 8 weken. Na immunisatie ontwikkelden de biggen hoge antistoftiters tegen MRP en EF. Na
challenge infectie met homologe en heterologe virulente serotype 2 stammen bleek dat biggen
gevaccineerd met MRP en EF goed beschermd waren tegen ziekte en sterfte. Biggen gevaccineerd
met enkel MRP of EF bleken minder goed beschermd. Klaarblijkelijk zijn beide eiwitten nodig
om een volledige bescherming te induceren. Geconcludeerd kan worden dat MRP en EF goede
kandidaten zijn voor een subunit vaccin voor de protectie tegen infectie met virulente serotype
2 stammen. Nader onderzoek zal moeten uitwijzen of het MRP en EF vaccin biggen ook
beschermt tegen infecties met andere serotypes, zoals serotype 1, 1/2, 9 en 14 die MRP en/of EF
varianten produceren.
Voor veel bacteriën met een polysaccharide kapsel geldt dat antilichamen tegen dit kapsel
beschermen tegen infectie. Van S. suis is nog weinig bekend over de bijdrage van dergelijke
antilichamen aan bescherming. Daarom werden vaccinatie challenge experimenten uitgevoerd
waarin getest werd of een avirulente kapselloze serotype 2 mutant beschermt na vaccinatie
(Hoofdstuk 6). Als vaccin werd een levende (CM-LIVE) of een geïnactiveerde cultuur van de
kapselloze mutant (CM-BAC) getest. De werkzaamheid van deze vaccins werd vergeleken met
de werkzaamheid van een geïnactiveerde cultuur van de virulente wildtype serotype 2 stam. Van
dit laatste vaccin is in eerder onderzoek gebleken dat het een goede bescherming induceert. SPF
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biggen werden intramusculair gevaccineerd op de leeftijd van 3 en 6 weken. Een intraveneuze
challenge infectie met de homologe, virulente wildtype serotype 2 stam werd uitgevoerd op een
leeftijd van 8 weken. Het WT-BAC vaccin bood volledige bescherming tegen ziekte en sterfte.
Het CM-BAC vaccin bood ook volledige bescherming tegen sterfte maar slechts gedeeltelijk
tegen ziekte. Alle biggen overleefden de challenge infectie maar vier van de vijf biggen uit deze
groep vertoonden specifieke klinische symptomen zoals kreupelheid en zenuwverschijnselen. Het
CM-LIVE vaccin bood geen bescherming. Alle biggen vertoonden specifieke klinische
symptomen na de challenge infectie en twee van de vijf biggen gingen dood. Hieruit kunnen we
concluderen dat CM-LIVE niet geschikt is als vaccin. Waarschijnlijk wordt de kapselloze mutant
te snel opgeruimd uit het lichaam om voldoende immuniteit op te wekken.
De beschermende werking van de vaccins correleerde met de antistoftiters. Antistoftiters tegen
MRP en tegen cellen van de wildtype en mutant stammen waren hoog in biggen gevaccineerd met
WT-BAC en CM-BAC. Biggen gevaccineerd met CM-LIVE hadden lagere antistoftiters.
Antistoftiters tegen kapsel polysaccharide werden alleen gemeten in het serum van biggen
gevaccineerd met WT-BAC. Uit deze resultaten kan geconcludeerd worden dat zowel kapsel
polysaccharide als andere bacteriële componenten van WT-BAC bijdragen aan protectie tegen
een infectie met een homoloog serotype.
Concluderend
Dit onderzoek laat zien dat met de Multiplex PCR testen snel en betrouwbaar dragers van de
meest frequent geïsoleerde serotypes en met virulentie geassocieerde fenotypes van S. suis
gedetecteerd kunnen worden. Bovendien laat dit onderzoek zien dat een subunit vaccin, gebaseerd
op MRP en EF, biggen effectief beschermd tegen een homologe challenge infectie. Zowel de PCR
testen als het MRP/EF vaccin kunnen daarom gebruikt worden voor de ontwikkeling van
programma’s om de ziekte in het veld te bestrijden.
Ziekte als gevolg van S. suis infecties kan bestreden worden door jonge biggen preventief te
vaccineren. Of het mogelijk is deze ziekte effectief te bestrijden op basis van detectie gevolgd
door eliminatie van dragers van de virulente S. suis stammen is momenteel onduidelijk. Nader
onderzoek zal moeten uitwijzen of een dergelijke benadering haalbaar is of dat deze
gecombineerd dient te worden met preventieve vaccinatie. De in dit proefschrift beschreven PCR
testen en MRP/EF vaccins kunnen aan dit onderzoek een belangrijke bijdrage leveren.
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Toen ik ruim twintig jaar geleden bij het toenmalige CDI ging werken had ik nooit gedacht nog
eens te gaan promoveren. Zonder de stimulansen en hulp van velen was het vast ook niet zo ver
gekomen. Hierbij wil ik een ieder hartelijk danken die er op één op andere manier bij geholpen
heeft.
Mijn beide copromotoren, Hilde Smith en Uri Vecht ben ik zeer erkentelijk voor de gelegenheid
die ze me geboden hebben om dit proefschrift te schrijven. Jullie werk is de basis geweest voor dit
proefschrift. Het is dan ook niet vreemd dat alle hoofdstukken in dit boekje gelardeerd zijn met
verwijzingen naar jullie artikelen. Beste Uri, jouw hulp, stimulans en begeleiding zijn onmisbaar
gebleken. Vele jaren heb ik onder jouw leiding mogen werken en altijd gaf je me alle ruimte voor
een stuk persoonlijke ontwikkeling. Niet alleen voor al die avondstudie’s die ik zo nodig moest
volgen maar ook op het lab. Bedankt! Beste Hilde, na Uri’s vertrek nam jij de dagelijkse leiding
over. Iedere keer was ik weer verbaasd hoe snel je een artikel gecorrigeerd had en er een lopend
verhaal van had gemaakt. Daarnaast bezit je het vermogen ingewikkelde zaken lekker simpel te
houden en zeer doelgericht je werk te doen. Dank je wel voor alle energie die je in deze promotie
en mijn dagelijkse begeleiding gestoken hebt.
Paranimf Aart Lammers, met veel genoegen denk ik terug aan de periode die we samen in één
onderzoeksgroep hebben gezeten. Altijd was je in voor een goed gesprek, een goede raad of een
mooie schaatstocht. Bijzonder is ook dat wij onze geloofsovertuiging op zo’n persoonlijke wijze
met elkaar delen.
Mijn beide promotoren, Jos Verheijden en Jos van Putten, dank ik hartelijk voor de hulp bij de
totstandkoming van dit proefschrift. De bijeenkomsten met jullie waren altijd zeer constructief en
stimulerend en vrijwel iedere opmerking of aanwijzing gaf stof tot nadenken en verwerking in het
proefschrift. Jos van Putten wil ik bedanken voor het aanbrengen van correcties in de Engelse taal.
Zonder de overige leden van de S. suis projectgroep zou dit boekje er ook nooit gelegen hebben.
Norbert Stockhofe-Zurwieden wil ik hartelijk bedanken voor alle bijdragen, in het bijzonder voor
de pathologische en veterinaire. Frans Reek legde, inmiddels al heel wat jaartjes geleden, een
belangrijke basis voor het PCR werk. Bedankt dat ik er verder mee mocht gaan. Astrid de Greeff
en Herma Buijs dank ik hartelijk voor alle medewerking en goede opmerkingen. Astrid, dank je wel
voor het grondig doorlezen van mijn manuscript. Ik wens je zeer veel succes toe bij het afronden
van je eigen proefschrift.
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Bijdragen aan dit proefschrift werden ook geleverd door de stagiares Linda van Genne, Monique
de Winter en Jeroen Joosten. Ik kijk met genoegen terug op jullie stageperiodes. Belangrijk was ook
de hulp van Klaas Peperkamp (GD Boxtel), Leo van Leengoed (Fac. Diergeneeskunde), Bas
Swildens (Fac. Diergeneeskunde), Chris Charpentier (DAP Diessen), Arnold de Vries (DAP
Diessen), Tineke van de Veerdonk (DAP Schaijk), Els Daniëls-Laarakker (GD Boxtel) en Rinus
Voets (GD Boxtel). Dankzij jullie contacten met de praktijk kwam ik aan bedrijven waar monsters
genomen konden worden om de PCR uit te testen.
De proefdierverzorgers ben ik erkentelijk voor alle inzet en betrokkenheid bij de uitvoering van
de dierexperimenten. Ad Korevaar en Ad Bartelse zorgden zoals altijd op ongedwongen wijze voor
de sectie van de biggen. Arie Hoogendoorn maakte ‘difjes’ van de vele bloedjes en Rob Buijs sneed
de coupes. Allen bedankt.
Mijn voormalige afdelingshoofd, Fred van Zijderveld, en mijn huidige ‘hoofd’, Paul Steverink
dank ik voor de ruimte en gelegenheid die mij geboden is om aan dit werk te mogen beginnen en
ook de tijd die me geboden is om het onderzoek en schrijfwerk af te ronden.
Zwager Joost Roorda verzorgde de omslag van dit boekje. Joost, hartelijk dank voor de zeer
fraaie weergave van biggetjes die hersenvliesontsteking kunnen krijgen. Fred van Welie zorgde er
voor dat de drukker direct met de omslag aan het werk kon.
En dan degenen die het allerbelangrijkste voor mij zijn. Lieve Leny, zonder jouw
onvoorwaardelijke ondersteuning, aanmoedigingen en enthousiasme in woord en daad was dit
proefschrift er nooit gekomen. Ik beschouw het als een groot voorrecht om mijn leven, samen met
onze vier dochters Corine, Willeke, Harriëtte en Daniëlle, met jou te mogen delen. Paranimf en
oudste dochter Corine, ik vind het fijn dat jij, als representant van mijn vrouwen, mij bij deze
promotie terzijde wilt staan.
De kerkenraad van de Geref. Kerk (vrijg.) te Lelystad ben ik erkentelijk voor de vrijstelling van
al mijn werkzaamheden gedurende een heel seizoen om dit proefschrift af te ronden. Het verschafte
mij de mogelijkheid om in de avonduren hieraan door te werken.
Tenslotte voel ik me een bevoorrecht mens dat ik God mag kennen. Hij die de wereld, de natuur
met zo’n enorme variatie en gecompliceerdheid geschapen heeft en waarvan wij in ons onderzoek
slechts maar ten dele in staat zijn te ontdekken hoe het in elkaar zit. Dit brengt me vaak tot
bewondering en verwondering voor Degene die dit alles zó gemaakt heeft. Hem zij de eer!
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Ik ben geboren op 22 juni 1958 te Groningen. Na eerst het MAVO en vervolgens het HAVO
diploma behaald te hebben ging ik in 1976 naar Bolsward om daar de opleiding aan de Middelbare
School voor Levensmiddelentechnologie te volgen. Na het afronden van deze studie in 1980 volgde
een jaar militaire dienst. In 1981 trad ik in dienst bij het Centraal Diergeneeskundig Instituut in
Lelystad. Daar werd ik als laborant voor het mastitisonderzoek aangesteld bij de afdeling
Bacteriologie. Een jaar later begon ik met de avondopleiding HBO-A, medische microbiologie.
Deze opleiding werd in 1986 succesvol afgerond. In 1991 pakte ik de ‘studiedraad’ weer op en een
jaar later haalde ik het diploma Hoger Laboratorium Onderwijs. Momenteel werk ik als sr. assistent-
onderzoeker bij de Divisie Infectieziekten en Ketenkwaliteit van ID-Lelystad en maak deel uit van
het cluster Bedrijfsgebonden Ziekten.
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